10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

0001193125-18-155618.txt : 20180508 0001193125-18-155618.hdr.sgml : 20180508 20180508123457 ACCESSION NUMBER: 0001193125-18-155618 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 89 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180508 DATE AS OF CHANGE: 20180508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 18813672 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 10-Q 1 d574491d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 000-14656

REPLIGEN CORPORATION

(Exact name of registrant as specified in its charter)


Delaware		04-2729386
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

41 Seyon Street, Bldg. 1, Suite 100 Waltham, MA		02453
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 250-0111

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes ☐ No ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of May 1, 2018.


Class		Number of Shares
Common Stock, par value $.01 per share		43,693,913

Table of Contents


		PAGE

PART I	FINANCIAL INFORMATION

Item 1.	Unaudited Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017			3

Condensed Consolidated Statements of Comprehensive Income for the Three-Month Periods Ended March 31, 2018 and 2017			4

Condensed Consolidated Statements of Cash Flows for the Three-Month Periods Ended March 31, 2018 and 2017			5

Notes to Unaudited Condensed Consolidated Financial Statements			6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		22

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		28

Item 4.	Controls and Procedures		28

PART II	OTHER INFORMATION		30

Item 1.	Legal Proceedings		30

Item 1A.	Risk Factors		30

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		30

Item 3.	Defaults Upon Senior Securities		30

Item 4.	Mine Safety Disclosures		30

Item 5.	Other Information		30

Item 6.	Exhibits		30

Signatures			32

REPLIGEN CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


(in thousands, except share data)	March 31, 2018			December 31, 2017
Assets
Current assets:
Cash and cash equivalents	$	173,876		$	173,759
Accounts receivable, less reserve for doubtful accounts of $59 at March 31, 2018 and $58 at December 31, 2017, respectively		29,352			27,585
Royalties and other receivables		31			153
Inventories, net		40,124			39,004
Prepaid expenses and other current assets		4,939			2,281

Total current assets		248,322			242,782
Property, plant and equipment, net		22,674			22,417
Intangible assets, net		142,273			144,753
Goodwill		327,989			327,333
Other assets		1,990			6,234

Total assets	$	743,248		$	743,519

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	6,200		$	7,282
Accrued liabilities		14,121			17,929

Total current liabilities		20,321			25,211
Convertible senior notes, net		100,276			99,250
Deferred tax liabilities		20,858			25,167
Other long-term liabilities		4,610			2,343
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $.01 par value, 5,000,000 shares authorized, no shares issued or outstanding		—			—
Common stock, $.01 par value, 80,000,000 shares authorized, 43,692,303 shares at March 31, 2018 and 43,587,079 shares at December 31, 2017 issued and outstanding		437			436
Additional paid-in capital		631,595			628,983
Accumulated other comprehensive loss		(6,112	)		(6,363	)
Accumulated deficit		(28,737	)		(31,508	)

Total stockholders’ equity		597,183			591,548

Total liabilities and stockholders’ equity	$	743,248		$	743,519

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPLIGEN CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)


	Three months ended March 31,
(in thousands, except share and per share data)	2018			2017
Revenue:
Product revenue	$	44,799		$	30,569
Royalty and other revenue		31			21

Total revenue		44,830			30,590
Operating expenses:
Cost of product revenue		19,668			13,990
Research and development		3,288			1,742
Selling, general and administrative		15,898			9,182

Total operating expenses		38,854			24,914

Income from operations		5,976			5,676
Investment income		181			96
Interest expense		(1,652	)		(1,585	)
Other income (expense)		71			(120	)

Income before income taxes		4,576			4,067
Income tax provision		1,128			999

Net income	$	3,448		$	3,068

Earnings per share:
Basic	$	0.08		$	0.09

Diluted	$	0.08		$	0.09

Weighted average shares outstanding:
Basic		43,621,270			33,891,702

Diluted		44,326,732			34,382,322

Other comprehensive income:
Unrealized gain on investments		—			4
Foreign currency translation gain		251			1,027

Comprehensive income	$	3,699		$	4,099

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPLIGEN CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Three months ended March 31,
(In thousands)	2018			2017
Cash flows from operating activities:
Net income	$	3,448		$	3,068
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		3,960			1,582
Non-cash interest expense		1,036			970
Stock-based compensation expense		2,268			1,531
Deferred tax expense		449			10
Loss on conversion of senior convertible notes		1			—
Loss on disposal of assets		—			59
Changes in assets and liabilities:
Accounts receivable		(1,529	)		(2,415	)
Other receivables		127			172
Inventories		(1,188	)		851
Prepaid expenses and other current assets		(1,608	)		34
Accounts payable		(1,550	)		(452	)
Accrued liabilities		(3,839	)		(4,220	)
Long-term liabilities		(3	)		(43	)

Net cash provided by operating activities		1,572			1,147

Cash flows from investing activities:
Purchases of marketable securities		—			(28	)
Redemptions of marketable securities		—			7,400
Purchases of property, plant and equipment		(1,564	)		(1,295	)

Net cash (used in) provided by investing activities		(1,564	)		6,077

Cash flows from financing activities:
Exercise of stock options		344			1,333
Repayment of senior convertible notes		(11	)		—
Payment of contingent consideration		—			(1,663	)

Net cash provided by (used in) financing activities		333			(330	)

Effect of exchange rate changes on cash and cash equivalents		(224	)		536

Net increase (decrease) in cash and cash equivalents		117			7,430
Cash, cash equivalents and restricted cash, beginning of period		173,759			122,683

Cash, cash equivalents and restricted cash, end of period	$	173,876		$	130,113

Supplemental disclosure of non-cash activities:
Income taxes paid	$	937		$	1,181

Non-cash effect of adoption of ASU 2016-16	$	5,609		$	—

Payment of contingent consideration in common stock	$	—		$	1,062

The accompanying notes are an integral part of these condensed consolidated financial statements.

REPLIGEN CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation

The condensed consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company,” “Repligen” or “we”) in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB (“Repligen Sweden”), Repligen GmbH, Repligen Singapore Pte. Ltd., our former subsidiary, TangenX Technology Corporation (“TangenX,” acquired on December 14, 2016 and merged into the Company as of June 30, 2017) and Spectrum LifeSciences, LLC (“Spectrum,” acquired on August 1, 2017). All significant intercompany accounts and transactions have been eliminated in consolidation.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” (“ASC 606”) which supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The adoption of this ASU included updates as provided under ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date”; ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)”; ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing”; and ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The Company adopted the provisions of ASC 606 using the modified retrospective method effective January 1, 2018. See Note 3 for further discussion of the effects of this standard on the Company’s consolidated financial statements.

In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” This guidance changes how entities measure equity investments that do not result in consolidation and are not accounted for under the equity method. Entities will be required to measure these investments at fair value at the end of each reporting period and recognize changes in fair value in net income. A practicability exception will be available for equity investments that do not have readily determinable fair values; however, the exception requires the Company to consider relevant transactions that can be reasonably known to identify any observable price changes that would impact the fair value. This guidance also changes certain disclosure requirements and other aspects of current U.S. GAAP. The Company adopted this guidance in the first quarter of 2018. Because the Company does not hold any equity securities as of December 31, 2017 and March 31, 2018, adoption of this standard did not have any impact on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability for most leases. Extensive quantitative and qualitative disclosures, including significant judgments made by management, will be required to provide greater insight into the extent of revenue and expense recognized and expected to be recognized from existing contracts. The accounting applied by a lessor is largely unchanged from that applied under the current standard. The standard must be adopted using a modified retrospective transition approach and provides for certain practical expedients. This ASU is effective for public entities for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has not assessed the impact of the new standard on its consolidated financial statements, but does expect this new standard to have a material impact on the Company’s consolidated balance sheet.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 203): Classification of Certain Cash Receipts and Cash Payments”. ASU No. 2016-15 addresses eight specific cash flow issues and clarifies their presentation and classification in the Statement of Cash Flows. This ASU is effective for fiscal years beginning after December 15, 2017 and is to be applied retrospectively with early adoption permitted. The Company has historically classified payments up to the amount of its contingent consideration liability recognized at the date of its acquisition as financing activities, with additional payments classified as operating activities. Because the Company has classified its contingent consideration payments as required by this standard, the adoption of this standard did not have any impact on its consolidated financial statements when applied on a retrospective basis.

In October 2016, the FASB issued ASU 2016-16, “Intra-Entity Transfers of Assets Other Than Inventory.” ASU 2016-16 requires that the income tax consequences of an intra-entity asset transfer other than inventory are recognized at the time of the transfer. An entity will continue to recognize the income tax consequences of an intercompany transfer of inventory when the inventory is sold to a third party. The Company adopted this standard on a modified-retrospective basis on January 1, 2018. See Note 12 for a discussion of the impact of this ASU on the Company’s financial statements.

In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash,” which requires that the statement of cash flows explain the change during the period in the total cash, which is inclusive of cash and cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning of period and end of period balances on the statement of cash flows upon adoption of this standard. The Company adopted this standard on a retrospective basis on January 1, 2018. The adoption resulted in an increase to cash, cash equivalents and restricted cash of $450,000 in the statement of cash flows at December 31, 2016 and March 31, 2017. The Company did not hold any restricted cash at December 31, 2017 or March 31, 2018.

In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business”, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The Company adopted this standard as of January 1, 2018, and the adoption of ASU 2017-01 did not have a material impact on the Company’s consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” eliminating the requirement to calculate the implied fair value, essentially eliminating step two from the goodwill impairment test. ASU No. 2017-04 requires goodwill impairment to be based upon the results of step one of the impairment test, which is defined as the excess of the carrying value of a reporting unit over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The standard is effective for the Company on a prospective basis beginning on January 1, 2020, with early adoption permitted. The Company adopted this standard as of January 1, 2018, and the adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

2. Acquisition of Spectrum LifeSciences, LLC

On August 1, 2017, the Company completed the acquisition of Spectrum pursuant to the terms of an Agreement and Plan of Merger and Reorganization, dated as of June 22, 2017 (such acquisition, the “Spectrum Acquisition”).

Spectrum is a diversified filtration company with a differentiated portfolio of hollow fiber cartridges, bench-top to commercial scale filtration and perfusion systems and a broad portfolio of disposable and single-use solutions. Spectrum’s products are primarily used for the filtration, isolation, purification and concentration of monoclonal antibodies, vaccines, recombinant proteins, diagnostic products and cell therapies where the company offers both standard and customized solutions to its bioprocessing customers.

Spectrum’s filtration products include its KrosFlo^® line of hollow-fiber cartridges, tangential flow filtration (TFF) systems and single-use flow path consumables, as well as its Spectra/Por^® portfolio of laboratory dialysis products and its Pro-Connex^® single-use hollow fiber Module-Bag-Tubing (MBT) sets. Outside of filtration, Spectrum sells its Spectra/Chrom^® liquid chromatography products for research applications. These bioprocessing products account for the majority of Spectrum revenues. Spectrum also offers a line of operating room products.

Consideration Transferred

The Company accounted for the Spectrum Acquisition as a purchase of a business under ASC 805, “Business Combinations.” The Spectrum Acquisition was funded through payment of approximately $122.9 million in cash, 6,153,995 unregistered shares of the Company’s common stock totaling $247.6 million and a working capital adjustment of $425,000 for a total purchase price of $370.9 million. Under the acquisition method of accounting, the assets of Spectrum were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired was approximately $370.9 million.

The estimated consideration and preliminary purchase price information has been prepared using a valuation that required the use of significant assumptions and estimates in its preparation. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable; however, actual results may differ from these estimates.

The total consideration transferred follows (in thousands):


Cash consideration	$	122,932
Equity consideration		247,575
Working capital adjustment		425

Net assets acquired	$	370,932

Acquisition-related costs are not included as a component of consideration transferred, but are expensed in the periods in which the costs are incurred. The Company has incurred $655,000 in costs related to the Spectrum Acquisition for the three-month period ended March 31, 2018 and $7,060,000 in costs for the year ended December 31, 2017. These costs are primarily included in selling, general and administrative expenses in the consolidated statements of operations.

Fair Value of Net Assets Acquired

The allocation of purchase price was based on the fair value of assets acquired and liabilities assumed as of August 1, 2017, based on the preliminary valuation. The components and allocation of the purchase price consists of the following amounts (in thousands):


Cash and cash equivalents	$	10,137
Accounts receivable		5,075
Inventory		13,570
Prepaid expenses and other assets		616
Fixed assets		6,004
Deferred tax assets		1,102
Customer relationships		78,400
Developed technology		38,560
Trademark and tradename		2,160
Non-competition agreements		960
Goodwill		265,654
Accounts payable		(1,335	)
Unrecognized tax benefit		(576	)
Accrued liabilities		(5,787	)
Deferred tax liabilities		(43,608	)

Fair value of net assets acquired	$	370,932

Of the consideration paid, $78.4 million represents the fair value of customer relationships that is amortized over the weighted average determined useful life of 15 years, and $38.6 million represents the fair value of developed technology that is amortized over a determined useful life of 20 years. $960,000 represents the fair value of non-competition agreements that are amortized over a determined life of 3 years. $2.2 million represents the fair value of trademarks and trade names that are determined to have an indefinite useful life. The aforementioned intangible assets are amortized on a straight-line basis.

The goodwill of $265.7 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. None of the goodwill recorded is expected to be deductible for income tax purposes.

The purchase price allocation may be subject to adjustment as purchase accounting is preliminary as of March 31, 2018 related to inventory valuation. The final allocation may include, but not be limited to, changes in allocations to inventory and goodwill.

Revenue, Net Income and Pro Forma Presentation

The Company recorded revenue from Spectrum of $11,719,000 for the three-month period ended March 31, 2018. The Company has included the operating results of Spectrum in its consolidated statements of operations since the August 1, 2017 acquisition date. The following table presents unaudited supplemental pro forma information as if the Spectrum Acquisition had occurred as of January 1, 2017 (in thousands, except per share data):


	Pro-forma Three months ended March 31, 2018		Pro-forma Three months ended March 31, 2017
Total revenue		44,830		39,875
Net income		3,939		3,266
Earnings per share:
Basic	$	0.09	$	0.08

Diluted	$	0.09	$	0.08

The unaudited pro forma information for the three-month period ended March 31, 2018 was calculated after applying the Company’s accounting policies and the impact of acquisition date fair value adjustments. The unaudited pro forma net income for the three-month period ended March 31, 2018 was adjusted to exclude acquisition-related transaction costs, as these expenses would have been incurred in the prior year assuming the Spectrum Acquisition closed on January 1, 2017.

These pro forma condensed consolidated financial results include certain adjustments to reflect the pro forma results of operations as if the acquisition had occurred as of January 1, 2017. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combinations occurred at the beginning of the period presented, or of future results of the consolidated entities.

3. Revenue Recognition

Adoption of ASC Topic 606, Revenue from Contracts with Customers

The Company adopted ASC 606 on January 1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with the practical expedient in paragraph ASC 606-10-65-1-(f)-4, which did not have a material effect on the cumulative impact of adopting ASC 606. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. The impact to the Company’s consolidated financial statements as a result of applying ASC 606 was immaterial. Deferred revenue resulting from contracts with customers is included in accrued expenses on the Company’s consolidated balance sheet.

Revenue Recognition

Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.

When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of March 31, 2018.

Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.

The Company recognizes product revenue under the terms of each customer agreement upon transfer of control to the customer, which occurs at a point in time.

Disaggregation of Revenue

Revenues for the three-month periods ended March 31, 2018 and 2017 were as follows:


	Three months ended March 31,
(in thousands, except percentages)	2018		2017		$ Change		% Change
Product revenue	$	44,799	$	30,569	$	14,230		47	%
Royalty and other revenue		31		21		10		48	%

Total revenue	$	44,830	$	30,590	$	14,240		47	%

When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenues are generated from two customers; therefore, economic factors specific to these two customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows.

The following tables disaggregate the Company’s revenue from contracts with customers by geographic region (in thousands).


	Three months ended March 31, 2018
North America	$	20,239
Europe		19,401
Asia and Pacific		4,947
Other		243

Total revenue	$	44,830

Revenue from significant customers is as follows (in thousands):


	Three months ended March 31, 2018
GE Healthcare	$	7,717
MilliporeSigma	$	6,465

Protein Products

The Company’s protein product line generates revenue through the sale of Protein A ligands, an essential component of Protein A chromatography resins (media) used in the purification of virtually all mAb-based drugs on the market or in development. The Company manufactures multiple forms of Protein A ligands under long term supply agreements with major life sciences companies, who in turn sell their Protein A chromatography media to end users (biopharmaceutical manufacturers). Each protein product is considered distinct and therefore represents a separate performance obligation. Protein product revenue is generally recognized at a point in time upon transfer of control to the customer.

Filtration Products

The Company’s filtration product line generates revenue through the sale of KrosFlo^® hollow-fiber (HF) tangential flow filtration (TFF) membranes and modules, ProConnex^® single-use flow path connectors, flat sheet TFF cassettes and hardware, and XCell™ alternating tangential flow (ATF) devices and related consumables.

The Company markets the KrosFlo line of HF cartridges and TFF systems and the ProConnex line of single-use flow path connectors which were acquired as part of the acquisition of Spectrum in August 2017. These products are used in the filtration, isolation, purification and concentration of biologics and diagnostic products. Sales of large-scale systems generally include components and consumables as well as training and installation services at the request of the customer. Because the initial sale of components and consumables are necessary for the operation of the system, such items are combined with the systems as a single performance obligation. Training and installation services do not significantly modify or customize these systems and therefore represent a distinct performance obligation. Each of the Company’s other product offerings are not highly interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Revenue on these products is generally recognized at a point in time upon transfer of control to the customer. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC 606-10-55-18.

The Company also markets flat sheet TFF cassettes and hardware, which were acquired as part of the acquisition of TangenX Technology in December 2016. TFF is a rapid and efficient method for separation and purification of biomolecules that is widely used in laboratory, process development and process scale applications in biopharmaceutical manufacturing. The Company’s single-use TFF (Sius™ TFF) cassettes and hardware are not highly interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Sius TFF product revenue is generally recognized at a point in time upon transfer of control to the customer.

The Company also markets the XCell™ ATF System, a technologically advanced filtration device used in upstream processes to continuously remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest. ATF Systems typically include a filtration system and consumables (i.e., tube devices, metal stands) as well as training and installation services at the request of the customer. The filtration system and consumables are considered distinct products and therefore represent separate performance obligations. First time purchasers of the systems typically purchase a controller that is shipped with the tube device(s) and metal stand(s). The controller is not considered distinct as it is a proprietary product that is highly interdependent with the filtration system; therefore, the controller is combined with the filtration system and accounted for as a single performance obligation. The training and installation services do not significantly modify or customize the ATF system and therefore represent a distinct performance obligation. ATF system product revenue related to the filtration system (including the controller if applicable) and consumables is generally recognized at a point in time upon transfer of control to the customer. ATF system service revenue related to training and installation services is generally recognized over time, as the customer simultaneously receives and consumes the benefits as the Company performs. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC 606-10-55-18.

Chromatography Products

The Company’s chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The majority of chromatography revenue relates to the OPUS pre-packed chromatography (PPC) column line and Protein A chromatography resins. OPUS columns typically consist of the outer hardware of the column with a resin as ordered by the customer packed inside of the column. OPUS columns may also be ordered without the packed resin. In either scenario, the OPUS column and resin are not interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Chromatography product revenue is generally recognized at a point in time upon transfer of control to the customer.

Other Products

The Company’s other products include ELISA test kits used by quality control departments to detect and measure the presence of leached Protein A and/or growth factor in the final product. Each ELISA kit is considered distinct and therefore represents a separate performance obligation. Other product revenue is generally recognized at a point in time upon transfer of control to the customer.

Transaction Price Allocated to Future Performance Obligations

Remaining performance obligations represents the transaction price of contracts for which work has not been performed or has been partially performed. The Company’s future performance obligations relate primarily to the installation and training of certain of its systems sold to customers. These performance obligations are completed within one year of receipt of a purchase order from its customers. Accordingly, the Company has elected to not disclose the value of these unsatisfied performance obligations as provided under ASC 606-10-50-14.

Contract Balances from Contracts with Customers

The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2018:


	2018
Balances from contracts with customers only:
Accounts receivable	$	29,352
Deferred revenue		1,547
Revenue recognized in the period relating to:
The beginning deferred revenue balance	$	434
Changes in pricing related to products or services satisfied in previous periods		—
Impairment losses on receivables		—

The timing of revenue recognition, billings and cash collections results in accounts receivables and deferred revenue on the Company’s consolidated balance sheets.

A contract asset is created when the Company satisfies a performance obligation by transferring a promised good to the customer. Contract assets may represent conditional or unconditional rights to consideration. The right is conditional, and recorded as a contract asset, if the Company must first satisfy another performance obligation in the contract before it is entitled to payment from the customer. Contract assets are transferred to billed receivables once the right becomes unconditional. If the Company has the unconditional right to receive consideration from the customer, the contract asset is accounted for as a billed receivable and presented separately from other contract assets. A right is unconditional if nothing other than the passage of time is required before payment of that consideration is due.

When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met.

Costs to Obtain or Fulfill a Customer Contract

The Company’s sales commission structure is based on achieving revenue targets. The commissions are driven by revenue derived from customer purchase orders which are short term in nature.

Applying the practical expedient in paragraph 340-40-25-4, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. When shipping and handling costs are incurred after a customer obtains control of the products, the Company accounts for these as costs to fulfill the promise and not as a separate performance obligation.

4. Accumulated Other Comprehensive Income

The following table summarizes the changes in accumulated other comprehensive income by component (in thousands):


(In thousands)	Foreign currency translation gain (loss)
Balance at December 31, 2017	$	(6,363	)
Foreign currency translation gain		251

Balance at March 31, 2018	$	(6,112	)

5. Earnings Per Share

The Company reports earnings per share in accordance with ASC Topic 260, “Earnings Per Share,” which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents then outstanding. Potential common share equivalents consist of restricted stock awards and the incremental common shares issuable upon the exercise of stock options. Under the treasury stock method, unexercised “in-the-money” stock options and warrants are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period. Share-based payment awards that entitle their holders to receive non-forfeitable dividends before vesting are considered participating securities and are considered in the calculation of basic and diluted earnings per share. There were no such participating securities outstanding during the three-month periods ended March 31, 2018 and 2017.

Basic and diluted weighted average shares outstanding were as follows:


	Three months ended March 31,
	2018		2017
Basic weighted average common shares outstanding		43,621,270		33,891,702
Effect of dilutive securities:
Stock options and restricted stock awards		389,702		490,620
Convertible senior notes		315,760		—

Weighted average common shares, assuming dilution		44,326,732		34,382,322

At March 31, 2018, there were outstanding options to purchase 1,109,353 shares of the Company’s common stock at a weighted average exercise price of $25.34 per share and 703,076 restricted stock units. For the three months ended March 31, 2018, 593,874 options to purchase shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive.

At March 31, 2017, there were outstanding options to purchase 805,903 shares of the Company’s common stock at a weighted average exercise price of $19.68 per share and 404,781 restricted stock units. For the three months ended March 31, 2017, 458,685 options to purchase shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive.

As provided by the terms of the indenture underlying the Company’s 2.125% Convertible Senior Notes due 2021 (the “Notes”), the Company has a choice to settle the conversion obligation for the Notes in cash, shares or any combination of the two. The Company currently intends to settle the par value of the Notes in cash and any excess conversion premium in shares. The Company applies the provisions of ASC 260, Earnings Per Share, Subsection 10-45-44, to determine the diluted weighted average shares outstanding as it relates to the conversion spread on its convertible notes. Accordingly, the par value of the Notes will not be included in the calculation of diluted income per share, but the dilutive effect of the conversion premium will be considered in the calculation of diluted net income per share using the treasury stock method. The dilutive impact of the Company’s convertible notes is based on the difference between the Company’s current period average stock price and the conversion price of the convertible notes, provided there is a premium. Pursuant to this accounting standard, there is no dilution from the accreted principal of the Notes as of March 31, 2018 and March 31, 2017.

6. Inventories

Inventories relate to the Company’s bioprocessing business. The Company values inventory at cost or, if lower, market value, using the first-in, first-out method. The Company reviews its inventories at least quarterly and records a provision for excess and obsolete inventory based on its estimates of expected sales volume, production capacity and expiration dates of raw materials, work-in-process and finished products. Expected sales volumes are determined based on supply forecasts provided by key customers for the next 3 to 12 months. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements to cost of product revenue. Manufacturing of bioprocessing finished goods is done to order and tested for quality specifications prior to shipment.

A change in the estimated timing or amount of demand for the Company’s products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. During all periods presented in the accompanying financial statements, there have been no material adjustments related to a revised estimate of inventory valuations.

Work-in-process and finished products inventories consist of material, labor, outside processing costs and manufacturing overhead. Inventories consist of the following (in thousands):


	March 31, 2018		December 31, 2017
Raw Materials	$	21,826	$	22,351
Work-in-process		3,828		4,083
Finished products		14,470		12,570

Total	$	40,124	$	39,004

7. Property, Plant and Equipment

Property, plant and equipment consist of the following (in thousands):


	March 31, 2018			December 31, 2017
Land	$	1,023		$	1,023
Buildings		764			764
Leasehold improvements		15,740			15,673
Equipment		22,497			21,904
Furniture and fixtures		4,605			4,272
Construction in progress		3,052			2,581

Total property, plant and equipment		47,681			46,217
Less: accumulated depreciation		(25,007	)		(23,800	)

Property, plant and equipment, net	$	22,674		$	22,417

Depreciation expense totaled approximately $1,284,000 and $928,000 for the three-month periods ended March 31, 2018 and 2017, respectively.

8. Intangible Assets

Intangible assets are amortized over their useful lives using the straight-line method, as applicable, and the amortization expense is recorded within selling, general and administrative expense in the Company’s statements of comprehensive income.

The Company reviews its indefinite-lived intangible assets not subject to amortization to determine if adverse conditions exist or a change in circumstances exists that would indicate an impairment. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for our products or changes in the size of the market for our products. An impairment results if the carrying value of the asset exceeds the estimated fair value of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its intangible assets are recoverable at March 31, 2018.

Intangible assets consisted of the following at March 31, 2018 (in thousands):


	Gross Carrying Amount		Accumulated Amortization			Weighted Average Useful Life (in years)
Technology – developed	$	51,860	$	(3,898	)		19
Patents		240		(240	)		8
Customer relationships		102,210		(11,446	)		14
Trademark – definite lived		2,160		(75	)		20
Trademark – indefinite lived		700		—			—
Other intangibles		1,066		(304	)		3

Total intangible assets	$	158,236	$	(15,963	)		16

Intangible assets consisted of the following at December 31, 2017 (in thousands):


	Gross Carrying Amount		Accumulated Amortization			Weighted Average Useful Life (in years)
Technology – developed	$	51,801	$	(3,201	)		19
Patents		240		(238	)		8
Customer relationships		102,120		(9,636	)		14
Trademarks – definite lived		2,160		(47	)		20
Trademarks – indefinite lived		700		—			—
Other intangibles		1,063		(209	)		3

Total intangible assets	$	158,084	$	(13,331	)		16

Amortization expense for amortized intangible assets was approximately $2,664,000 and $715,000 for the three-month periods ended March 31, 2018 and 2017, respectively. As of March 31, 2018, the Company expects to record amortization expense as follows (in thousands):


Years Ending	Amortization Expense
December 31, 2018 (nine months remaining)	$	7,978
December 31, 2019		10,513
December 31, 2020		9,910
December 31, 2021		9,395
December 31, 2022		9,395

9. Accrued Liabilities

Accrued liabilities consist of the following (in thousands):


	March 31, 2018		December 31, 2017
Employee compensation	$	5,246	$	9,560
Taxes		2,049		1,668
Royalty and license fees		1,243		1,383
Accrued purchases		521		1,191
Professional fees		827		947
Unearned revenue		1,547		960
Other accrued expenses		2,688		2,220

Total	$	14,121	$	17,929

10. Convertible Senior Notes

The carrying value of the Company’s convertible senior notes is as follows:


	March 31, 2018			December 31, 2017
2.125% Convertible Senior Notes due 2021:
Principal amount	$	114,989		$	115,000
Unamortized debt discount		(12,513	)		(13,395	)
Unamortized debt issuance costs		(2,200	)		(2,355	)

Total convertible senior notes	$	100,276		$	99,250

On May 24, 2016, the Company issued $115 million aggregate principal amount of its Notes. The net proceeds from the sale of the Notes, after deducting the underwriting discounts and commissions and other related offering expenses, were approximately $111.1 million. The Notes bear interest at the rate of 2.125% per annum, payable semiannually in arrears on June 1 and December 1 of each year, beginning December 1, 2016.

The Notes will mature on June 1, 2021, unless earlier repurchased, redeemed or converted in accordance with their terms. Prior to March 1, 2021, the Notes will be convertible at the option of holders of the Notes only upon satisfaction of certain conditions and during certain periods, and thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, holders of the Notes will receive shares of the Company’s common stock, cash or a combination thereof, at the Company’s election. It is the Company’s current intent and policy to settle all conversions through combination settlement, which involves satisfying the principal amount outstanding with cash and any note conversion value over the principal amount in shares of the Company’s common stock.

Notes with a par value of $11,000 were submitted for conversion in the fourth quarter of 2017, and this conversion was settled in the first quarter of 2018. The conversion resulted in the issuance of a nominal amount of shares of the Company’s common stock, and the Company recorded a loss of $1,000 on the conversion of these Notes. The Notes are not convertible as of March 31, 2018 and are classified as long term liabilities on the Company’s consolidated balance sheet as of December 31, 2017.

The conversion rate for the Notes will initially be 31.1813 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $32.07 per common share, and is subject to adjustment under the terms of the Notes. Holders of the Notes may require the Company to repurchase their Notes upon the occurrence of a fundamental change prior to maturity for cash at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest, if any, to, but excluding, the repurchase date.

The Company will not have the right to redeem the Notes prior to June 5, 2019, but may redeem the Notes, at its option, in whole or in part, on any business day on or after June 5, 2019 and prior to the maturity date if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides written notice of redemption. The redemption price will be equal to 100% of the principal amount of the principal amount of Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.

The Notes contain customary terms and events of default. If an event of default (other than certain events of bankruptcy, insolvency or reorganization involving the Company) occurs and is continuing, the holders of at least 25% in aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and any accrued and unpaid interest on, all of the Notes to be due and payable. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving the Company, 100% of the principal of and accrued and unpaid interest, if any, on all of the Notes will become due and payable automatically. Notwithstanding the foregoing, the Notes provide that, to the extent the Company elects and for up to 270 days, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants consist exclusively of the right to receive additional interest on the Notes. The Company is not aware of any events of default, current events or market conditions that would allow holders to call or convert the Notes as of March 31, 2018.

The cash conversion feature of the Notes required bifurcation from the Notes and was initially accounted for as an equity instrument classified to stockholders’ equity, as the conversion feature was determined to be clearly and closely related to the Company’s stock. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry and asset base and with similar maturity, the Company estimated the implied interest rate, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market interest rates, credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Notes, which resulted in a fair value of the liability component of $96,289,000 upon issuance, calculated as the present value of implied future payments based on the $115 million aggregate principal amount. The equity component of the Notes was recognized as a debt discount, recorded in additional paid-in capital, and represents the difference between the aggregate principal of the Notes and the fair value of the Notes without conversion option on their issuance date. The debt discount is amortized to interest expense using the effective interest method over five years, or the life of the Notes. The Company assesses the equity classification of the cash conversion feature quarterly, and it is not remeasured as long as it continues to meet the conditions for equity classification.

Interest expense recognized on the Notes during the three-month period ended March 31, 2018 includes $611,000, $881,000 and $155,000 for the contractual coupon interest, the accretion of the debt discount and the amortization of the debt issuance costs, respectively. The effective interest rate on the Notes is 6.6%, which includes the interest on the Notes, amortization of the debt discount and debt issuance costs. As of March 31, 2018, the carrying value of the Notes was approximately $100.3 million and the fair value of the principal was approximately $150.5 million. The fair value of the Notes was determined based on the most recent trade activity of the Notes as of March 31, 2018.

11. Stock-Based Compensation

For the three-month periods ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense of approximately $2,268,000 and $1,531,000, respectively, for share-based awards granted under the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the “2001 Plan”) and the Repligen Corporation Amended and Restated 2012 Stock Option and Incentive Plan (the “2012 Plan,” and together with the 2001 Plan, the “Plans”).

The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (in thousands):


	Three Months Ended March 31,
	2018		2017
Cost of product revenue	$	266	$	141
Research and development		170		132
Selling, general and administrative		1,832		1,258

Total	$	2,268	$	1,531

The 2012 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock and other equity awards. Employee grants under the Plans generally vest over a three- to five-year period, with 20%-33% vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to non-employee directors under the Plans generally vest over one year. In the first quarter of 2018, to create a longer term retention incentive, the Company’s Compensation Committee granted long term incentive compensation awards to its chief executive officer consisting of both stock options and restricted stock units that are subject to time-based vesting over nine years. Options granted under the Plans have a maximum term of ten years from the date of grant and generally, the exercise price of the stock options equals the fair market value of the Company’s common stock on the date of grant. At March 31, 2018, options to purchase 1,109,353 shares and 703,076 restricted stock units were outstanding under the Plans. At March 31, 2018, 254,907 shares were available for future grant under the 2012 Plan.

The Company uses the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date, and the Company uses the value of the common stock as of the grant date to value restricted stock units. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award. The Company recognizes expense on awards with service based vesting over the employee’s requisite service period on a straight-line basis. In the third quarter of 2017, the Company issued performance stock units to certain individuals related to the Spectrum Acquisition which are tied to the achievement of certain revenue and gross margin metrics and the passage of time. The Company recognizes expense on performance based awards over the vesting period based on the probability that the performance metrics will be achieved. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures.

Information regarding option activity for the three-month period ended March 31, 2018 under the Plans is summarized below:


	Options Outstanding			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		(in thousands) Aggregate Intrinsic Value
Options outstanding at December 31, 2017		734,940		$	20.80
Granted		398,532			33.85
Exercised		(14,531	)		23.70
Forfeited/cancelled		(9,588	)		29.71

Options outstanding at March 31, 2018		1,109,353		$	25.34		7.51	$	12,176

Options exercisable at March 31, 2018		499,504		$	17.73		5.50	$	9,300

Vested and expected to vest at March 31, 2018 (1)		1,057,255		$	24.96		7.40	$	12,015

⁽¹⁾

Represents the number of vested options as of March 31, 2018 plus the number of unvested options expected to vest as of March 31, 2018 based on the unvested outstanding options at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on March 31, 2018 of $36.18 per share and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on March 31, 2018.

The weighted average grant date fair value of options granted during the three-month periods ended March 31, 2018 and 2017 was $18.27 and $16.46, respectively. The total fair value of stock options that vested during the three-month periods ended March 31, 2018 and 2017 was approximately $1,339,000 and $1,195,000, respectively.

Information regarding restricted stock unit and performance stock unit activity for the three-month period ended March 31, 2018 under the Plans is summarized below:


	Units Outstanding			Weighted- Average Remaining Contractual Term (in years)		(in thousands) Aggregate Intrinsic Value
Restricted and performance stock units outstanding at December 31, 2017		505,235
Granted		319,701
Exercised		(90,691	)
Forfeited/cancelled		(31,169	)

Restricted stock units outstanding at March 31, 2018		703,076			4.06	$	25,437

Vested and expected to vest at March 31, 2018 (1)		639,530			3.75	$	23,138

⁽¹⁾

Represents the number of vested restricted stock units as of March 31, 2018 plus the number of unvested restricted stock units expected to vest as of March 31, 2018 based on the unvested outstanding restricted stock units at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (equal to the closing price of the common stock on March 31, 2018 of $36.18 per share) that would have been received by the restricted stock unit holders had all restricted stock units vested on March 31, 2018. The aggregate intrinsic value of restricted stock units vested during the three-month periods ended March 31, 2018 and 2017 was approximately $3,224,000 and $2,064,000, respectively.

The weighted average grant date fair value of restricted stock units granted during the three-month periods ended March 31, 2018 and 2017 was $33.80 and $32.18, respectively. The total grant date fair value of restricted stock units that vested during the three-month periods ended March 31, 2018 and 2017 was approximately $2,619,000 and $1,616,000, respectively.

As of March 31, 2018, there was $30,762,000 of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 4.66 years.

12. Income Taxes

The Company’s effective tax rate for the three-month period ended March 31, 2018 was 24.7% compared to 24.6% for the corresponding period in the prior year. The effective tax rate for the three-month period ended March 31, 2018 was higher than the U.S. statutory tax rate of 21% due to state tax effects and the impact of the Global Intangible Low-Taxed Income (“GILTI”) tax enacted as part of the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017. The effective tax rate for the three-month period ended March 31, 2017 was lower than the U.S. statutory tax rate of 34% mainly due to lower statutory tax rates in foreign jurisdictions.

ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized when the intra-entity transfer occurs rather than deferring recognition of income tax consequences until the transfer was made with an outside party. The Company adopted the provisions of this ASU in the first quarter of 2018. The adoption resulted in a decrease of $5,609,000 to other assets, a decrease of $4,932,000 to deferred tax liabilities and a decrease of $677,000 to accumulated deficit at January 1, 2018.

At December 31, 2017, the Company had net operating loss carryforwards of approximately $19,652,000 in the U.S., net operating loss carryforwards of approximately €603,000 (approximately $743,000) in Germany, federal business tax credit carryforwards of $297,000 and state business tax credit carryforwards of approximately $99,000 available to reduce future domestic income taxes, if any. The net operating loss and business tax credits carryforwards will continue to expire at various dates through December 2037. The net operating loss and business tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. While an IRC Section 382 study was completed in the second quarter of 2017, and no current limitations were identified, use of these net operating loss and business tax credit carryforwards may be limited in the future based on certain changes in the ownership interest of significant stockholders.

On December 22, 2017, the Act was signed into law. The Act made significant changes to federal tax law, including, but not limited to, a reduction in the federal income tax rate from 35% to 21%, taxation of certain global intangible low-taxed income, allowing for immediate expensing of qualified assets, stricter limits on deductions for interest and certain executive compensation, and a one-time transition tax on previously deferred earnings of certain foreign subsidiaries. Due to the complexities involved in accounting for the enactment of the Act, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”), which allows a registrant to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Under the SAB 118 guidance, we have determined that our accounting for the following items is incomplete where noted, we are able to make reasonable estimates for certain effects of tax reform and therefore have recorded provisional amounts.

The Act lowered the Company’s U.S. statutory federal tax rate from 35% to 21% effective January 1, 2018. The Company recorded a tax benefit of $12,812,000 in the year ended December 31, 2017 for the reduction in its US deferred tax assets and liabilities resulting from the rate change.

The Act also includes a one-time deemed repatriation transition tax whereby entities that are shareholders of a specified foreign corporation must include in gross income the undistributed and previously untaxed post-1986 earnings and profits of the specified foreign corporation. The provisional amount recorded at December 31, 2017 increased the Company’s tax provision by $3,266,000. This amount may change as the Company refines its calculations of post-1986 earnings and profits for our foreign subsidiaries, as well as the amounts held in cash.

The Company anticipates that future guidance and interpretations with the respect to the Act will cause the Company to further adjust its provisional amounts recorded as of December 31, 2017. No further adjustments have been made to these provisional amounts in the first quarter of 2018. Any measurement period adjustments will be reported as a component of provision for income taxes in the reporting period the amounts are determined. The final accounting will be completed no later than one year from the enactment of the Act.

The Company’s tax returns are subject to examination by federal, state and international taxing authorities for the following periods:


Jurisdiction		Fiscal years subject to examination
United States – federal and state		2014-2017
Sweden		2011-2017
Germany		2017
Netherlands		2012-2017

13. Fair Value Measurement

In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:


Level 1–		Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access

Level 2–		Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly

Level 3–		Valuations based on inputs that are unobservable and significant to the overall fair value measurement

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.

The Company’s fixed income investments have historically comprised of obligations of U.S. government agencies and corporate marketable securities. These investments have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. At least annually, the Company validates applicable prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active.

As of March 31, 2018 and December 31, 2017, the Company had no assets or liabilities for which fair value measurement is either required or has been elected to be applied.

In May 2016, the Company issued $115 million aggregate principal amount of the Notes due June 1, 2021. Interest is payable semi-annually in arrears on June 1 and December 1 of each year, beginning December 1, 2016. As of March 31, 2018, the carrying value of the Notes was approximately $100.3 million, net of unamortized discount, and the fair value of the Notes was approximately $150.5 million. The fair value of the Notes was determined based on the most recent trade activity of the Notes as of March 31, 2018. These valuations are Level 1 valuations, as the valuations are based on unadjusted quoted prices in active markets that the Company has the ability to access. The Notes are discussed in more detail in Note 10, “Long Term Debt.”

There were no re-measurements to fair value during the three months ended March 31, 2018 of financial assets and liabilities that are not measured at fair value on a recurring basis.

14. Commitments and Contingencies

The Company leases its headquarters in Waltham, Massachusetts as well as certain of its office and manufacturing space around the world.

In February 2018, the Company entered into an agreement to lease 63,761 square feet of office and manufacturing space in Marlborough, Massachusetts from U.S. REIF 111 Locke Drive Massachusetts, LLC (the “Premises”).

The lease commences during the second quarter of 2018 (the “Commencement Date”) and shall continue for a period of 126 consecutive months, unless earlier terminated in accordance with the terms of the lease (the “Lease Term”). Under the lease, the Company has the option to extend the Lease Term for two additional five-year periods.

Fixed rent with respect to 40,000 square feet of the Premises only shall commence on the Commencement Date, and rent for the full 63,761 square feet of the Premises shall begin 19 months following the Commencement Date. Under the terms of the lease, the Company has provided a letter of credit of approximately $163,000 as a security deposit and is required to pay its pro rata share of any building operating expenses and real estate taxes.

Future minimum rental commitments under the Company’s leases as of March 31, 2018 are as follows (in thousands):


	Minimum Rental Commitments
2018 (nine months remaining)	$	3,191
2019		3,808
2020		3,653
2021		3,342
2022		1,968
Thereafter		4,401

15. Related Party Transactions

Certain facilities leased by Spectrum are owned by the former owner of Spectrum, who currently holds greater than 10% of the Company’s outstanding common stock. The lease amounts paid to this shareholder were negotiated in connection with the Spectrum Acquisition. The Company has incurred rent expense totaling $201,000 for the three-month period ended March 31, 2018 related to these leases.

16. Segment Reporting

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment. As a result, the financial information disclosed herein represents all of the material financial information related to the Company’s sole operating segment.

The following table represents the Company’s total revenue by geographic area (based on the location of the customer):


	Three months ended March 31,
	2018			2017
North America		45	%		38	%
Europe		43	%		54	%
Asia and Australia		11	%		8	%
Other		1	%		—

Total		100	%		100	%

Revenue from significant customers as a percentage of the Company’s total revenue is as follows:


	Three months ended March 31,
	2018			2017
GE Healthcare		17	%		27	%
MilliporeSigma		14	%		21	%

Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable are as follows:


	March 31, 2018			December 31, 2017
GE Healthcare		19	%		11	%
MilliporeSigma		20	%		19	%

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Repligen and its subsidiaries, collectively doing business as Repligen Corporation (“Repligen”, “we”, “our”, or “the Company”) is a leading provider of advanced bioprocessing technology and solutions used in the process of manufacturing biologic drugs. Our products are made to substantially increase biopharmaceutical manufacturing efficiencies and flexibility. As the global biologics market continues to experience strong growth and expansion, our customers – primarily large biopharmaceutical companies and contract manufacturing organizations – face critical production cost, capacity, quality and time pressures that our products are made to address. Our commitment to bioprocessing is helping to set new standards for the way our customers manufacture biologic drugs – monoclonal antibodies, recombinant proteins, vaccines and gene therapies. We are dedicated to inspiring advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.

Prior to 2012, the Company was focused on drug development, with clinical trial costs supported by bioprocessing product sales. At that time our bioprocessing business was largely represented by sales of Protein A ligands, which we sell through long term original equipment manufacturer (OEM) supply agreements. Our 2011 acquisition of Novozymes Biopharma Sweden AB further expanded our proteins product portfolio and provided impetus to set a new direction for the company. By mid-2012, we permanently discontinued and have since divested all drug development programs. We retained our proteins OEM business and, through internal innovation and strategic acquisitions, we have built chromatography and filtration product offerings that we sell direct to biologics manufacturers. We continue to seek out strategic opportunities to strengthen and expand our bioprocessing business.

We currently operate as one bioprocessing business, with a comprehensive suite of products to serve both upstream and downstream processes in biologic drug manufacturing. Building on over 35 years of industry expertise, we have developed a broad and diversified product portfolio that reflects our commitment to build a best-in-class bioprocessing technology company with a world-class direct sales and commercial organization. Our OEM Protein products are represented by our Protein A ligands and cell culture growth factor products. Our direct-to customer Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs, including our OPUS pre-packed chromatography column line, chromatography resins and ELISA test kits. Our direct-to-customer Filtration product line includes our XCell™ ATF system for use in upstream process intensification, our Sius™ TFF cassettes for use in downstream purification and formulation processes, our KrosFlo^®line of hollow-fiber cartridges and TFF systems, and our ProConnex^® single-use tubing sets. With the addition of Spectrum LifeSciences LLC in August 2017 (the “Spectrum Acquisition”), we now in-house manufacture hollow-fiber filters that can be used in our XCell ATF system and have increased our direct sales presence in Europe and Asia, while diversifying our end markets beyond monoclonal antibodies to include vaccines, recombinant protein and gene therapies.

Critical Accounting Policies and Estimates

A “critical accounting policy” is one which is both important to the portrayal of our financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For additional information, please see the discussion of our critical accounting policies in Management’s Discussion and Analysis of Financial Condition and Results of Operations and our significant accounting policies in Note 2 to the Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.

Results of Operations

Revenues

Revenues for the three-month periods ended March 31, 2018 and 2017 were as follows:


	Three months ended March 31,
(in thousands, except percentages)	2018		2017		$ Change		% Change
Product revenue	$	44,799	$	30,569	$	14,230		47	%
Royalty and other revenue		31		21		10		48	%

Total revenue	$	44,830	$	30,590	$	14,240		47	%

Sales of bioprocessing products for the three months ended March 31, 2018 and 2017 were $44,799,000 and $30,569,000, respectively, representing an increase of $14,230,000, or 47%. This increase was primarily due to continued adoption of our products by our key bioprocessing customers and, for the first quarter of 2018, the addition of revenues following the Spectrum Acquisition. Sales of our bioprocessing products are impacted by the timing of orders, development efforts at our customers or end-users and regulatory approvals for biologics that incorporate our products, which may result in significant quarterly fluctuations. Such quarterly fluctuations are expected, but they may not be predictive of future revenue or otherwise indicate a trend.

Costs and operating expenses

Total costs and operating expenses for the three-month periods ended March 31, 2018 and 2017 were comprised of the following:


	Three months ended March 31,
(in thousands, except percentages)	2018		2017		$ Change		% Change
Cost of product revenue	$	19,668	$	13,990	$	5,678		41	%
Research and development		3,288		1,742		1,546		89	%
Selling, general and administrative		15,898		9,182		6,716		73	%

Total costs and operating expenses	$	38,854	$	24,914	$	13,940		56	%

Cost of product revenue was approximately $19,668,000 and $13,990,000 for the three-month periods ended March 31, 2018 and 2017, respectively, an increase of $5,678,000, or 41%. This increase is primarily due to the increased product revenue noted above. Gross margins may fluctuate over the remainder of 2018 based on expected production volume and shipments and product mix.

Research and development expenses were approximately $3,288,000 and $1,742,000 for the three-month periods ended March 31, 2018 and 2017, respectively, an increase of $1,546,000, or 89%. This increase is related to product development activities acquired as part of the Spectrum Acquisition and increased activity on our various bioprocessing product development projects. Expenses generally include personnel costs, external development costs, supplies and other expenses related to our new products in development.

Selling, general and administrative expenses were approximately $15,898,000 and $9,182,000 for the three-month periods ended March 31, 2018 and 2017, respectively, an increase of $6,716,000, or 73%. This increase is due to selling and administrative activities incurred following the Spectrum Acquisition, as well as the continued buildout of our administrative infrastructure to support future growth and continued expansion of our customer-facing activities to drive sales of our bioprocessing products.

Investment income

Investment income for the three-month periods ended March 31, 2018 and 2017 was as follows:


	Three months ended March 31,
(in thousands, except percentages)	2018		2017		$ Change		% Change
Investment income	$	181	$	96	$	85		89	%

Investment income includes income earned on invested cash balances. The increase in investment income in the first quarter of 2018 over the prior year period is attributable to higher average invested cash balances and higher interest rates on such cash balances.

Interest expense

Interest expense for the three-month periods ended March 31, 2018 and 2017 was as follows:


	Three months ended March 31,
(in thousands, except percentages)	2018			2017			$ Change			% Change
Interest expense	$	(1,652	)	$	(1,585	)	$	(67	)		(4	%)

Interest expense in the three-month periods ended March 31, 2018 and 2017 is attributable to interest on our convertible senior notes issued in May 2016.

Other income (expense)

Other expense for the three-month periods ended March 31, 2018 and 2017 was as follows:


	Three months ended March 31,
(in thousands, except percentages)	2018		2017			$ Change		% Change
Other expense	$	71	$	(120	)	$	191		159	%

Other income was approximately $71,000 and other expense was approximately ($120,000) for the three-month periods ended March 31, 2018 and 2017, respectively. Other income (expense) in each period was primarily attributable to foreign currency gains (losses) on cash balances denominated in U.S. dollars and British pounds held and subsequently converted to local currency holdings by Repligen Sweden.

Provision for income taxes

Provision for income taxes for the three-month periods ended March 31, 2018 and 2017 was as follows:


	Three months ended March 31,
(in thousands, except percentages)	2018		2017		$ Change		% Change
Income tax provision	$	1,128	$	999	$	129		13	%

For the three months ended March 31, 2018, we had income before taxes of $4,576,000 and recorded a tax provision of $1,128,000 for an effective tax rate of 24.7%. The effective income tax rate is based upon the estimated income for the year and the composition of the income in different jurisdictions. The effective tax rate is higher the U.S. statutory tax rate of 21% due to state tax effects and the impact of the Global Intangible Low-Taxed Income (“GILTI”) tax enacted as part of the Tax Cuts and Jobs Act enacted in December 2017. For the three months ended March 31, 2017, we had income before taxes of $4,067,000 and recorded a tax provision of $999,000 for an effective tax rate of approximately 24.6%. The effective tax rate differs from the U.S. statutory tax rate primarily due to lower statutory tax rates in foreign jurisdictions.

Non-GAAP Financial Measures

We provide non-GAAP adjusted income from operations; adjusted net income; and adjusted EBITDA as supplemental measures to GAAP measures regarding our operating performance. These financial measures exclude the items detailed below and, therefore, have not been calculated in accordance with GAAP. A detailed explanation and a reconciliation of each non-GAAP financial measure to its most comparable GAAP financial measure is provided below.

We include this financial information because we believe these measures provide a more accurate comparison of our financial results between periods and more accurately reflect how management reviews its financial results. We excluded the impact of certain acquisition-related items because we believe that the resulting charges do not accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Adjusted Income from Operations

Adjusted income from operations is measured by taking income from operations as reported in accordance with GAAP and excluding acquisition and integration costs, amortization of intangible assets and inventory step-up charges booked through our consolidated statements of comprehensive income. The following is a reconciliation of income from operations in accordance with GAAP to adjusted income from operations for the three-month periods ended March 31, 2018 and 2017 (in thousands):


	Three Months Ended March 31,
	2018		2017
GAAP income from operations	$	5,976	$	5,676
Adjustments to income from operations:
Acquisition and integration costs		655		402
Intangible amortization		2,664		715
Inventory step-up charges		—		224

Adjusted income from operations	$	9,295	$	7,017

Adjusted Net Income

Adjusted net income is measured by taking net income as reported in accordance with GAAP and excluding acquisition and integration costs and related tax effects, amortization of intangible assets and related tax effects, inventory step-up charges and non-cash interest expense booked through our consolidated statements of comprehensive income. The following is a reconciliation of net income in accordance with GAAP to adjusted net income for the three-month periods ended March 31, 2018 and 2017:


	Three Months Ended March 31,
	2018						2017
	(in thousands) Amount			Fully Diluted Earnings per Share			(in thousands) Amount			Fully Diluted Earnings per Share
GAAP net income	$	3,448		$	0.08		$	3,068		$	0.09
Adjustments to net income:
Acquisition and integration costs		655			0.01			402			0.01
Intangible amortization		2,664			0.06			715			0.02
Inventory step-up charges		—			—			224			0.01
Non-cash interest expense		1,036			0.02			970			0.03
Tax effect of intangible amortization and acquisition costs		(271	)		(0.01	)		(101	)		(0.00	)

Adjusted net income	$	7,532		$	0.17		$	5,278		$	0.15

Per share totals may not add due to rounding.

Adjusted EBITDA

Adjusted EBITDA is measured by taking net income as reported in accordance with GAAP, excluding investment income, interest expense, taxes, depreciation and amortization, and excluding acquisition and integration costs and inventory step-up charges booked through our consolidated statements of comprehensive income. The following is a reconciliation of net income in accordance with GAAP to adjusted EBITDA for the three-month periods ended March 31, 2018 and 2017 (in thousands):


	Three Months Ended March 31,
	2018			2017
GAAP net income	$	3,448		$	3,068
Adjustments to net income:
Investment income		(181	)		(96	)
Interest expense		1,652			1,585
Tax provision		1,128			999
Depreciation		1,284			928
Amortization		2,664			715

EBITDA		9,995			7,199
Other adjustments:
Acquisition and integration costs		655			402
Inventory step-up charges		—			224

Adjusted EBITDA	$	10,650		$	7,825

Liquidity and Capital Resources

We have financed our operations primarily through revenues derived from product sales, research grants, proceeds and royalties from license arrangements, a litigation settlement, sales of equity securities and issuance of convertible debt. Our revenue for the foreseeable future will primarily be limited to our bioprocessing product revenue.

At March 31, 2018, we had cash and cash equivalents of $173,876,000 compared to cash and cash equivalents of $173,759,000 at December 31, 2017.

Operating activities

For the three-month period ended March 31, 2018, our operating activities provided cash of $1,572,000 reflecting net income of $3,448,000 and non-cash charges totaling $7,714,000 primarily related to depreciation, amortization, non-cash interest expense, deferred tax expense and stock-based compensation charges. An increase in accounts receivable consumed $1,529,000 of cash, and was primarily driven by the 46% quarter over quarter increase in revenues. Payments of accounts payable and accrued liabilities consumed $5,389,000 of cash, and were mainly due to the timing of payments of payables and payment of 2017 incentive compensation programs. The remaining cash flow used in operations resulted from net unfavorable changes in various other working capital accounts.

For the three-month period ended March 31, 2017, our operating activities provided cash of $1,147,000 reflecting net income of $3,068,000 and non-cash charges totaling $4,152,000 primarily related to depreciation, amortization, non-cash interest expense and stock-based compensation charges. An increase in accounts receivable consumed $2,415,000 of cash, and was primarily due to the 22% quarter over quarter increase in revenues. A decrease in accounts payable consumed $452,000 of cash, which was primarily due to the timing of purchases and payments to vendors. Payments of accrued liabilities consumed $4,220,000 of cash, and were mainly due to the payment of contingent consideration to Refine Technology and Atoll GmbH related to 2016 sales milestones. The remaining cash flow used in operations resulted from net favorable changes in various other working capital accounts.

Investing activities

Our investing activities consumed $1,564,000 of cash related to capital expenditures for the three-month period ended March 31, 2018. Our investing activities provided $6,077,000 for the three-month period ended March 31, 2017, primarily due to net redemptions of marketable securities of $7,372,000 offset by $1,295,000 used for fixed asset additions.

Financing activities

For the three-month period ended March 31, 2018, our financing activities provided $333,000 of cash. We received proceeds of $344,000 from stock option exercises, partially offset by cash outlays of $11,000 related to the conversion of certain senior convertible notes in the first quarter of 2018. For the three-month period ended March 31, 2017, our financing activities used $330,000 of cash. We made contingent consideration payments of $1,663,000 related to the initial valuation of the likelihood that the 2016 XCell™ ATF sales milestones and Atoll revenue growth milestones would be achieved. These payments were partially offset by proceeds from stock option exercises totaling $1,333,000.

We do not currently use derivative financial instruments.

Working capital increased by approximately $10,430,000 to $228,001,000 at March 31, 2018 from $217,571,000 at December 31, 2017 due to the various changes noted above.

Our future capital requirements will depend on many factors, including the following:

•

the expansion of our bioprocessing business;

•

our identification and execution of strategic acquisitions or business combinations;

•

the ability to sustain sales and profits of our bioprocessing products;

•

market acceptance of our new products;

•

our ability to acquire additional bioprocessing products;

•

the resources required to successfully integrate our recently acquired businesses and recognize expected synergies;

•

the scope of and progress made in our research and development activities;

•

the extent of any share repurchase activity;

•

the election of any Note holders to convert their Notes during an eligible period; and

•

the success of any proposed financing efforts.

Absent acquisitions of additional businesses, products, product candidates or intellectual property, we believe our current cash balances are adequate to meet our cash needs for at least twelve months from the date of this filing. We expect operating expenses to increase as we integrate Spectrum into our business, continue to develop and expand our bioprocessing product lines and expand our commercial capabilities for the foreseeable future. Our future capital requirements may include, but are not limited to, purchases of property, plant and equipment, the acquisition of additional bioprocessing products and technologies to complement our existing manufacturing capabilities, continued investment in our intellectual property portfolio and future repayment of convertible debt.

We plan to continue to invest in our bioprocessing business and in key research and development activities associated with the development of new bioprocessing products. We actively evaluate various strategic transactions on an ongoing basis, including monetizing existing assets and licensing or acquiring complementary products, technologies or businesses that would complement our existing portfolio of development programs. We continue to seek to acquire such potential assets that may offer us the best opportunity to create value for our shareholders. In order to acquire such assets, we may need to seek additional financing to fund these investments. This may require the issuance or sale of additional equity or debt securities. The sale of additional equity may result in additional dilution to our stockholders. Should we need to secure additional financing to acquire a product, fund future investment in research and development, or meet our future liquidity requirements, we may not be able to secure such financing, or obtain such financing on favorable terms because of the volatile nature of the biotechnology marketplace.

Off-Balance Sheet Arrangements

We do not have any special purpose entities or off-balance sheet financing arrangements as of March 31, 2018.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements in this Quarterly Report on Form 10-Q do not constitute guarantees of future performance. Investors are cautioned that statements in this Quarterly Report on Form 10-Q which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance

and position, potential impairment of future earnings, management’s strategy, plans and objectives for future operations or acquisitions, product development and sales, product candidate research, development and regulatory approval, selling, general and administrative expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources and financing plans constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative or supply relationships, including our agreements with BioMarin, GE Healthcare and MilliporeSigma, our ability to successfully grow our bioprocessing business, including as a result of acquisitions, commercialization or partnership opportunities, and our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our patent and other intellectual property rights, the risk of litigation with collaborative partners, our limited manufacturing capabilities and our dependence on third-party manufacturers and value-added resellers, our ability to hire and retain skilled personnel, the market acceptance of our products, reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition, our ability to compete with larger, better financed life sciences companies, our history of losses and expectation of incurring losses, our ability to generate future revenues, our ability to successfully integrate our recently acquired businesses, our ability to raise additional capital to fund potential acquisitions, our volatile stock price, and the effects of our anti-takeover provisions. Further information on potential risk factors that could affect our financial results are included in the filings made by us from time to time with the Securities and Exchange Commission including under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest rate risk

We have historically invested funds in U.S. Government and agency securities. As a result, we have been exposed to potential loss from market risks that may occur as a result of changes in interest rates, changes in credit quality of the issuer or otherwise. As of March 31, 2018, we do not have any such investments; however, we may seek to invest funds in similar investment vehicles in the future, as specified in our investment policy guidelines. Our investment policy limits the amount of our credit exposure to any one issuer, (with the exception of U.S. government and agency securities) and type of instrument.

Foreign exchange risk

The reporting currency of the Company is U.S. dollars, and the functional currency of each of our foreign subsidiaries is its respective local currency. Our foreign currency exposures include the Swedish kronor, Euro, British pound, Chinese yuan, Japanese yen, Singapore dollar, South Korean won and Indian rupee; of these, the primary foreign currency exposures are the Swedish kronor, Euro and British pound. Exchange gains or losses resulting from the translation between the transactional currency and the functional currency are included in net income. Fluctuations in exchange rates may adversely affect our results of operations, financial position and cash flows. We currently do not seek to hedge this exposure to fluctuations in exchange rates.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company’s management, with the participation of the principal executive officer and the principal financial officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report. Based on such evaluation, the principal executive officer and principal financial officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, on a timely basis, and is accumulated and communicated to the Company’s management, including the Company’s principal executive officer and the Company’s principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control

We acquired Spectrum LifeSciences, LLC (“Spectrum”) in August 2017. The financial results of Spectrum are included in our consolidated financial statements as of and for the three-month period ended March 31, 2018. Spectrum represented approximately $35,159,000 of our total assets as of March 31, 2018 and $11,719,000 of revenues for the three-month period ended March 31, 2018. As this acquisition occurred during the second half of 2017, the scope of our assessment of our internal control over financial

reporting does not include Spectrum. This exclusion is in accordance with the SEC’s general guidance that an assessment of a recently acquired business may be omitted from our scope in the year of acquisition. We are actively reviewing and updating Spectrum’s internal control procedures, and management will report on Spectrum’s internal controls in its report on internal control over financial reporting as of and for the year ended December 31, 2018.

Effective January 1, 2018, we adopted the provisions of ASC 606, “Revenue from Contracts with Customers.” As part of the adoption of this standard, we reviewed our control procedures and have modified certain of our processes to ensure compliance with the new standard.

Other than the foregoing, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

ITEM 1A. RISK FACTORS

The matters discussed in this Quarterly Report on Form 10-Q include forward-looking statements that involve risks or uncertainties. These statements are neither promises nor guarantees, but are based on various assumptions by management regarding future circumstances, over many of which Repligen has little or no control. A number of important risks and uncertainties, including those identified under the caption “Risk Factors” in Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2017 and subsequent filings, could cause our actual results to differ materially from those in the forward-looking statements. There are no material changes to the Risk Factors described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

(a) Exhibits


Exhibit Number		Document Description

3.1		Restated Certificate of Incorporation, dated September 30, 1992 and amended September 17, 1999 (filed as Exhibit 3.1 to Repligen Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 1999 and incorporated herein by reference).

3.2		Certificate of Amendment to the Certificate of Incorporation of Repligen Corporation, effective as of May 16, 2014 (filed as Exhibit 3.1 to Repligen Corporation’s Current Report on Form 8-K filed on May 19, 2014 and incorporated herein by reference).

3.3		Second Amended and Restated Bylaws (filed as Exhibit 3.1 to Repligen Corporation’s Current Report on Form 8-K filed on May 23, 2017 and incorporated herein by reference).

10.1		Lease Agreement, dated February 6, 2018, by and between Repligen Corporation and U.S. REIF III Locke Drive Massachusetts, LLC (filed as Exhibit 10.1 to Repligen Corporation’s Current Report on Form 8-K filed on February 8, 2018 and incorporated herein by reference).

10.2+#		Amendment No. 4 to Strategic Supplier Alliance Agreement, dated February 20, 2018, by and between Repligen Sweden AB and GE Healthcare Bio-Sciences AB.


Exhibit Number		Document Description

10.3 +		Repligen Corporation Amended and Restated Non-Employee Directors’ Deferred Compensation Plan.

31.1 +		Rule 13a-14(a)/15d-14(a) Certification.

31.2 +		Rule 13a-14(a)/15d-14(a) Certification.

32.1 *		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101 +		The following materials from Repligen Corporation on Form 10-Q for the quarterly period ended March 31, 2018, formatted in Extensible Business Reporting Language (xBRL): (i) Condensed Consolidated Statements of Comprehensive Income (Loss), (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.

+	Filed herewith.

*	Furnished herewith.

#	Confidential treatment has been requested for portions of the exhibit and is pending clearance with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	REPLIGEN CORPORATION

Date: May 8, 2018	By:	/S/ TONY J. HUNT
		Tony J. Hunt
		President and Chief Executive Officer
		(Principal executive officer)
		Repligen Corporation

Date: May 8, 2018	By:	/S/ JON SNODGRES
		Jon Snodgres
		Chief Financial Officer
		(Principal financial officer)
		Repligen Corporation

EX-10.2 2 d574491dex102.htm EX-10.2 EX-10.2


		Exhibit 10.2

AMENDMENT NO. 4 TO STRATEGIC SUPPLIER ALLIANCE AGREEMENT

This Amendment No. 4 (the “Fourth Amendment”) to the certain Strategic Supplier Alliance Agreement dated as of July 7, 2011 (the “Supplier Agreement”) by and between Repligen Sweden AB, formerly known as Novozymes Biopharma AB, (the “Supplier”) a company organized under the laws of Sweden and a wholly owned subsidiary of Repligen Corporation (“Repligen”) and GE Healthcare Bio-Sciences AB, a company organized under the laws of Sweden (“GEHC”) is made effective as of the date of last signature (the “Amendment Effective Date”) with reference to the following:

WITNESSETH:

WHEREAS, the Supplier Agreement has previously been amended three times in accordance with; (1) an amendment made effective as of October 27, 2011 (the “Amendment No. 1”); (2) an amendment made effective February 22, 2013 (the “2013 Amendment”); and (3) an amendment made effective as of February 22, 2016 (the Amendment No. 3), together the “Previous Amendments”; and

WHEREAS, the Previous Amendments and the Supplier Agreement jointly hereinafter the “Agreement”

WHEREAS, GEHC and Supplier mutually wish to make certain modifications to the terms and conditions of the Agreement

WHEREAS, Section 18.8 of Attachment E to the Supplier Agreement provides that the Supplier Agreement may be modified only by a writing signed by both parties.

In the event that any terms and conditions contained herein are in conflict with the terms and conditions set forth in the Agreement or previously executed amendments thereto, the terms and conditions set forth in this Amendment shall be deemed to be the controlling terms and conditions.

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties to this Amendment agree as follows:

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Exchange Act; [*] denotes omissions.

Page 1

1. Amendment.

Section 1(a) and (iii) of Amendment No. 3 erroneously called the Fourth Amendment. Both references to the “Fourth Amendment” shall be corrected to “Third Amendment.”

The first sentence of Section 3(c), as previously amended by Section 2(c) of Amendment No. 3, is deleted and replaced with the following sentence:

“GEHC shall settle any undisputed invoices arising under this Agreement [*] after date of invoice prepared in accordance with the terms of this Agreement.”

The first paragraph of Section 16.1 of Attachment E, as previously amended by Amendment No.1 and Section 2(l) of Amendment No. 3, is amended and replaced in its entirety as follows:

“This Agreement shall commence on the Effective Date and, subject as hereinafter provided, shall continue in effect until Dec 31^st 2019. Notwithstanding the aforementioned, GEHC may reduce its minimum purchase commitments for any or all Products from Supplier hereunder [*] upon [*] written notice to Supplier, provided that GEHC may not issue such notice of reduction until after [*]. However, in the event GEHC reduces its purchase commitment, what is set out in Section 2g of Amendment No. 3 shall apply accordingly.

If the Supplier deems that an investment is needed to meet the GEHC volume forecast for 2019, the Supplier shall notify and describe the clear rationale to GEHC for such an investment before implementation and GEHC shall review the request and send the Supplier GEHC´s recommendation to the requested investment within [*]. If GEHC express its support to the investment and only in the case that GEHC thereafter send a notice to the Supplier to reduce the purchase commitment, GEHC will reimburse the Supplier with the verified investments costs but maximum up to the level that was agreed in advance. For avoidance of doubt the GEHC reimbursement commitment is limited to [*].”

2. Ratification. The Agreement as amended hereby is ratified by each of the parties hereto and shall remain in full force and effect in accordance with its terms as so amended. This Amendment is not a consent to any waiver or modification of any other terms or conditions of the Agreement and shall not prejudice any rights which any of the parties may now or hereafter have in connection with the Agreement.

3. Counterparts. This Amendment may be signed in any number of counterparts, each of which shall be an original, and all of which taken together shall constitute a single amendment, with the same effect as if the signatures hereto and thereto were upon the same instrument.

Page 2

IN WITNESS WHEREOF, each of the parties hereto has caused this Amendment to the Agreement to be executed by its duly authorized officer or representative set forth below as of the Amendment Effective Date.


GE Healthcare Bio-Sciences AB		Repligen Sweden AB

/s/ Bo Lundström		/s/ Tony Hunt
By (Signature)		By (Signature)

Bo Lundström		Tony Hunt
Printed Name		Printed Name

Management Director		President & CEO
Title		Title

20/2-2018		February 12, 2018
Date		Date

Page 3

EX-10.3 3 d574491dex103.htm EX-10.3 EX-10.3

Exhibit 10.3

REPLIGEN CORPORATION

AMENDED AND RESTATED

NON-EMPLOYEE DIRECTORS’ COMPENSATION POLICY

Cash Fees

Annual Retainer:


	Annual Retainer
*Board of Directors (the “Board***”)
Each Non-Employee Member of the Board	$	50,000
Additional Retainer for the Chairperson	$	90,000

Audit Committee
Committee Chairperson	$	30,000
Other Committee Members	$	10,000

Compensation Committee
Committee Chairperson	$	20,000
Other Committee Members	$	10,000

Nominating and Corporate Governance Committee
Committee Chairperson	$	16,000
Other Committee Members	$	5,000

The Annual Retainer will be paid quarterly, in arrears, or upon the earlier resignation or removal of the non-employee director. Amounts owing to non-employee directors as Annual Retainer shall be annualized, meaning that for non-employee directors who join the Board during the calendar year, such amounts shall be pro rated based on the number of calendar days served by such director.

Per Meeting fees:

None, unless otherwise specifically duly approved by the Board or any committee thereof hereafter.

Equity

Initial Equity Grant for a Non-Employee Director:

On the effective date of a new director’s appointment or first election to the Board, such new director shall receive an option to purchase 24,000 shares of Common Stock on the date he or she joins the Board (the “Initial Award”). The “strike price” for the Initial Award shall be the Closing Price. The Initial Award shall vest annually in three equal installments on the first, second and third anniversary of the date of grant, provided that if a new director is first elected to the Board at an annual meeting of stockholders, then each vesting date in respect of such Initial Award shall be on such anniversary of the date of grant or the date of the annual meeting of stockholders during such year, whichever is earlier, subject in all cases to service on the Board on such date.

Annual Equity Grant for each Non-Employee Director:

Each non-employee director reelected to the Board at any annual meeting of stockholders shall receive an award of a stock option to purchase shares of Common Stock and an award of restricted stock units on such date (collectively, the “Annual Award”).

The stock option to be granted in the Annual Award (i) to the Chairperson of the Board shall have an aggregate value of $87,500 and (ii) to all other non-employee directors shall each have an aggregate value of $62,500. The number of shares subject to each such stock option shall be determined by the Company using a Black Scholes methodology and its customary assumptions therefor.

The number of restricted stock units to be granted in the Annual Award (i) to the Chairperson of the Board shall $87,500 divided by the Closing Price and (ii) to all other non-employee directors shall each be equal to shall be equal to $62,500 divided by the Closing Price.

Each Annual Award shall be fully vested on the anniversary of the date of grant or the date of the next annual meeting of stockholders, whichever is earlier, subject to service on the Board on such date.

Definitions

“Closing Price” shall mean the reported closing price of Repligen Corporation’s Common Stock on the Nasdaq Global Market on any grant date, or the preceding business date if there are no market quotations on such date.

“Common Stock” shall mean the common stock of Repligen Corporation, par value $0.01 per share.

* * *

ADOPTED BY THE BOARD OF DIRECTORS on March 1, 2018.

EX-31.1 4 d574491dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Tony J. Hunt, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Repligen Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2018

/s/ TONY J. HUNT

Tony J. Hunt

President and Chief Executive Officer

(Principal executive officer)

EX-31.2 5 d574491dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Jon Snodgres, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Repligen Corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2018

/s/ JON SNODGRES

Jon Snodgres

Chief Financial Officer

(Principal financial officer)

EX-32.1 6 d574491dex321.htm EX-32.1 EX-32.1

Exhibit 32.1*

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repligen Corporation (the “Company”) on Form 10-Q for the period ending March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 8, 2018	By:	/S/ TONY J. HUNT
		Tony J. Hunt
		Chief Executive Officer and President
		(Principal executive officer)

Date: May 8, 2018	By:	/S/ JON SNODGRES
		Jon Snodgres
		Chief Financial Officer
		(Principal financial officer)

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-101.INS 7 rgen-20180331.xml XBRL INSTANCE DOCUMENT

0.02125

32.07

115000000

96289000

0.25

38560000

960000

2160000

78400000

43608000

1335000

616000

6004000

13570000

10137000

1102000

5075000

370932000

265654000

5787000 576000 43693913

130113000

450000

805903

19.68

24.96

80000000

43692303

1057255

254907

0.01

43692303

499504

17.73

1109353

25.34

0.01

5000000

36.18

-28737000

4610000

3653000

743248000

5246000

1547000

-6112000

6200000

521000

597183000

3191000

1968000

3808000

1547000

437000

631595000

25007000

827000

3342000

15963000

20858000

59000

2049000

2688000

20321000

100276000

1243000

14121000

248322000

3828000

22674000

9300000

764000

173876000

30762000

9395000

142273000

40124000

1023000

12015000

29352000

3052000

7978000

4605000

22497000

31000

47681000

743248000

9395000

9910000

10513000

327989000

158236000

14470000

21826000

15740000

1990000

4939000

12176000

4401000 0.03 0.08

703076

36.18

0.03 0.08

703076

25437000

23138000

1109353

25.34

0.066

0.02125

150500000

114989000

100276000

12513000

2200000

0.10

163000

-6112000

3898000

51860000

240000

75000

2160000

11446000

102210000

304000

1066000

700000

122683000

450000

80000000

43587079

0.01

43587079

734940

20.80

0.01

5000000

-31508000

2343000

743519000

9560000

960000

-6363000

7282000

1191000

591548000

436000

628983000

23800000

947000

13331000

25167000

58000

1668000

2220000

25211000

99250000

1383000

17929000

242782000

4083000

22417000

764000

173759000

144753000

39004000

1023000

27585000

2581000

4272000

21904000

153000

46217000

743519000

327333000

158084000

12570000

22351000

15673000

6234000

2281000

505235

11000

115000000

99250000

13395000

2355000

297000

99000

-6363000

603000

743000

19652000

3201000

51801000

238000

240000

47000

2160000

9636000

102120000

209000

1063000

700000

5609000

677000

4932000

31.1813

111100000

P270D

1.00

1.30

P20Y

P3Y

P15Y

6153995

122932000

370932000

247575000

425000 40000 63761 2018-06-01 P126M

0.35

P16Y

Expire at various dates through December 2037.

12812000 3266000

P19Y

P8Y

P20Y

P14Y

P3Y

7060000

0.19

0.11

P10Y

P5Y

0.20

P3Y

0.33

P1Y

458685

0.09

0.34

1147000

34382322

33891702

16.46

0.09

0.246

490620

1195000

30590000

1295000

96000

30569000

28000

1663000

4000

5676000

3068000

-851000

2415000

4099000

21000

1027000

1181000

-120000

-172000

-34000

4067000

-59000

10000

928000

536000

999000

-452000

1585000

6077000

1531000

970000

1582000

-43000

9182000

24914000

-4220000

-330000

1742000

715000

7430000

13990000

7400000

1333000

1062000

404781

32.18

2064000

1616000

0.54

0.38

0.08

3266000

39875000

1.00

0.21

0.27

1258000

141000

132000

<div> 9. Accrued Liabilities Accrued liabilities consist of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Employee compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,246</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,560</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,049</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,668</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Royalty and license fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,243</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,383</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued purchases </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">521</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,191</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">827</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">947</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Unearned revenue </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,547</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">960</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,688</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,220</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,121</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,929</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

593874

<div> 14. Commitments and Contingencies The Company leases its headquarters in Waltham, Massachusetts as well as certain of its office and manufacturing space around the world. In February 2018, the Company entered into an agreement to lease 63,761 square feet of office and manufacturing space in Marlborough, Massachusetts from U.S. REIF 111 Locke Drive Massachusetts, LLC (the “Premises”). The lease commences during the second quarter of 2018 (the “Commencement Date”) and shall continue for a period of 126 consecutive months, unless earlier terminated in accordance with the terms of the lease (the “Lease Term”). Under the lease, the Company has the option to extend the Lease Term for two additional five-year periods. Fixed rent with respect to 40,000 square feet of the Premises only shall commence on the Commencement Date, and rent for the full 63,761 square feet of the Premises shall begin 19 months following the Commencement Date. Under the terms of the lease, the Company has provided a letter of credit of approximately $163,000 as a security deposit and is required to pay its pro rata share of any building operating expenses and real estate taxes. Future minimum rental commitments under the Company’s leases as of March 31, 2018 are as follows (in thousands):   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="81%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Minimum Rental Commitments</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2018 (nine months remaining) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,191</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2019 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,808</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2020 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,653</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2021 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,342</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2022 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,968</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Thereafter </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,401</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> </table> </div>

<div> The carrying value of the Company’s convertible senior notes is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2.125% Convertible Senior Notes due 2021: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Principal amount </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114,989</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">115,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unamortized debt discount </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12,513</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(13,395</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,200</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,355</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total convertible senior notes </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">100,276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">99,250</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 11. Stock-Based Compensation For the three-month periods ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense of approximately $2,268,000 and $1,531,000, respectively, for share-based awards granted under the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the “2001 Plan”) and the Repligen Corporation Amended and Restated 2012 Stock Option and Incentive Plan (the “2012 Plan,” and together with the 2001 Plan, the “Plans”). The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cost of product revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">266</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">141</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">170</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Selling, general and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,832</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,258</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,268</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,531</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The 2012 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock and other equity awards. Employee grants under the Plans generally vest over a three- to five-year period, with 20%-33% vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to non-employee directors under the Plans generally vest over one year. In the first quarter of 2018, to create a longer term retention incentive, the Company’s Compensation Committee granted long term incentive compensation awards to its chief executive officer consisting of both stock options and restricted stock units that are subject to time-based vesting over nine years. Options granted under the Plans have a maximum term of ten years from the date of grant and generally, the exercise price of the stock options equals the fair market value of the Company’s common stock on the date of grant. At March 31, 2018, options to purchase 1,109,353 shares and 703,076 restricted stock units were outstanding under the Plans. At March 31, 2018, 254,907 shares were available for future grant under the 2012 Plan. The Company uses the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date, and the Company uses the value of the common stock as of the grant date to value restricted stock units. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award. The Company recognizes expense on awards with service based vesting over the employee’s requisite service period on a straight-line basis. In the third quarter of 2017, the Company issued performance stock units to certain individuals related to the Spectrum Acquisition which are tied to the achievement of certain revenue and gross margin metrics and the passage of time. The Company recognizes expense on performance based awards over the vesting period based on the probability that the performance metrics will be achieved. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures. Information regarding option activity for the three-month period ended March 31, 2018 under the Plans is summarized below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Options Outstanding</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price Per Share</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term (in years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(in thousands) Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">734,940</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.80</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">398,532</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33.85</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14,531</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.70</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,588</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29.71</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,109,353</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25.34</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.51</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,176</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Options exercisable at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">499,504</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17.73</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.50</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,300</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Vested and expected to vest at March 31, 2018 (1) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,057,255</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.96</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.40</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,015</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(1) </td> <td valign="top" align="left">Represents the number of vested options as of March 31, 2018 plus the number of unvested options expected to vest as of March 31, 2018 based on the unvested outstanding options at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.</td> </tr> </table> The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on March 31, 2018 of $36.18 per share and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on March 31, 2018.   The weighted average grant date fair value of options granted during the three-month periods ended March 31, 2018 and 2017 was $18.27 and $16.46, respectively. The total fair value of stock options that vested during the three-month periods ended March 31, 2018 and 2017 was approximately $1,339,000 and $1,195,000, respectively. Information regarding restricted stock unit and performance stock unit activity for the three-month period ended March 31, 2018 under the Plans is summarized below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Units Outstanding</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term (in years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(in thousands) Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Restricted and performance stock units outstanding at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">505,235</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">319,701</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(90,691</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(31,169</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Restricted stock units outstanding at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">703,076</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.06</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,437</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Vested and expected to vest at March 31, 2018 (1) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">639,530</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.75</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,138</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(1) </td> <td valign="top" align="left">Represents the number of vested restricted stock units as of March 31, 2018 plus the number of unvested restricted stock units expected to vest as of March 31, 2018 based on the unvested outstanding restricted stock units at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.</td> </tr> </table> The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (equal to the closing price of the common stock on March 31, 2018 of $36.18 per share) that would have been received by the restricted stock unit holders had all restricted stock units vested on March 31, 2018. The aggregate intrinsic value of restricted stock units vested during the three-month periods ended March 31, 2018 and 2017 was approximately $3,224,000 and $2,064,000, respectively. The weighted average grant date fair value of restricted stock units granted during the three-month periods ended March 31, 2018 and 2017 was $33.80 and $32.18, respectively. The total grant date fair value of restricted stock units that vested during the three-month periods ended March 31, 2018 and 2017 was approximately $2,619,000 and $1,616,000, respectively. As of March 31, 2018, there was $30,762,000 of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 4.66 years. </div>

Q1 2018 10-Q

0.08

0.21

0000730272

P16Y

<div> 6. Inventories Inventories relate to the Company’s bioprocessing business. The Company values inventory at cost or, if lower, market value, using the first-in, first-out method. The Company reviews its inventories at least quarterly and records a provision for excess and obsolete inventory based on its estimates of expected sales volume, production capacity and expiration dates of raw materials, work-in-process and finished products. Expected sales volumes are determined based on supply forecasts provided by key customers for the next 3 to 12 months. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements to cost of product revenue. Manufacturing of bioprocessing finished goods is done to order and tested for quality specifications prior to shipment. A change in the estimated timing or amount of demand for the Company’s products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. During all periods presented in the accompanying financial statements, there have been no material adjustments related to a revised estimate of inventory valuations. Work-in-process and finished products inventories consist of material, labor, outside processing costs and manufacturing overhead. Inventories consist of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Raw Materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,826</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,351</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Work-in-process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,828</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,083</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Finished products </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,470</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,570</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,124</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,004</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1572000

<div> The following table summarizes the changes in accumulated other comprehensive income by component (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> (In thousands) </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Foreign currency translation gain (loss)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,363</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Foreign currency translation gain </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">251</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,112</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Future minimum rental commitments under the Company’s leases as of March 31, 2018 are as follows (in thousands):   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="81%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Minimum Rental Commitments</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2018 (nine months remaining) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,191</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2019 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,808</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2020 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,653</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2021 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,342</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2022 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,968</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Thereafter </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,401</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> </table> </div>

9588

P7Y6M3D

23.70

<div> 3. Revenue Recognition Adoption of ASC Topic 606, Revenue from Contracts with Customers The Company adopted ASC 606 on January 1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with the practical expedient in paragraph ASC 606-10-65-1-(f)-4, which did not have a material effect on the cumulative impact of adopting ASC 606. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. The impact to the Company’s consolidated financial statements as a result of applying ASC 606 was immaterial. Deferred revenue resulting from contracts with customers is included in accrued expenses on the Company’s consolidated balance sheet. Revenue Recognition Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of March 31, 2018.   Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The Company recognizes product revenue under the terms of each customer agreement upon transfer of control to the customer, which occurs at a point in time. Disaggregation of Revenue Revenues for the three-month periods ended March 31, 2018 and 2017 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="53%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> (in thousands, except percentages)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">$ Change</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">% Change</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Product revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,799</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,569</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,230</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Royalty and other revenue </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,830</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,590</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,240</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenues are generated from two customers; therefore, economic factors specific to these two customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. The following tables disaggregate the Company’s revenue from contracts with customers by geographic region (in thousands).   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three months ended March 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> North America </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,239</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,401</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Asia and Pacific </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,947</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">243</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,830</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Revenue from significant customers is as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="17%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three months ended March 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> GE Healthcare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,717</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> MilliporeSigma </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,465</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> Protein Products The Company’s protein product line generates revenue through the sale of Protein A ligands, an essential component of Protein A chromatography resins (media) used in the purification of virtually all mAb-based drugs on the market or in development. The Company manufactures multiple forms of Protein A ligands under long term supply agreements with major life sciences companies, who in turn sell their Protein A chromatography media to end users (biopharmaceutical manufacturers). Each protein product is considered distinct and therefore represents a separate performance obligation. Protein product revenue is generally recognized at a point in time upon transfer of control to the customer.   Filtration Products The Company’s filtration product line generates revenue through the sale of KrosFlo® hollow-fiber (HF) tangential flow filtration (TFF) membranes and modules, ProConnex® single-use flow path connectors, flat sheet TFF cassettes and hardware, and XCell™ alternating tangential flow (ATF) devices and related consumables. The Company markets the KrosFlo line of HF cartridges and TFF systems and the ProConnex line of single-use flow path connectors which were acquired as part of the acquisition of Spectrum in August 2017. These products are used in the filtration, isolation, purification and concentration of biologics and diagnostic products. Sales of large-scale systems generally include components and consumables as well as training and installation services at the request of the customer. Because the initial sale of components and consumables are necessary for the operation of the system, such items are combined with the systems as a single performance obligation. Training and installation services do not significantly modify or customize these systems and therefore represent a distinct performance obligation. Each of the Company’s other product offerings are not highly interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Revenue on these products is generally recognized at a point in time upon transfer of control to the customer. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC 606-10-55-18. The Company also markets flat sheet TFF cassettes and hardware, which were acquired as part of the acquisition of TangenX Technology in December 2016. TFF is a rapid and efficient method for separation and purification of biomolecules that is widely used in laboratory, process development and process scale applications in biopharmaceutical manufacturing. The Company’s single-use TFF (Sius™ TFF) cassettes and hardware are not highly interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Sius TFF product revenue is generally recognized at a point in time upon transfer of control to the customer. The Company also markets the XCell™ ATF System, a technologically advanced filtration device used in upstream processes to continuously remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest. ATF Systems typically include a filtration system and consumables (i.e., tube devices, metal stands) as well as training and installation services at the request of the customer. The filtration system and consumables are considered distinct products and therefore represent separate performance obligations. First time purchasers of the systems typically purchase a controller that is shipped with the tube device(s) and metal stand(s). The controller is not considered distinct as it is a proprietary product that is highly interdependent with the filtration system; therefore, the controller is combined with the filtration system and accounted for as a single performance obligation. The training and installation services do not significantly modify or customize the ATF system and therefore represent a distinct performance obligation. ATF system product revenue related to the filtration system (including the controller if applicable) and consumables is generally recognized at a point in time upon transfer of control to the customer. ATF system service revenue related to training and installation services is generally recognized over time, as the customer simultaneously receives and consumes the benefits as the Company performs. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC 606-10-55-18. Chromatography Products The Company’s chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The majority of chromatography revenue relates to the OPUS pre-packed chromatography (PPC) column line and Protein A chromatography resins. OPUS columns typically consist of the outer hardware of the column with a resin as ordered by the customer packed inside of the column. OPUS columns may also be ordered without the packed resin. In either scenario, the OPUS column and resin are not interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Chromatography product revenue is generally recognized at a point in time upon transfer of control to the customer. Other Products The Company’s other products include ELISA test kits used by quality control departments to detect and measure the presence of leached Protein A and/or growth factor in the final product. Each ELISA kit is considered distinct and therefore represents a separate performance obligation. Other product revenue is generally recognized at a point in time upon transfer of control to the customer.   Transaction Price Allocated to Future Performance Obligations Remaining performance obligations represents the transaction price of contracts for which work has not been performed or has been partially performed. The Company’s future performance obligations relate primarily to the installation and training of certain of its systems sold to customers. These performance obligations are completed within one year of receipt of a purchase order from its customers. Accordingly, the Company has elected to not disclose the value of these unsatisfied performance obligations as provided under ASC 606-10-50-14. Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balances from contracts with customers only: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts receivable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,352</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred revenue </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,547</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Revenue recognized in the period relating to: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> The beginning deferred revenue balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">434</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Changes in pricing related to products or services satisfied in previous periods </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Impairment losses on receivables </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> The timing of revenue recognition, billings and cash collections results in accounts receivables and deferred revenue on the Company’s consolidated balance sheets. A contract asset is created when the Company satisfies a performance obligation by transferring a promised good to the customer. Contract assets may represent conditional or unconditional rights to consideration. The right is conditional, and recorded as a contract asset, if the Company must first satisfy another performance obligation in the contract before it is entitled to payment from the customer. Contract assets are transferred to billed receivables once the right becomes unconditional. If the Company has the unconditional right to receive consideration from the customer, the contract asset is accounted for as a billed receivable and presented separately from other contract assets. A right is unconditional if nothing other than the passage of time is required before payment of that consideration is due. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Costs to Obtain or Fulfill a Customer Contract The Company’s sales commission structure is based on achieving revenue targets. The commissions are driven by revenue derived from customer purchase orders which are short term in nature. Applying the practical expedient in paragraph 340-40-25-4, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. When shipping and handling costs are incurred after a customer obtains control of the products, the Company accounts for these as costs to fulfill the promise and not as a separate performance obligation. </div>

<div> The Company’s tax returns are subject to examination by federal, state and international taxing authorities for the following periods:   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="79%"></td> <td valign="bottom" width="10%"></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom" nowrap="nowrap"> Jurisdiction </td> <td valign="bottom">  </td> <td valign="bottom" align="center" style="border-bottom:1.00pt solid #000000"> Fiscal years subject to examination</td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> United States – federal and state </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2014-2017</td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Sweden </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2011-2017</td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Germany </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2017</td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Netherlands </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2012-2017</td> </tr> </table> </div>

RGEN

44326732

43621270

false

<div> The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balances from contracts with customers only: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts receivable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,352</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred revenue </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,547</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Revenue recognized in the period relating to: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> The beginning deferred revenue balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">434</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Changes in pricing related to products or services satisfied in previous periods </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Impairment losses on receivables </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> 12. Income Taxes The Company’s effective tax rate for the three-month period ended March 31, 2018 was 24.7% compared to 24.6% for the corresponding period in the prior year. The effective tax rate for the three-month period ended March 31, 2018 was higher than the U.S. statutory tax rate of 21% due to state tax effects and the impact of the Global Intangible Low-Taxed Income (“GILTI”) tax enacted as part of the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017. The effective tax rate for the three-month period ended March 31, 2017 was lower than the U.S. statutory tax rate of 34% mainly due to lower statutory tax rates in foreign jurisdictions. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized when the intra-entity transfer occurs rather than deferring recognition of income tax consequences until the transfer was made with an outside party. The Company adopted the provisions of this ASU in the first quarter of 2018. The adoption resulted in a decrease of $5,609,000 to other assets, a decrease of $4,932,000 to deferred tax liabilities and a decrease of $677,000 to accumulated deficit at January 1, 2018. At December 31, 2017, the Company had net operating loss carryforwards of approximately $19,652,000 in the U.S., net operating loss carryforwards of approximately €603,000 (approximately $743,000) in Germany, federal business tax credit carryforwards of $297,000 and state business tax credit carryforwards of approximately $99,000 available to reduce future domestic income taxes, if any. The net operating loss and business tax credits carryforwards will continue to expire at various dates through December 2037. The net operating loss and business tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. While an IRC Section 382 study was completed in the second quarter of 2017, and no current limitations were identified, use of these net operating loss and business tax credit carryforwards may be limited in the future based on certain changes in the ownership interest of significant stockholders.   On December 22, 2017, the Act was signed into law. The Act made significant changes to federal tax law, including, but not limited to, a reduction in the federal income tax rate from 35% to 21%, taxation of certain global intangible low-taxed income, allowing for immediate expensing of qualified assets, stricter limits on deductions for interest and certain executive compensation, and a one-time transition tax on previously deferred earnings of certain foreign subsidiaries. Due to the complexities involved in accounting for the enactment of the Act, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”), which allows a registrant to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Under the SAB 118 guidance, we have determined that our accounting for the following items is incomplete where noted, we are able to make reasonable estimates for certain effects of tax reform and therefore have recorded provisional amounts. The Act lowered the Company’s U.S. statutory federal tax rate from 35% to 21% effective January 1, 2018. The Company recorded a tax benefit of $12,812,000 in the year ended December 31, 2017 for the reduction in its US deferred tax assets and liabilities resulting from the rate change. The Act also includes a one-time deemed repatriation transition tax whereby entities that are shareholders of a specified foreign corporation must include in gross income the undistributed and previously untaxed post-1986 earnings and profits of the specified foreign corporation. The provisional amount recorded at December 31, 2017 increased the Company’s tax provision by $3,266,000. This amount may change as the Company refines its calculations of post-1986 earnings and profits for our foreign subsidiaries, as well as the amounts held in cash. The Company anticipates that future guidance and interpretations with the respect to the Act will cause the Company to further adjust its provisional amounts recorded as of December 31, 2017. No further adjustments have been made to these provisional amounts in the first quarter of 2018. Any measurement period adjustments will be reported as a component of provision for income taxes in the reporting period the amounts are determined. The final accounting will be completed no later than one year from the enactment of the Act. The Company’s tax returns are subject to examination by federal, state and international taxing authorities for the following periods:   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="79%"></td> <td valign="bottom" width="10%"></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom" nowrap="nowrap"> Jurisdiction </td> <td valign="bottom">  </td> <td valign="bottom" align="center" style="border-bottom:1.00pt solid #000000"> Fiscal years subject to examination</td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> United States – federal and state </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2014-2017</td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Sweden </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2011-2017</td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Germany </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2017</td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Netherlands </td> <td valign="bottom">  </td> <td valign="bottom" align="center">2012-2017</td> </tr> </table> </div>

P5Y

<div> Property, plant and equipment consist of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Land </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,023</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,023</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Buildings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">764</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">764</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,740</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,673</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,497</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,904</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Furniture and fixtures </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,605</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,272</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Construction in progress </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,052</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,581</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47,681</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">46,217</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less: accumulated depreciation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(25,007</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(23,800</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Property, plant and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,674</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,417</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following tables disaggregate the Company’s revenue from contracts with customers by geographic region (in thousands).   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three months ended March 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> North America </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,239</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,401</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Asia and Pacific </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,947</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">243</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,830</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cost of product revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">266</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">141</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">170</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Selling, general and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,832</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,258</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,268</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,531</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Inventories consist of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Raw Materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,826</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,351</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Work-in-process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,828</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,083</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Finished products </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,470</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,570</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,124</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,004</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Revenue from significant customers as a percentage of the Company’s total revenue is as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> GE Healthcare </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> MilliporeSigma </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

<div> Basic and diluted weighted average shares outstanding were as follows:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Basic weighted average common shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,621,270</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,891,702</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Effect of dilutive securities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Stock options and restricted stock awards </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">389,702</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">490,620</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Convertible senior notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">315,760</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average common shares, assuming dilution </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,326,732</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34,382,322</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

33.85

P5Y6M0D

18.27

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> 2. Acquisition of Spectrum LifeSciences, LLC <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On August 1, 2017, the Company completed the acquisition of Spectrum pursuant to the terms of an Agreement and Plan of Merger and Reorganization, dated as of June 22, 2017 (such acquisition, the “Spectrum Acquisition”). <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Spectrum is a diversified filtration company with a differentiated portfolio of hollow fiber cartridges, bench-top to commercial scale filtration and perfusion systems and a broad portfolio of disposable and single-use solutions. Spectrum’s products are primarily used for the filtration, isolation, purification and concentration of monoclonal antibodies, vaccines, recombinant proteins, diagnostic products and cell therapies where the company offers both standard and customized solutions to its bioprocessing customers. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Spectrum’s filtration products include its KrosFlo® line of hollow-fiber cartridges, tangential flow filtration (TFF) systems and single-use flow path consumables, as well as its Spectra/Por® portfolio of laboratory dialysis products and its Pro-Connex® single-usehollow fiber Module-Bag-Tubing (MBT) sets. Outside of filtration, Spectrum sells its Spectra/Chrom® liquid chromatography products for research applications. These bioprocessing products account for the majority of Spectrum revenues. Spectrum also offers a line of operating room products. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Consideration Transferred <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company accounted for the Spectrum Acquisition as a purchase of a business under ASC 805, “Business Combinations.” The Spectrum Acquisition was funded through payment of approximately $122.9 million in cash, 6,153,995 unregistered shares of the Company’s common stock totaling $247.6 million and a working capital adjustment of $425,000 for a total purchase price of $370.9 million. Under the acquisition method of accounting, the assets of Spectrum were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired was approximately $370.9 million. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The estimated consideration and preliminary purchase price information has been prepared using a valuation that required the use of significant assumptions and estimates in its preparation. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable; however, actual results may differ from these estimates. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The total consideration transferred follows (in thousands): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash consideration </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">122,932</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Equity consideration </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">247,575</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Working capital adjustment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">425</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net assets acquired </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">370,932</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Acquisition-related costs are not included as a component of consideration transferred, but are expensed in the periods in which the costs are incurred. The Company has incurred $655,000 in costs related to the Spectrum Acquisition for the three-month period ended March 31, 2018 and $7,060,000 in costs for the year ended December 31, 2017. These costs are primarily included in selling, general and administrative expenses in the consolidated statements of operations. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Fair Value of Net Assets Acquired <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The allocation of purchase price was based on the fair value of assets acquired and liabilities assumed as of August 1, 2017, based on the preliminary valuation. The components and allocation of the purchase price consists of the following amounts (in thousands): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,137</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Accounts receivable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,075</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Inventory </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,570</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Prepaid expenses and other assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">616</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fixed assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,004</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Deferred tax assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,102</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">78,400</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Developed technology </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,560</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trademark and tradename </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,160</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Non-competition agreements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">960</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Goodwill </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">265,654</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,335</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unrecognized tax benefit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(576</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,787</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred tax liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(43,608</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Fair value of net assets acquired </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">370,932</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Of the consideration paid, $78.4 million represents the fair value of customer relationships that is amortized over the weighted average determined useful life of 15 years, and $38.6 million represents the fair value of developed technology that is amortized over a determined useful life of 20 years. $960,000 represents the fair value of non-competition agreements that are amortized over a determined life of 3 years. $2.2 million represents the fair value of trademarks and trade names that are determined to have an indefinite useful life. The aforementioned intangible assets are amortized on a straight-line basis. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The goodwill of $265.7 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. None of the goodwill recorded is expected to be deductible for income tax purposes. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The purchase price allocation may be subject to adjustment as purchase accounting is preliminary as of March 31, 2018 related to inventory valuation. The final allocation may include, but not be limited to, changes in allocations to inventory and goodwill. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Revenue, Net Income and Pro Forma Presentation <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company recorded revenue from Spectrum of $11,719,000 for the three-month period ended March 31, 2018. The Company has included the operating results of Spectrum in its consolidated statements of operations since the August 1, 2017 acquisition date. The following table presents unaudited supplemental pro forma information as if the Spectrum Acquisition had occurred as of January 1, 2017 (in thousands, except per share data): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pro-forma Three months ended March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Pro-forma Three months ended March 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total revenue </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,830</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,875</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net income </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,939</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,266</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Earnings per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.09</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.09</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.08</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The unaudited pro forma information for the three-month period ended March 31, 2018 was calculated after applying the Company’s accounting policies and the impact of acquisition date fair value adjustments. The unaudited pro forma net income for the three-month period ended March 31, 2018 was adjusted to exclude acquisition-related transaction costs, as these expenses would have been incurred in the prior year assuming the Spectrum Acquisition closed on January 1, 2017. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> These pro forma condensed consolidated financial results include certain adjustments to reflect the pro forma results of operations as if the acquisition had occurred as of January 1, 2017. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combinations occurred at the beginning of the period presented, or of future results of the consolidated entities. </div>

<div> 4. Accumulated Other Comprehensive Income The following table summarizes the changes in accumulated other comprehensive income by component (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> (In thousands) </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Foreign currency translation gain (loss)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,363</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Foreign currency translation gain </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">251</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,112</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

--12-31

0.08

2018-03-31 Large Accelerated Filer

<div> As of March 31, 2018, the Company expects to record amortization expense as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="18%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Years Ending </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortization Expense</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> December 31, 2018 (nine months remaining) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,978</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> December 31, 2019 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,513</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> December 31, 2020 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,910</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> December 31, 2021 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,395</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> December 31, 2022 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,395</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> 8. Intangible Assets Intangible assets are amortized over their useful lives using the straight-line method, as applicable, and the amortization expense is recorded within selling, general and administrative expense in the Company’s statements of comprehensive income. The Company reviews its indefinite-lived intangible assets not subject to amortization to determine if adverse conditions exist or a change in circumstances exists that would indicate an impairment. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for our products or changes in the size of the market for our products. An impairment results if the carrying value of the asset exceeds the estimated fair value of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its intangible assets are recoverable at March 31, 2018. Intangible assets consisted of the following at March 31, 2018 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Carrying Amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Useful Life (in years)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Technology – developed </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51,860</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,898</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Patents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">240</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(240</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">102,210</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(11,446</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trademark – definite lived </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,160</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(75</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trademark – indefinite lived </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">700</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other intangibles </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,066</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(304</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">158,236</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(15,963</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> Intangible assets consisted of the following at December 31, 2017 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Carrying Amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Useful Life (in years)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Technology – developed </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51,801</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,201</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Patents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">240</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(238</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">102,120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,636</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trademarks – definite lived </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,160</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(47</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trademarks – indefinite lived </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">700</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other intangibles </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,063</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(209</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">158,084</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(13,331</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> Amortization expense for amortized intangible assets was approximately $2,664,000 and $715,000 for the three-month periods ended March 31, 2018 and 2017, respectively. As of March 31, 2018, the Company expects to record amortization expense as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="18%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Years Ending </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortization Expense</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> December 31, 2018 (nine months remaining) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,978</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> December 31, 2019 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,513</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> December 31, 2020 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,910</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> December 31, 2021 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,395</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> December 31, 2022 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,395</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> 7. Property, Plant and Equipment Property, plant and equipment consist of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Land </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,023</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,023</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Buildings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">764</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">764</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,740</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,673</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,497</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,904</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Furniture and fixtures </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,605</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,272</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Construction in progress </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,052</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,581</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47,681</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">46,217</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less: accumulated depreciation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(25,007</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(23,800</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Property, plant and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,674</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,417</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Depreciation expense totaled approximately $1,284,000 and $928,000 for the three-month periods ended March 31, 2018 and 2017, respectively. </div>

<div> Information regarding option activity for the three-month period ended March 31, 2018 under the Plans is summarized below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Options Outstanding</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price Per Share</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term (in years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(in thousands) Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">734,940</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.80</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">398,532</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33.85</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14,531</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.70</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,588</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29.71</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,109,353</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25.34</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.51</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,176</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Options exercisable at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">499,504</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17.73</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.50</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,300</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Vested and expected to vest at March 31, 2018 (1) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,057,255</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.96</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.40</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,015</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(1) </td> <td valign="top" align="left">Represents the number of vested options as of March 31, 2018 plus the number of unvested options expected to vest as of March 31, 2018 based on the unvested outstanding options at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.</td> </tr> </table> </div>

14531

<div> Revenues for the three-month periods ended March 31, 2018 and 2017 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="53%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> (in thousands, except percentages)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">$ Change</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">% Change</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Product revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,799</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,569</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,230</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Royalty and other revenue </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,830</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,590</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,240</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

<div> 5. Earnings Per Share The Company reports earnings per share in accordance with ASC Topic 260, “Earnings Per Share,” which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents then outstanding. Potential common share equivalents consist of restricted stock awards and the incremental common shares issuable upon the exercise of stock options. Under the treasury stock method, unexercised “in-the-money” stock options and warrants are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period. Share-based payment awards that entitle their holders to receive non-forfeitable dividends before vesting are considered participating securities and are considered in the calculation of basic and diluted earnings per share. There were no such participating securities outstanding during the three-month periods ended March 31, 2018 and 2017. Basic and diluted weighted average shares outstanding were as follows:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Basic weighted average common shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,621,270</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,891,702</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Effect of dilutive securities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Stock options and restricted stock awards </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">389,702</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">490,620</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Convertible senior notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">315,760</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average common shares, assuming dilution </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,326,732</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34,382,322</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> At March 31, 2018, there were outstanding options to purchase 1,109,353 shares of the Company’s common stock at a weighted average exercise price of $25.34 per share and 703,076 restricted stock units. For the three months ended March 31, 2018, 593,874 options to purchase shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive. At March 31, 2017, there were outstanding options to purchase 805,903 shares of the Company’s common stock at a weighted average exercise price of $19.68 per share and 404,781 restricted stock units. For the three months ended March 31, 2017, 458,685 options to purchase shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive. As provided by the terms of the indenture underlying the Company’s 2.125% Convertible Senior Notes due 2021 (the “Notes”), the Company has a choice to settle the conversion obligation for the Notes in cash, shares or any combination of the two. The Company currently intends to settle the par value of the Notes in cash and any excess conversion premium in shares. The Company applies the provisions of ASC 260, Earnings Per Share, Subsection 10-45-44, to determine the diluted weighted average shares outstanding as it relates to the conversion spread on its convertible notes. Accordingly, the par value of the Notes will not be included in the calculation of diluted income per share, but the dilutive effect of the conversion premium will be considered in the calculation of diluted net income per share using the treasury stock method. The dilutive impact of the Company’s convertible notes is based on the difference between the Company’s current period average stock price and the conversion price of the convertible notes, provided there is a premium. Pursuant to this accounting standard, there is no dilution from the accreted principal of the Notes as of March 31, 2018 and March 31, 2017. </div>

0.247

P4Y7M28D

REPLIGEN CORP

<div> 13. Fair Value Measurement In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="6%"></td> <td valign="bottom" width="2%"></td> <td width="92%"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top" nowrap="nowrap">Level 1–</td> <td valign="bottom">  </td> <td valign="top">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top" nowrap="nowrap">Level 2–</td> <td valign="bottom">  </td> <td valign="top">Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly</td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top" nowrap="nowrap">Level 3–</td> <td valign="bottom">  </td> <td valign="top">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</td> </tr> </table> The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.   The Company’s fixed income investments have historically comprised of obligations of U.S. government agencies and corporate marketable securities. These investments have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. At least annually, the Company validates applicable prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. As of March 31, 2018 and December 31, 2017, the Company had no assets or liabilities for which fair value measurement is either required or has been elected to be applied. In May 2016, the Company issued $115 million aggregate principal amount of the Notes due June 1, 2021. Interest is payable semi-annually in arrears on June 1 and December 1 of each year, beginning December 1, 2016. As of March 31, 2018, the carrying value of the Notes was approximately $100.3 million, net of unamortized discount, and the fair value of the Notes was approximately $150.5 million. The fair value of the Notes was determined based on the most recent trade activity of the Notes as of March 31, 2018. These valuations are Level 1 valuations, as the valuations are based on unadjusted quoted prices in active markets that the Company has the ability to access. The Notes are discussed in more detail in Note 10, “Long Term Debt.” There were no re-measurements to fair value during the three months ended March 31, 2018 of financial assets and liabilities that are not measured at fair value on a recurring basis. </div>

315760

<div> 10. Convertible Senior Notes The carrying value of the Company’s convertible senior notes is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> 2.125% Convertible Senior Notes due 2021: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Principal amount </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114,989</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">115,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unamortized debt discount </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12,513</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(13,395</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,200</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,355</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total convertible senior notes </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">100,276</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">99,250</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> On May 24, 2016, the Company issued $115 million aggregate principal amount of its Notes. The net proceeds from the sale of the Notes, after deducting the underwriting discounts and commissions and other related offering expenses, were approximately $111.1 million. The Notes bear interest at the rate of 2.125% per annum, payable semiannually in arrears on June 1 and December 1 of each year, beginning December 1, 2016.   The Notes will mature on June 1, 2021, unless earlier repurchased, redeemed or converted in accordance with their terms. Prior to March 1, 2021, the Notes will be convertible at the option of holders of the Notes only upon satisfaction of certain conditions and during certain periods, and thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, holders of the Notes will receive shares of the Company’s common stock, cash or a combination thereof, at the Company’s election. It is the Company’s current intent and policy to settle all conversions through combination settlement, which involves satisfying the principal amount outstanding with cash and any note conversion value over the principal amount in shares of the Company’s common stock. Notes with a par value of $11,000 were submitted for conversion in the fourth quarter of 2017, and this conversion was settled in the first quarter of 2018. The conversion resulted in the issuance of a nominal amount of shares of the Company’s common stock, and the Company recorded a loss of $1,000 on the conversion of these Notes. The Notes are not convertible as of March 31, 2018 and are classified as long term liabilities on the Company’s consolidated balance sheet as of December 31, 2017. The conversion rate for the Notes will initially be 31.1813 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $32.07 per common share, and is subject to adjustment under the terms of the Notes. Holders of the Notes may require the Company to repurchase their Notes upon the occurrence of a fundamental change prior to maturity for cash at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest, if any, to, but excluding, the repurchase date. The Company will not have the right to redeem the Notes prior to June 5, 2019, but may redeem the Notes, at its option, in whole or in part, on any business day on or after June 5, 2019 and prior to the maturity date if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides written notice of redemption. The redemption price will be equal to 100% of the principal amount of the principal amount of Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. The Notes contain customary terms and events of default. If an event of default (other than certain events of bankruptcy, insolvency or reorganization involving the Company) occurs and is continuing, the holders of at least 25% in aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and any accrued and unpaid interest on, all of the Notes to be due and payable. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving the Company, 100% of the principal of and accrued and unpaid interest, if any, on all of the Notes will become due and payable automatically. Notwithstanding the foregoing, the Notes provide that, to the extent the Company elects and for up to 270 days, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants consist exclusively of the right to receive additional interest on the Notes. The Company is not aware of any events of default, current events or market conditions that would allow holders to call or convert the Notes as of March 31, 2018. The cash conversion feature of the Notes required bifurcation from the Notes and was initially accounted for as an equity instrument classified to stockholders’ equity, as the conversion feature was determined to be clearly and closely related to the Company’s stock. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry and asset base and with similar maturity, the Company estimated the implied interest rate, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market interest rates, credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Notes, which resulted in a fair value of the liability component of $96,289,000 upon issuance, calculated as the present value of implied future payments based on the $115 million aggregate principal amount. The equity component of the Notes was recognized as a debt discount, recorded in additional paid-in capital, and represents the difference between the aggregate principal of the Notes and the fair value of the Notes without conversion option on their issuance date. The debt discount is amortized to interest expense using the effective interest method over five years, or the life of the Notes. The Company assesses the equity classification of the cash conversion feature quarterly, and it is not remeasured as long as it continues to meet the conditions for equity classification. Interest expense recognized on the Notes during the three-month period ended March 31, 2018 includes $611,000, $881,000 and $155,000 for the contractual coupon interest, the accretion of the debt discount and the amortization of the debt issuance costs, respectively. The effective interest rate on the Notes is 6.6%, which includes the interest on the Notes, amortization of the debt discount and debt issuance costs. As of March 31, 2018, the carrying value of the Notes was approximately $100.3 million and the fair value of the principal was approximately $150.5 million. The fair value of the Notes was determined based on the most recent trade activity of the Notes as of March 31, 2018. </div>

<div> 15. Related Party Transactions Certain facilities leased by Spectrum are owned by the former owner of Spectrum, who currently holds greater than 10% of the Company’s outstanding common stock. The lease amounts paid to this shareholder were negotiated in connection with the Spectrum Acquisition. The Company has incurred rent expense totaling $201,000 for the three-month period ended March 31, 2018 related to these leases. </div>

<div> Accrued liabilities consist of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Employee compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,246</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,560</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,049</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,668</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Royalty and license fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,243</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,383</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued purchases </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">521</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,191</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">827</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">947</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Unearned revenue </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,547</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">960</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,688</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,220</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,121</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,929</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 16. Segment Reporting The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment. As a result, the financial information disclosed herein represents all of the material financial information related to the Company’s sole operating segment. The following table represents the Company’s total revenue by geographic area (based on the location of the customer):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> North America </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Asia and Australia </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Revenue from significant customers as a percentage of the Company’s total revenue is as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> GE Healthcare </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> MilliporeSigma </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> GE Healthcare </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> MilliporeSigma </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

29.71

398532

P7Y4M24D

389702

1339000

44830000

1564000

181000

44799000

5976000

3448000

1188000

1529000

3699000

31000

251000

937000

11000

71000

5609000

-127000

1608000

4576000

449000

1284000

-224000

1128000

-1550000

1652000

-1564000

2268000

1036000

3960000

-3000

15898000

38854000

-3839000

333000

3288000

2664000

117000

19668000

344000

<div> Intangible assets consisted of the following at March 31, 2018 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Carrying Amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Useful Life (in years)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Technology – developed </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51,860</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,898</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Patents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">240</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(240</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">102,210</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(11,446</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trademark – definite lived </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,160</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(75</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trademark – indefinite lived </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">700</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other intangibles </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,066</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(304</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">158,236</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(15,963</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> Intangible assets consisted of the following at December 31, 2017 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Carrying Amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Useful Life (in years)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Technology – developed </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51,801</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,201</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Patents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">240</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(238</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">102,120</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,636</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Trademarks – definite lived </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,160</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(47</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trademarks – indefinite lived </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">700</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other intangibles </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,063</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(209</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">158,084</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(13,331</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div> -1000 0.47 14240000 2 <div> Revenue from significant customers is as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="17%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three months ended March 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> GE Healthcare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,717</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> MilliporeSigma </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,465</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div> 434000 Fixed rent with respect to 40,000 square feet of the Premises only shall commence on the Commencement Date, and rent for the full 63,761 square feet of the Premises shall begin 19 months following the Commencement Date. 0.48 0.47 10000 14230000 0

703076

33.80

3224000

2619000

31169

P4Y0M22D

<div> Information regarding restricted stock unit and performance stock unit activity for the three-month period ended March 31, 2018 under the Plans is summarized below:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Units Outstanding</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term (in years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">(in thousands) Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Restricted and performance stock units outstanding at December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">505,235</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">319,701</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(90,691</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(31,169</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Restricted stock units outstanding at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">703,076</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.06</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,437</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Vested and expected to vest at March 31, 2018 (1) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">639,530</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.75</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,138</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(1) </td> <td valign="top" align="left">Represents the number of vested restricted stock units as of March 31, 2018 plus the number of unvested restricted stock units expected to vest as of March 31, 2018 based on the unvested outstanding restricted stock units at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.</td> </tr> </table> </div>

319701

90691 P3Y9M0D 639530

P9Y

2016-12-01

Semi-annually

2021-06-01

611000

881000

155000

-1000

201000

251000

2017

2012

4947000

19401000

0.43

20239000

0.45

2017

2011

2017

2014

243000

0.01

0.11

P19Y

P8Y

P20Y

P14Y

P3Y

0.09

<div> The total consideration transferred follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash consideration </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">122,932</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Equity consideration </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">247,575</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Working capital adjustment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">425</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net assets acquired </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">370,932</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.09

<div> The components and allocation of the purchase price consists of the following amounts (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,137</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts receivable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,075</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Inventory </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,570</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Prepaid expenses and other assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">616</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fixed assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,004</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Deferred tax assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,102</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">78,400</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Developed technology </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,560</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Trademark and tradename </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,160</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Non-competition agreements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">960</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Goodwill </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">265,654</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,335</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unrecognized tax benefit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(576</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,787</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred tax liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(43,608</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Fair value of net assets acquired </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">370,932</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

11719000

3939000

44830000

655000

<div> The following table represents the Company’s total revenue by geographic area (based on the location of the customer):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> North America </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">54</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Asia and Australia </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1.00

0.14

0.17

<div> Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable are as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> GE Healthcare </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> MilliporeSigma </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

0.20

0.19

1832000

266000

170000

6465000

7717000

0000730272 rgen:GeneralElectricHealthcareMember 2018-01-01 2018-03-31 0000730272 rgen:MilliporeSigmaMember 2018-01-01 2018-03-31 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0000730272 us-gaap:CostOfSalesMember 2018-01-01 2018-03-31 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000730272 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberrgen:GeneralElectricHealthcareMember 2018-01-01 2018-03-31 0000730272 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberrgen:MilliporeSigmaMember 2018-01-01 2018-03-31 0000730272 us-gaap:AccountsReceivableMember 2018-01-01 2018-03-31 0000730272 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberrgen:GeneralElectricHealthcareMember 2018-01-01 2018-03-31 0000730272 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberrgen:MilliporeSigmaMember 2018-01-01 2018-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMemberus-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMember 2018-01-01 2018-03-31 0000730272 rgen:SpectrumIncMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000730272 rgen:SpectrumIncMember 2018-01-01 2018-03-31 0000730272 us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-03-31 0000730272 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-03-31 0000730272 us-gaap:TrademarksMember 2018-01-01 2018-03-31 0000730272 us-gaap:PatentsMember 2018-01-01 2018-03-31 0000730272 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMemberus-gaap:GeographicConcentrationRiskMemberrgen:AsiaAndAustraliaMember 2018-01-01 2018-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMemberus-gaap:GeographicConcentrationRiskMemberrgen:AllOtherMember 2018-01-01 2018-03-31 0000730272 rgen:AllOtherMember 2018-01-01 2018-03-31 0000730272 country:USus-gaap:EarliestTaxYearMember 2018-01-01 2018-03-31 0000730272 country:USus-gaap:LatestTaxYearMember 2018-01-01 2018-03-31 0000730272 country:SEus-gaap:EarliestTaxYearMember 2018-01-01 2018-03-31 0000730272 country:SEus-gaap:LatestTaxYearMember 2018-01-01 2018-03-31 0000730272 country:DE 2018-01-01 2018-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NorthAmericaMember 2018-01-01 2018-03-31 0000730272 us-gaap:NorthAmericaMember 2018-01-01 2018-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EuropeMember 2018-01-01 2018-03-31 0000730272 us-gaap:EuropeMember 2018-01-01 2018-03-31 0000730272 us-gaap:AsiaPacificMember 2018-01-01 2018-03-31 0000730272 country:NLus-gaap:EarliestTaxYearMember 2018-01-01 2018-03-31 0000730272 country:NLus-gaap:LatestTaxYearMember 2018-01-01 2018-03-31 0000730272 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-03-31 0000730272 us-gaap:PrincipalOwnerMember 2018-01-01 2018-03-31 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2018-01-01 2018-03-31 0000730272 rgen:EmployeeStockOptionAndRestrictedStockUnitsMember 2018-01-01 2018-03-31 0000730272 rgen:RestrictedStockUnitsAndPerformanceStockUnitsMember 2018-01-01 2018-03-31 0000730272 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0000730272 2018-01-01 2018-03-31 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0000730272 us-gaap:CostOfSalesMember 2017-01-01 2017-03-31 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-03-31 0000730272 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberrgen:GeneralElectricHealthcareMember 2017-01-01 2017-03-31 0000730272 us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberrgen:MilliporeSigmaMember 2017-01-01 2017-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMemberus-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-03-31 0000730272 rgen:SpectrumIncMember 2017-01-01 2017-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMemberus-gaap:GeographicConcentrationRiskMemberrgen:AsiaAndAustraliaMember 2017-01-01 2017-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NorthAmericaMember 2017-01-01 2017-03-31 0000730272 us-gaap:SalesRevenueGoodsNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EuropeMember 2017-01-01 2017-03-31 0000730272 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0000730272 2017-01-01 2017-03-31 0000730272 rgen:NonEmployeeDirectorStockOptionMember 2012-01-01 2012-12-31 0000730272 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2012-01-01 2012-12-31 0000730272 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2012-01-01 2012-12-31 0000730272 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2012-01-01 2012-12-31 0000730272 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2012-01-01 2012-12-31 0000730272 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberrgen:GeneralElectricHealthcareMember 2017-01-01 2017-12-31 0000730272 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberrgen:MilliporeSigmaMember 2017-01-01 2017-12-31 0000730272 rgen:SpectrumIncMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000730272 us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-12-31 0000730272 us-gaap:CustomerRelationshipsMember 2017-01-01 2017-12-31 0000730272 us-gaap:TrademarksMember 2017-01-01 2017-12-31 0000730272 us-gaap:PatentsMember 2017-01-01 2017-12-31 0000730272 us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-12-31 0000730272 2017-01-01 2017-12-31 0000730272 2018-02-01 2018-02-28 0000730272 us-gaap:ScenarioForecastMember 2018-06-01 2018-06-01 0000730272 rgen:SpectrumIncMember 2017-08-01 2017-08-01 0000730272 rgen:SpectrumIncMemberus-gaap:CustomerRelationshipsMember 2017-08-01 2017-08-01 0000730272 rgen:SpectrumIncMemberus-gaap:NoncompeteAgreementsMember 2017-08-01 2017-08-01 0000730272 rgen:SpectrumIncMemberus-gaap:DevelopedTechnologyRightsMember 2017-08-01 2017-08-01 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember 2016-05-24 2016-05-24 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2016-05-24 2016-05-24 0000730272 us-gaap:AccountingStandardsUpdate201606Memberrgen:DeferredTaxLiabilityMember 2018-01-01 0000730272 us-gaap:AccountingStandardsUpdate201606Memberrgen:RetainedEarningsAccumulatedDeficitMember 2018-01-01 0000730272 us-gaap:AccountingStandardsUpdate201606Memberus-gaap:OtherAssetsMember 2018-01-01 0000730272 us-gaap:TrademarksMember 2017-12-31 0000730272 us-gaap:OtherIntangibleAssetsMember 2017-12-31 0000730272 us-gaap:CustomerRelationshipsMember 2017-12-31 0000730272 us-gaap:TrademarksMember 2017-12-31 0000730272 us-gaap:PatentsMember 2017-12-31 0000730272 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0000730272 country:US 2017-12-31 0000730272 country:DE 2017-12-31 0000730272 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000730272 us-gaap:StateAndLocalJurisdictionMember 2017-12-31 0000730272 us-gaap:DomesticCountryMember 2017-12-31 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2017-12-31 0000730272 rgen:RestrictedStockUnitsAndPerformanceStockUnitsMember 2017-12-31 0000730272 2017-12-31 0000730272 us-gaap:AccountingStandardsUpdate201618Memberrgen:CashCashEquivalentsAndRestrictedCashMember 2016-12-31 0000730272 2016-12-31 0000730272 us-gaap:TrademarksMember 2018-03-31 0000730272 us-gaap:OtherIntangibleAssetsMember 2018-03-31 0000730272 us-gaap:CustomerRelationshipsMember 2018-03-31 0000730272 us-gaap:TrademarksMember 2018-03-31 0000730272 us-gaap:PatentsMember 2018-03-31 0000730272 us-gaap:DevelopedTechnologyRightsMember 2018-03-31 0000730272 us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0000730272 us-gaap:LetterOfCreditMember 2018-03-31 0000730272 us-gaap:MinimumMemberus-gaap:PrincipalOwnerMember 2018-03-31 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2018-03-31 0000730272 rgen:OptionToPurchaseCommonStockMember 2018-03-31 0000730272 rgen:RestrictedStockUnitsAndPerformanceStockUnitsMember 2018-03-31 0000730272 us-gaap:RestrictedStockUnitsRSUMemberrgen:NonExecutiveMember 2018-03-31 0000730272 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ExecutiveOfficerMember 2018-03-31 0000730272 us-gaap:RestrictedStockUnitsRSUMember 2018-03-31 0000730272 us-gaap:EmployeeStockOptionMemberrgen:NonExecutiveMember 2018-03-31 0000730272 us-gaap:EmployeeStockOptionMemberus-gaap:ExecutiveOfficerMember 2018-03-31 0000730272 2018-03-31 0000730272 rgen:OptionToPurchaseCommonStockMember 2017-03-31 0000730272 us-gaap:AccountingStandardsUpdate201618Memberrgen:CashCashEquivalentsAndRestrictedCashMember 2017-03-31 0000730272 2017-03-31 0000730272 2018-05-01 0000730272 rgen:SpectrumIncMember 2017-08-01 0000730272 rgen:SpectrumIncMemberus-gaap:CustomerRelationshipsMember 2017-08-01 0000730272 rgen:SpectrumIncMemberus-gaap:TrademarksAndTradeNamesMember 2017-08-01 0000730272 rgen:SpectrumIncMemberus-gaap:NoncompeteAgreementsMember 2017-08-01 0000730272 rgen:SpectrumIncMemberus-gaap:DevelopedTechnologyRightsMember 2017-08-01 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2016-05-24 pure iso4217:USD shares iso4217:USD shares iso4217:EUR utr:D utr:sqft Represents the number of vested options as of March 31, 2018 plus the number of unvested options expected to vest as of March 31, 2018 based on the unvested outstanding options at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees. Represents the number of vested restricted stock units as of March 31, 2018 plus the number of unvested restricted stock units expected to vest as of March 31, 2018 based on the unvested outstanding restricted stock units at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

EX-101.SCH 8 rgen-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Acquisition of Spectrum LifeSciences, LLC link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Revenue Recognition link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Accumulated Other Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Earnings Per Share link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Property, Plant and Equipment link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Accrued Liabilities link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Convertible Senior Notes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Fair Value Measurement link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Acquisition of Spectrum LifeSciences, LLC (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Revenue Recognition (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Accumulated Other Comprehensive Income (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Earnings Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Property, Plant and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Accrued Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Convertible Senior Notes (Tables) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Segment Reporting (Tables) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Acquisition of Spectrum LifeSciences, LLC - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Consideration Transferred (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Components and Allocation of Purchase Price (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Unaudited Supplemental Pro Forma Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Revenue from Contracts with Customers by Geographic Region (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Revenue from Significant Customers (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Change in Accumulated Other Comprehensive Income (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Earnings Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Basic and Diluted Weighted Average Shares Outstanding (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Schedule of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Property, Plant and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Property, Plant and Equipment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Amortization Expense for Amortized Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Schedule of Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Carrying Value of Convertible Senior Notes (Detail) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Carrying Value of Convertible Senior Notes (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 157 - Disclosure - Convertible Senior Notes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 158 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 159 - Disclosure - Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 160 - Disclosure - Summary of Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 161 - Disclosure - Summary of Option Activity (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 162 - Disclosure - Summary of Restricted Stock Unit and Performance Stock Unit Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 163 - Disclosure - Summary of Restricted Stock Unit and Performance Stock Unit Activity (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 164 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 165 - Disclosure - Summary of Tax Returns Periods Subject to Examination by Federal, State and International Taxing Authorities (Detail) link:calculationLink link:presentationLink link:definitionLink 166 - Disclosure - Fair Value Measurement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 167 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 168 - Disclosure - Future Minimum Rental Commitments under Company's Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 169 - Disclosure - Related Party Transactions - Additional Information (Detail) (Detail) link:calculationLink link:presentationLink link:definitionLink 170 - Disclosure - Percentage of Revenue by Geographic Area (Detail) link:calculationLink link:presentationLink link:definitionLink 171 - Disclosure - Percentage of Revenue from Significant Customers (Detail) link:calculationLink link:presentationLink link:definitionLink 172 - Disclosure - Percentage of Accounts Receivable by Significant Customers (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 rgen-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 rgen-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 rgen-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounting Standards Update 2016-06 [Member] Accounting Standards Update 2016-06 Accounting Standards Update 2016-18 [Member] ASU No. 2016-18 Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities Accounts Payable, Current Accounts payable Accounts Payable, Trade, Current Accrued purchases Accounts Receivable [Member] Accounts Receivable Accounts Receivable, Net, Current Accounts receivable Accounts receivable, less reserve for doubtful accounts of $59 at March 31, 2018 and $58 at December 31, 2017, respectively Accrued Income Taxes, Current Taxes Accrued Liabilities, Current Accrued liabilities Total Accrued Professional Fees, Current Professional fees Accrued Royalties, Current Royalty and license fees Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Foreign currency translation gain (loss) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Finite lived intangible asset, useful life Additional Paid in Capital, Common Stock Additional paid-in capital Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: All Other [Member] All Other [Member] Other Allowance for Doubtful Accounts Receivable, Current Accounts receivable, reserve for doubtful accounts Amendment Flag Amendment Flag Amortization of Debt Discount (Premium) Accretion of the debt discount Non-cash interest expense Amortization of Debt Issuance Costs Amortization of the debt issuance costs Amortization of Intangible Assets Amortization expense Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common stock excluded from calculation of diluted earnings per share Asia and Australia. Asia and Australia [Member] Asia and Australia Asia Pacific [Member] Asia and Pacific Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Award Type [Axis] Award Type [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Basis of Accounting [Text Block] Basis of Presentation Buildings and Improvements, Gross Buildings Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Shares issued for business acquisition Business Acquisition [Line Items] Business Acquisition [Line Items] Business Acquisition, Pro Forma, Earnings Per Share [Abstract] Business Acquisition, Pro Forma, Earnings Per Share [Abstract] Earnings per share: Business Acquisition, Pro Forma Earnings Per Share, Basic Basic Business Acquisition, Pro Forma Earnings Per Share, Diluted Diluted Business Acquisition, Pro Forma Information [Table Text Block] Unaudited Supplemental Pro Forma Information Business Acquisition, Goodwill, Expected Tax Deductible Amount Goodwill expected to be deductible for tax purposes amount Business Acquisition, Pro Forma Net Income (Loss) Net income Business Acquisition, Pro Forma Revenue Total revenue Business Acquisition Working Capital Adjustments Business Acquisition Working Capital Adjustments Working capital adjustment Business Combination, Acquisition Related Costs Business combination, acquisition related costs Business Combination, Consideration Transferred Purchase price business acquisition Total consideration transferred Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Equity consideration Value of common stock issued Business Combination Disclosure [Text Block] Acquisition of Spectrum LifeSciences, LLC Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Business acquisition, revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Prepaid expenses and other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accounts payable Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Liabilities Accrued liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Deferred tax assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business combination, intangible assets Fair value of acquired finite lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Fixed assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unrecognized Tax Benefit Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unrecognized Tax Benefit Unrecognized tax benefit Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Fair value of net assets acquired Net assets acquired Business Combinations [Abstract] Business Combinations [Abstract] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents and Restricted Cash [Member] Cash, Cash Equivalents and Restricted Cash [Member] Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, beginning of period Change in Contract with Customer, Asset and Liability [Abstract] Revenue recognized in the period relating to: Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitments and Contingencies Commitments and contingencies (Note 14) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $.01 par value, 80,000,000 shares authorized, 43,692,303 shares at March 31, 2018 and 43,587,079 shares at December 31, 2017 issued and outstanding Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (Loss) Note [Text Block] Accumulated Other Comprehensive Income Computation of Earnings Per Share [Line Items] Computation of Earnings Per Share [Line Items] Computation of Earnings Per Share [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration Risk, Percentage Revenues, percentage by country Accounts receivable, percentage by customer Revenue from significant customers as a percentage of total revenue Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Construction in Progress, Gross Construction in progress Contract with Customer, Asset and Liability [Abstract] Balances from contracts with customers only: Contract with Customer, Asset and Liability [Table Text Block] Summary of Receivables and Deferred Revenue from Contracts with Customers Contract with customer liability beginning balance. Contract with Customer Liability Beginning Balance The beginning deferred revenue balance Contract with Customer, Performance Obligation Satisfied in Previous Period Changes in pricing related to products or services satisfied in previous periods Convertible Debt [Table Text Block] Carrying Value of Convertible Senior Notes Convertible Notes Payable, Noncurrent Convertible senior notes, net Cost of Goods Sold Cost of product revenue Cost of Sales [Member] Cost of product revenue Costs and Expenses Total operating expenses Costs and Expenses [Abstract] Operating expenses: Current Fiscal Year End Date Current Fiscal Year End Date Customer Concentration Risk [Member] Customer Concentration Risk Customer Relationships [Member] Customer relationships GERMANY Germany Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Long-term Debt, Gross Principal amount Debt Instrument, Convertible, Conversion Price Notes initial conversion price Debt Instrument, Convertible, Conversion Ratio Notes conversion ratio per $1,000 principal amount Debt Instrument, Convertible, Threshold Consecutive Trading Days Notes threshold consecutive trading days Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Notes threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Trading Days Notes threshold trading days Debt Instrument, Date of First Required Payment Notes, date of first required payment Debt instrument debt covenants debt default holder percent to declare all notes due minimum. Debt Instrument Debt Covenants Debt Default Holder Percent To Declare All Notes Due Minimum Debt covenants debt default holder percent to declare all notes due minimum Debt Instrument, Face Amount Notes issued Principal amount Debt Instrument, Fair Value Disclosure Notes issued, fair value Debt Instrument, Frequency of Periodic Payment Notes, frequency of periodic payment Debt Instrument, Interest Rate, Effective Percentage Effective interest rate on the Notes Debt Instrument, Interest Rate, Stated Percentage Notes, interest rate Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Notes, due date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt instrument number of days within which entity fails to satisfy obligations considered as event of default. Debt Instrument Number Of Days Within Which Entity Fails To Satisfy Obligations Considered As Event Of Default Number of days within which entity fails to satisfy obligations considered as event of default Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period One [Member] On any business day on or after June 5, 2019 and prior to the maturity date Debt Instrument, Redemption Price, Percentage Notes redemption price Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Unamortized Discount Unamortized debt discount Debt Issuance Costs, Net Unamortized debt issuance costs Deferred Income Tax Expense (Benefit) Deferred tax expense Deferred Revenue Deferred revenue Deferred Revenue, Current Unearned revenue Deferred Tax Liabilities, Net, Noncurrent Deferred tax liabilities Deferred Tax Liability [Member] Deferred Tax Liability [Member] Deferred Tax Liabilities Depreciation Depreciation expense of property and equipment Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Developed Technology Rights [Member] Technology - developed Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Effect of dilutive securities: Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Domestic Tax Authority [Member] Domestic Tax Authority Earliest Tax Year [Member] Earliest Tax Year Earnings Per Share [Abstract] Earnings per share: Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Earnings Per Share [Table] Earnings Per Share [Table] Earnings Per Share [Table] Earnings Per Share [Text Block] Earnings Per Share Effective Income Tax Rate Reconciliation, Percent Effective tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent U.S. statutory tax rate Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Employee-related Liabilities, Current Employee compensation Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Total unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost, weighted average remaining requisite service period Employee Stock Option And Restricted Stock Units [Member] Employee Stock Option And Restricted Stock Units [Member] Employee Stock Option and Restricted Stock Units (RSUs) Employee Stock Option [Member] Employee Stock Option Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Europe [Member] Europe Executive Officer [Member] Awards Granted to Executive Level Employees Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurement Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Amortization Expense, December 31, 2018 (nine months remaining) Finite-lived Intangible Assets Amortization Expense [Table Text Block] Schedule of Amortization Expense for Amortized Intangible Assets Finite-Lived Intangible Assets, Amortization Expense, Year Five Amortization Expense, December 31, 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Four Amortization Expense, December 31, 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Three Amortization Expense, December 31, 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Two Amortization Expense, December 31, 2019 Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Gross Carrying Amount EX-101.PRE 12 rgen-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 13 g574491g60x80.jpg GRAPHIC begin 644 g574491g60x80.jpg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end XML 14 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 01, 2018
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Trading Symbol	RGEN
Entity Registrant Name	REPLIGEN CORP
Entity Central Index Key	0000730272
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		43,693,913

XML 15 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 173,876	$ 173,759
Accounts receivable, less reserve for doubtful accounts of $59 at March 31, 2018 and $58 at December 31, 2017, respectively	29,352	27,585
Royalties and other receivables	31	153
Inventories, net	40,124	39,004
Prepaid expenses and other current assets	4,939	2,281
Total current assets	248,322	242,782
Property, plant and equipment, net	22,674	22,417
Intangible assets, net	142,273	144,753
Goodwill	327,989	327,333
Other assets	1,990	6,234
Total assets	743,248	743,519
Current liabilities:
Accounts payable	6,200	7,282
Accrued liabilities	14,121	17,929
Total current liabilities	20,321	25,211
Convertible senior notes, net	100,276	99,250
Deferred tax liabilities	20,858	25,167
Other long-term liabilities	4,610	2,343
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $.01 par value, 5,000,000 shares authorized, no shares issued or outstanding
Common stock, $.01 par value, 80,000,000 shares authorized, 43,692,303 shares at March 31, 2018 and 43,587,079 shares at December 31, 2017 issued and outstanding	437	436
Additional paid-in capital	631,595	628,983
Accumulated other comprehensive loss	(6,112)	(6,363)
Accumulated deficit	(28,737)	(31,508)
Total stockholders' equity	597,183	591,548
Total liabilities and stockholders' equity	$ 743,248	$ 743,519

XML 16 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounts receivable, reserve for doubtful accounts	$ 59	$ 58
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	43,692,303	43,587,079
Common stock, shares outstanding	43,692,303	43,587,079

XML 17 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Product revenue	$ 44,799	$ 30,569
Royalty and other revenue	31	21
Total revenue	44,830	30,590
Operating expenses:
Cost of product revenue	19,668	13,990
Research and development	3,288	1,742
Selling, general and administrative	15,898	9,182
Total operating expenses	38,854	24,914
Income from operations	5,976	5,676
Investment income	181	96
Interest expense	(1,652)	(1,585)
Other income (expense)	71	(120)
Income before income taxes	4,576	4,067
Income tax provision	1,128	999
Net income	$ 3,448	$ 3,068
Earnings per share:
Basic	$ 0.08	$ 0.09
Diluted	$ 0.08	$ 0.09
Weighted average shares outstanding:
Basic	43,621,270	33,891,702
Diluted	44,326,732	34,382,322
Other comprehensive income:
Unrealized gain on investments		$ 4
Foreign currency translation gain	$ 251	1,027
Comprehensive income	$ 3,699	$ 4,099

XML 18 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net income	$ 3,448	$ 3,068
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,960	1,582
Non-cash interest expense	1,036	970
Stock-based compensation expense	2,268	1,531
Deferred tax expense	449	10
Loss on conversion of senior convertible notes	1
Loss on disposal of assets		59
Changes in assets and liabilities:
Accounts receivable	(1,529)	(2,415)
Other receivables	127	172
Inventories	(1,188)	851
Prepaid expenses and other current assets	(1,608)	34
Accounts payable	(1,550)	(452)
Accrued liabilities	(3,839)	(4,220)
Long-term liabilities	(3)	(43)
Net cash provided by operating activities	1,572	1,147
Cash flows from investing activities:
Purchases of marketable securities		(28)
Redemptions of marketable securities		7,400
Purchases of property, plant and equipment	(1,564)	(1,295)
Net cash (used in) provided by investing activities	(1,564)	6,077
Cash flows from financing activities:
Exercise of stock options	344	1,333
Repayment of senior convertible notes	(11)
Payment of contingent consideration		(1,663)
Net cash provided by (used in) financing activities	333	(330)
Effect of exchange rate changes on cash and cash equivalents	(224)	536
Net increase (decrease) in cash and cash equivalents	117	7,430
Cash, cash equivalents and restricted cash, beginning of period	173,759	122,683
Cash, cash equivalents and restricted cash, end of period	173,876	130,113
Supplemental disclosure of non-cash activities:
Income taxes paid	937	1,181
Non-cash effect of adoption of ASU 2016-16	$ 5,609
Payment of contingent consideration in common stock		$ 1,062

XML 19 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Mar. 31, 2018

Basis of Presentation

1. Basis of Presentation

Recently Issued Accounting Pronouncements

XML 20 R7.htm IDEA: XBRL DOCUMENT

Acquisition of Spectrum LifeSciences, LLC

3 Months Ended

Mar. 31, 2018

Acquisition of Spectrum LifeSciences, LLC

2. Acquisition of Spectrum LifeSciences, LLC

Spectrum’s filtration products include its KrosFlo^® line of hollow-fiber cartridges, tangential flow filtration (TFF) systems and single-use flow path consumables, as well as its Spectra/Por^® portfolio of laboratory dialysis products and its Pro-Connex^® single-usehollow fiber Module-Bag-Tubing (MBT) sets. Outside of filtration, Spectrum sells its Spectra/Chrom^® liquid chromatography products for research applications. These bioprocessing products account for the majority of Spectrum revenues. Spectrum also offers a line of operating room products.

Consideration Transferred

The total consideration transferred follows (in thousands):


Cash consideration	$	122,932
Equity consideration		247,575
Working capital adjustment		425

Net assets acquired	$	370,932

Fair Value of Net Assets Acquired


Cash and cash equivalents	$	10,137
Accounts receivable		5,075
Inventory		13,570
Prepaid expenses and other assets		616
Fixed assets		6,004
Deferred tax assets		1,102
Customer relationships		78,400
Developed technology		38,560
Trademark and tradename		2,160
Non-competition agreements		960
Goodwill		265,654
Accounts payable		(1,335	)
Unrecognized tax benefit		(576	)
Accrued liabilities		(5,787	)
Deferred tax liabilities		(43,608	)

Fair value of net assets acquired	$	370,932

Revenue, Net Income and Pro Forma Presentation


	Pro-forma Three months ended March 31, 2018		Pro-forma Three months ended March 31, 2017
Total revenue		44,830		39,875
Net income		3,939		3,266
Earnings per share:
Basic	$	0.09	$	0.08

Diluted	$	0.09	$	0.08

XML 21 R8.htm IDEA: XBRL DOCUMENT

Revenue Recognition

3 Months Ended

Mar. 31, 2018

Revenue Recognition

3. Revenue Recognition

Adoption of ASC Topic 606, Revenue from Contracts with Customers

Revenue Recognition

The Company recognizes product revenue under the terms of each customer agreement upon transfer of control to the customer, which occurs at a point in time.

Disaggregation of Revenue

Revenues for the three-month periods ended March 31, 2018 and 2017 were as follows:


	Three months ended March 31,
(in thousands, except percentages)	2018		2017		$ Change		% Change
Product revenue	$	44,799	$	30,569	$	14,230		47	%
Royalty and other revenue		31		21		10		48	%

Total revenue	$	44,830	$	30,590	$	14,240		47	%

The following tables disaggregate the Company’s revenue from contracts with customers by geographic region (in thousands).


	Three months ended March 31, 2018
North America	$	20,239
Europe		19,401
Asia and Pacific		4,947
Other		243

Total revenue	$	44,830

Revenue from significant customers is as follows (in thousands):


	Three months ended March 31, 2018
GE Healthcare	$	7,717
MilliporeSigma	$	6,465

Protein Products

Filtration Products

Chromatography Products

Other Products

Transaction Price Allocated to Future Performance Obligations

Contract Balances from Contracts with Customers

The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2018:


	2018
Balances from contracts with customers only:
Accounts receivable	$	29,352
Deferred revenue		1,547
Revenue recognized in the period relating to:
The beginning deferred revenue balance	$	434
Changes in pricing related to products or services satisfied in previous periods		—
Impairment losses on receivables		—

The timing of revenue recognition, billings and cash collections results in accounts receivables and deferred revenue on the Company’s consolidated balance sheets.

Costs to Obtain or Fulfill a Customer Contract

The Company’s sales commission structure is based on achieving revenue targets. The commissions are driven by revenue derived from customer purchase orders which are short term in nature.

XML 22 R9.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income

3 Months Ended

Mar. 31, 2018

Accumulated Other Comprehensive Income

4. Accumulated Other Comprehensive Income

The following table summarizes the changes in accumulated other comprehensive income by component (in thousands):


(In thousands)	Foreign currency translation gain (loss)
Balance at December 31, 2017	$	(6,363	)
Foreign currency translation gain		251

Balance at March 31, 2018	$	(6,112	)

XML 23 R10.htm IDEA: XBRL DOCUMENT

Earnings Per Share

3 Months Ended

Mar. 31, 2018

Earnings Per Share

5. Earnings Per Share

Basic and diluted weighted average shares outstanding were as follows:


	Three months ended March 31,
	2018		2017
Basic weighted average common shares outstanding		43,621,270		33,891,702
Effect of dilutive securities:
Stock options and restricted stock awards		389,702		490,620
Convertible senior notes		315,760		—

Weighted average common shares, assuming dilution		44,326,732		34,382,322

XML 24 R11.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2018

Inventories

6. Inventories

Work-in-process and finished products inventories consist of material, labor, outside processing costs and manufacturing overhead. Inventories consist of the following (in thousands):


	March 31, 2018		December 31, 2017
Raw Materials	$	21,826	$	22,351
Work-in-process		3,828		4,083
Finished products		14,470		12,570

Total	$	40,124	$	39,004

XML 25 R12.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment

3 Months Ended

Mar. 31, 2018

Property, Plant and Equipment

7. Property, Plant and Equipment

Property, plant and equipment consist of the following (in thousands):


	March 31, 2018			December 31, 2017
Land	$	1,023		$	1,023
Buildings		764			764
Leasehold improvements		15,740			15,673
Equipment		22,497			21,904
Furniture and fixtures		4,605			4,272
Construction in progress		3,052			2,581

Total property, plant and equipment		47,681			46,217
Less: accumulated depreciation		(25,007	)		(23,800	)

Property, plant and equipment, net	$	22,674		$	22,417

Depreciation expense totaled approximately $1,284,000 and $928,000 for the three-month periods ended March 31, 2018 and 2017, respectively.

XML 26 R13.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Mar. 31, 2018

Intangible Assets

8. Intangible Assets

Intangible assets consisted of the following at March 31, 2018 (in thousands):


	Gross Carrying Amount		Accumulated Amortization			Weighted Average Useful Life (in years)
Technology – developed	$	51,860	$	(3,898	)		19
Patents		240		(240	)		8
Customer relationships		102,210		(11,446	)		14
Trademark – definite lived		2,160		(75	)		20
Trademark – indefinite lived		700		—			—
Other intangibles		1,066		(304	)		3

Total intangible assets	$	158,236	$	(15,963	)		16

Intangible assets consisted of the following at December 31, 2017 (in thousands):


	Gross Carrying Amount		Accumulated Amortization			Weighted Average Useful Life (in years)
Technology – developed	$	51,801	$	(3,201	)		19
Patents		240		(238	)		8
Customer relationships		102,120		(9,636	)		14
Trademarks – definite lived		2,160		(47	)		20
Trademarks – indefinite lived		700		—			—
Other intangibles		1,063		(209	)		3

Total intangible assets	$	158,084	$	(13,331	)		16


Years Ending	Amortization Expense
December 31, 2018 (nine months remaining)	$	7,978
December 31, 2019		10,513
December 31, 2020		9,910
December 31, 2021		9,395
December 31, 2022		9,395

XML 27 R14.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

3 Months Ended

Mar. 31, 2018

Accrued Liabilities

9. Accrued Liabilities

Accrued liabilities consist of the following (in thousands):


	March 31, 2018		December 31, 2017
Employee compensation	$	5,246	$	9,560
Taxes		2,049		1,668
Royalty and license fees		1,243		1,383
Accrued purchases		521		1,191
Professional fees		827		947
Unearned revenue		1,547		960
Other accrued expenses		2,688		2,220

Total	$	14,121	$	17,929

XML 28 R15.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes

3 Months Ended

Mar. 31, 2018

Convertible Senior Notes

10. Convertible Senior Notes

The carrying value of the Company’s convertible senior notes is as follows:


	March 31, 2018			December 31, 2017
2.125% Convertible Senior Notes due 2021:
Principal amount	$	114,989		$	115,000
Unamortized debt discount		(12,513	)		(13,395	)
Unamortized debt issuance costs		(2,200	)		(2,355	)

Total convertible senior notes	$	100,276		$	99,250

XML 29 R16.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2018

Stock-Based Compensation

11. Stock-Based Compensation

The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (in thousands):


	Three Months Ended March 31,
	2018		2017
Cost of product revenue	$	266	$	141
Research and development		170		132
Selling, general and administrative		1,832		1,258

Total	$	2,268	$	1,531

Information regarding option activity for the three-month period ended March 31, 2018 under the Plans is summarized below:


	Options Outstanding			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		(in thousands) Aggregate Intrinsic Value
Options outstanding at December 31, 2017		734,940		$	20.80
Granted		398,532			33.85
Exercised		(14,531	)		23.70
Forfeited/cancelled		(9,588	)		29.71

Options outstanding at March 31, 2018		1,109,353		$	25.34		7.51	$	12,176

Options exercisable at March 31, 2018		499,504		$	17.73		5.50	$	9,300

Vested and expected to vest at March 31, 2018 (1)		1,057,255		$	24.96		7.40	$	12,015

⁽¹⁾

Information regarding restricted stock unit and performance stock unit activity for the three-month period ended March 31, 2018 under the Plans is summarized below:


	Units Outstanding			Weighted- Average Remaining Contractual Term (in years)		(in thousands) Aggregate Intrinsic Value
Restricted and performance stock units outstanding at December 31, 2017		505,235
Granted		319,701
Exercised		(90,691	)
Forfeited/cancelled		(31,169	)

Restricted stock units outstanding at March 31, 2018		703,076			4.06	$	25,437

Vested and expected to vest at March 31, 2018 (1)		639,530			3.75	$	23,138

⁽¹⁾

XML 30 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2018

Income Taxes

12. Income Taxes

The Company’s tax returns are subject to examination by federal, state and international taxing authorities for the following periods:


Jurisdiction		Fiscal years subject to examination
United States – federal and state		2014-2017
Sweden		2011-2017
Germany		2017
Netherlands		2012-2017

XML 31 R18.htm IDEA: XBRL DOCUMENT

Fair Value Measurement

3 Months Ended

Mar. 31, 2018

Fair Value Measurement

13. Fair Value Measurement


Level 1–		Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access

Level 2–		Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly

Level 3–		Valuations based on inputs that are unobservable and significant to the overall fair value measurement

As of March 31, 2018 and December 31, 2017, the Company had no assets or liabilities for which fair value measurement is either required or has been elected to be applied.

There were no re-measurements to fair value during the three months ended March 31, 2018 of financial assets and liabilities that are not measured at fair value on a recurring basis.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 32 R19.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies

14. Commitments and Contingencies

The Company leases its headquarters in Waltham, Massachusetts as well as certain of its office and manufacturing space around the world.

Future minimum rental commitments under the Company’s leases as of March 31, 2018 are as follows (in thousands):


	Minimum Rental Commitments
2018 (nine months remaining)	$	3,191
2019		3,808
2020		3,653
2021		3,342
2022		1,968
Thereafter		4,401

XML 33 R20.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2018

Related Party Transactions

15. Related Party Transactions

XML 34 R21.htm IDEA: XBRL DOCUMENT

Segment Reporting

3 Months Ended

Mar. 31, 2018

Segment Reporting

16. Segment Reporting

The following table represents the Company’s total revenue by geographic area (based on the location of the customer):


	Three months ended March 31,
	2018			2017
North America		45	%		38	%
Europe		43	%		54	%
Asia and Australia		11	%		8	%
Other		1	%		—

Total		100	%		100	%

Revenue from significant customers as a percentage of the Company’s total revenue is as follows:


	Three months ended March 31,
	2018			2017
GE Healthcare		17	%		27	%
MilliporeSigma		14	%		21	%

Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable are as follows:


	March 31, 2018			December 31, 2017
GE Healthcare		19	%		11	%
MilliporeSigma		20	%		19	%

XML 35 R22.htm IDEA: XBRL DOCUMENT

Acquisition of Spectrum LifeSciences, LLC (Tables) - Spectrum Inc.

3 Months Ended

Mar. 31, 2018

Consideration Transferred

The total consideration transferred follows (in thousands):


Cash consideration	$	122,932
Equity consideration		247,575
Working capital adjustment		425

Net assets acquired	$	370,932

Components and Allocation of Purchase Price

The components and allocation of the purchase price consists of the following amounts (in thousands):


Cash and cash equivalents	$	10,137
Accounts receivable		5,075
Inventory		13,570
Prepaid expenses and other assets		616
Fixed assets		6,004
Deferred tax assets		1,102
Customer relationships		78,400
Developed technology		38,560
Trademark and tradename		2,160
Non-competition agreements		960
Goodwill		265,654
Accounts payable		(1,335	)
Unrecognized tax benefit		(576	)
Accrued liabilities		(5,787	)
Deferred tax liabilities		(43,608	)

Fair value of net assets acquired	$	370,932

Unaudited Supplemental Pro Forma Information

The following table presents unaudited supplemental pro forma information as if the Spectrum Acquisition had occurred as of January 1, 2017 (in thousands, except per share data):


	Pro-forma Three months ended March 31, 2018		Pro-forma Three months ended March 31, 2017
Total revenue		44,830		39,875
Net income		3,939		3,266
Earnings per share:
Basic	$	0.09	$	0.08

Diluted	$	0.09	$	0.08

XML 36 R23.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2018

Disaggregation of Revenue

Revenues for the three-month periods ended March 31, 2018 and 2017 were as follows:


	Three months ended March 31,
(in thousands, except percentages)	2018		2017		$ Change		% Change
Product revenue	$	44,799	$	30,569	$	14,230		47	%
Royalty and other revenue		31		21		10		48	%

Total revenue	$	44,830	$	30,590	$	14,240		47	%

Disaggregation of Revenue from Contracts with Customers by Geographic Region

The following tables disaggregate the Company’s revenue from contracts with customers by geographic region (in thousands).


	Three months ended March 31, 2018
North America	$	20,239
Europe		19,401
Asia and Pacific		4,947
Other		243

Total revenue	$	44,830

Revenue from Significant Customers

Revenue from significant customers is as follows (in thousands):


	Three months ended March 31, 2018
GE Healthcare	$	7,717
MilliporeSigma	$	6,465

Summary of Receivables and Deferred Revenue from Contracts with Customers

The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2018:


	2018
Balances from contracts with customers only:
Accounts receivable	$	29,352
Deferred revenue		1,547
Revenue recognized in the period relating to:
The beginning deferred revenue balance	$	434
Changes in pricing related to products or services satisfied in previous periods		—
Impairment losses on receivables		—

XML 37 R24.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income (Tables)

3 Months Ended

Mar. 31, 2018

Summary of Changes in Accumulated Other Comprehensive Income

The following table summarizes the changes in accumulated other comprehensive income by component (in thousands):


(In thousands)	Foreign currency translation gain (loss)
Balance at December 31, 2017	$	(6,363	)
Foreign currency translation gain		251

Balance at March 31, 2018	$	(6,112	)

XML 38 R25.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2018

Basic and Diluted Weighted Average Shares Outstanding

Basic and diluted weighted average shares outstanding were as follows:


	Three months ended March 31,
	2018		2017
Basic weighted average common shares outstanding		43,621,270		33,891,702
Effect of dilutive securities:
Stock options and restricted stock awards		389,702		490,620
Convertible senior notes		315,760		—

Weighted average common shares, assuming dilution		44,326,732		34,382,322

XML 39 R26.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of Inventories

Inventories consist of the following (in thousands):


	March 31, 2018		December 31, 2017
Raw Materials	$	21,826	$	22,351
Work-in-process		3,828		4,083
Finished products		14,470		12,570

Total	$	40,124	$	39,004

XML 40 R27.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Tables)

3 Months Ended

Mar. 31, 2018

Property, Plant and Equipment

Property, plant and equipment consist of the following (in thousands):


	March 31, 2018			December 31, 2017
Land	$	1,023		$	1,023
Buildings		764			764
Leasehold improvements		15,740			15,673
Equipment		22,497			21,904
Furniture and fixtures		4,605			4,272
Construction in progress		3,052			2,581

Total property, plant and equipment		47,681			46,217
Less: accumulated depreciation		(25,007	)		(23,800	)

Property, plant and equipment, net	$	22,674		$	22,417

XML 41 R28.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2018

Intangible assets

Intangible assets consisted of the following at March 31, 2018 (in thousands):


	Gross Carrying Amount		Accumulated Amortization			Weighted Average Useful Life (in years)
Technology – developed	$	51,860	$	(3,898	)		19
Patents		240		(240	)		8
Customer relationships		102,210		(11,446	)		14
Trademark – definite lived		2,160		(75	)		20
Trademark – indefinite lived		700		—			—
Other intangibles		1,066		(304	)		3

Total intangible assets	$	158,236	$	(15,963	)		16

Intangible assets consisted of the following at December 31, 2017 (in thousands):


	Gross Carrying Amount		Accumulated Amortization			Weighted Average Useful Life (in years)
Technology – developed	$	51,801	$	(3,201	)		19
Patents		240		(238	)		8
Customer relationships		102,120		(9,636	)		14
Trademarks – definite lived		2,160		(47	)		20
Trademarks – indefinite lived		700		—			—
Other intangibles		1,063		(209	)		3

Total intangible assets	$	158,084	$	(13,331	)		16

Schedule of Amortization Expense for Amortized Intangible Assets

As of March 31, 2018, the Company expects to record amortization expense as follows (in thousands):


Years Ending	Amortization Expense
December 31, 2018 (nine months remaining)	$	7,978
December 31, 2019		10,513
December 31, 2020		9,910
December 31, 2021		9,395
December 31, 2022		9,395

XML 42 R29.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2018

Accrued Liabilities

Accrued liabilities consist of the following (in thousands):


	March 31, 2018		December 31, 2017
Employee compensation	$	5,246	$	9,560
Taxes		2,049		1,668
Royalty and license fees		1,243		1,383
Accrued purchases		521		1,191
Professional fees		827		947
Unearned revenue		1,547		960
Other accrued expenses		2,688		2,220

Total	$	14,121	$	17,929

XML 43 R30.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes (Tables)

3 Months Ended

Mar. 31, 2018

Carrying Value of Convertible Senior Notes

The carrying value of the Company’s convertible senior notes is as follows:


	March 31, 2018			December 31, 2017
2.125% Convertible Senior Notes due 2021:
Principal amount	$	114,989		$	115,000
Unamortized debt discount		(12,513	)		(13,395	)
Unamortized debt issuance costs		(2,200	)		(2,355	)

Total convertible senior notes	$	100,276		$	99,250

XML 44 R31.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2018

Stock-Based Compensation Expense

The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (in thousands):


	Three Months Ended March 31,
	2018		2017
Cost of product revenue	$	266	$	141
Research and development		170		132
Selling, general and administrative		1,832		1,258

Total	$	2,268	$	1,531

Summary of Option Activity

Information regarding option activity for the three-month period ended March 31, 2018 under the Plans is summarized below:


	Options Outstanding			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		(in thousands) Aggregate Intrinsic Value
Options outstanding at December 31, 2017		734,940		$	20.80
Granted		398,532			33.85
Exercised		(14,531	)		23.70
Forfeited/cancelled		(9,588	)		29.71

Options outstanding at March 31, 2018		1,109,353		$	25.34		7.51	$	12,176

Options exercisable at March 31, 2018		499,504		$	17.73		5.50	$	9,300

Vested and expected to vest at March 31, 2018 (1)		1,057,255		$	24.96		7.40	$	12,015

⁽¹⁾

Restricted Stock Units and Performance Stock Units

Summary of Restricted Stock Unit and Performance Stock Unit Activity

Information regarding restricted stock unit and performance stock unit activity for the three-month period ended March 31, 2018 under the Plans is summarized below:


	Units Outstanding			Weighted- Average Remaining Contractual Term (in years)		(in thousands) Aggregate Intrinsic Value
Restricted and performance stock units outstanding at December 31, 2017		505,235
Granted		319,701
Exercised		(90,691	)
Forfeited/cancelled		(31,169	)

Restricted stock units outstanding at March 31, 2018		703,076			4.06	$	25,437

Vested and expected to vest at March 31, 2018 (1)		639,530			3.75	$	23,138

⁽¹⁾

XML 45 R32.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

3 Months Ended

Mar. 31, 2018

Summary of Tax Returns Periods Subject to Examination by Federal, State and International Taxing Authorities

The Company’s tax returns are subject to examination by federal, state and international taxing authorities for the following periods:


Jurisdiction		Fiscal years subject to examination
United States – federal and state		2014-2017
Sweden		2011-2017
Germany		2017
Netherlands		2012-2017

XML 46 R33.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2018

Future Minimum Rental Commitments under Company's Leases

Future minimum rental commitments under the Company’s leases as of March 31, 2018 are as follows (in thousands):


	Minimum Rental Commitments
2018 (nine months remaining)	$	3,191
2019		3,808
2020		3,653
2021		3,342
2022		1,968
Thereafter		4,401

XML 47 R34.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2018

Percentage of Revenue from Significant Customers

Revenue from significant customers as a percentage of the Company’s total revenue is as follows:


	Three months ended March 31,
	2018			2017
GE Healthcare		17	%		27	%
MilliporeSigma		14	%		21	%

Total Revenue

Percentage by Geographic Area or Significant Customers

The following table represents the Company’s total revenue by geographic area (based on the location of the customer):


	Three months ended March 31,
	2018			2017
North America		45	%		38	%
Europe		43	%		54	%
Asia and Australia		11	%		8	%
Other		1	%		—

Total		100	%		100	%

Accounts Receivable

Percentage by Geographic Area or Significant Customers

Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable are as follows:


	March 31, 2018			December 31, 2017
GE Healthcare		19	%		11	%
MilliporeSigma		20	%		19	%

XML 48 R35.htm IDEA: XBRL DOCUMENT

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
ASU No. 2016-18 \| Cash, Cash Equivalents and Restricted Cash
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New accounting pronouncement, cumulative effect of change on cash, cash equivalents and restricted cash	$ 450	$ 450

XML 49 R36.htm IDEA: XBRL DOCUMENT

Acquisition of Spectrum LifeSciences, LLC - Additional Information (Detail) - USD ($)		3 Months Ended	12 Months Ended
	Aug. 01, 2017	Mar. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Finite lived intangible asset, useful life		16 years	16 years
Goodwill		$ 327,989,000	$ 327,333,000
Customer relationships
Business Acquisition [Line Items]
Finite lived intangible asset, useful life		14 years	14 years
Technology - developed
Business Acquisition [Line Items]
Finite lived intangible asset, useful life		19 years	19 years
Spectrum Inc.
Business Acquisition [Line Items]
Cash payment to acquire business	$ 122,932,000
Shares issued for business acquisition	6,153,995
Value of common stock issued	$ 247,575,000
Working capital adjustment	425,000
Purchase price business acquisition	370,932,000
Fair value of net assets acquired	370,932,000
Goodwill	265,654,000
Goodwill expected to be deductible for tax purposes amount	0
Business acquisition, revenue		$ 11,719,000
Spectrum Inc. \| Customer relationships
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 78,400,000
Finite lived intangible asset, useful life	15 years
Spectrum Inc. \| Technology - developed
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 38,560,000
Finite lived intangible asset, useful life	20 years
Spectrum Inc. \| Non-competition agreements
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 960,000
Finite lived intangible asset, useful life	3 years
Spectrum Inc. \| Trademark and Tradename
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 2,160,000
Spectrum Inc. \| Selling, general and administrative
Business Acquisition [Line Items]
Business combination, acquisition related costs		$ 655,000	$ 7,060,000

XML 50 R37.htm IDEA: XBRL DOCUMENT

Consideration Transferred (Detail) - Spectrum Inc. $ in Thousands	Aug. 01, 2017 USD ($)
Business Acquisition [Line Items]
Cash consideration	$ 122,932
Equity consideration	247,575
Working capital adjustment	425
Total consideration transferred	$ 370,932

XML 51 R38.htm IDEA: XBRL DOCUMENT

Components and Allocation of Purchase Price (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Aug. 01, 2017
Business Acquisition [Line Items]
Goodwill	$ 327,989	$ 327,333
Spectrum Inc.
Business Acquisition [Line Items]
Cash and cash equivalents			$ 10,137
Accounts receivable			5,075
Inventory			13,570
Prepaid expenses and other assets			616
Fixed assets			6,004
Deferred tax assets			1,102
Goodwill			265,654
Accounts payable			(1,335)
Unrecognized tax benefit			(576)
Accrued liabilities			(5,787)
Deferred tax liabilities			(43,608)
Net assets acquired			370,932
Spectrum Inc. \| Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets			78,400
Spectrum Inc. \| Technology - developed
Business Acquisition [Line Items]
Business combination, intangible assets			38,560
Spectrum Inc. \| Trademark and Tradename
Business Acquisition [Line Items]
Business combination, intangible assets			2,160
Spectrum Inc. \| Non-competition agreements
Business Acquisition [Line Items]
Business combination, intangible assets			$ 960

XML 52 R39.htm IDEA: XBRL DOCUMENT

Unaudited Supplemental Pro Forma Information (Detail) - Spectrum Inc. - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Business Acquisition [Line Items]
Total revenue	$ 44,830	$ 39,875
Net income	$ 3,939	$ 3,266
Earnings per share:
Basic	$ 0.09	$ 0.08
Diluted	$ 0.09	$ 0.08

XML 53 R40.htm IDEA: XBRL DOCUMENT

Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disaggregation of Revenue [Line Items]
Product revenue	$ 44,799	$ 30,569
Royalty and other revenue	31	21
Total revenue	44,830	$ 30,590
Product revenue, percentage change amount	14,230
Royalty and other revenue, percentage change amount	10
Total revenue, percentage change amount	$ 14,240
Product revenue, percentage change	47.00%
Royalty and other revenue, percentage change	48.00%
Total revenue, percentage change	47.00%

XML 54 R41.htm IDEA: XBRL DOCUMENT

Revenue from Contracts with Customers by Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Concentration Risk [Line Items]
Total revenue	$ 44,830	$ 30,590
North America
Concentration Risk [Line Items]
Total revenue	20,239
Europe
Concentration Risk [Line Items]
Total revenue	19,401
Asia and Pacific
Concentration Risk [Line Items]
Total revenue	4,947
Other
Concentration Risk [Line Items]
Total revenue	$ 243

XML 55 R42.htm IDEA: XBRL DOCUMENT

Revenue from Significant Customers (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Concentration Risk [Line Items]
Total revenue	$ 44,830	$ 30,590
GE Healthcare
Concentration Risk [Line Items]
Total revenue	7,717
MilliporeSigma
Concentration Risk [Line Items]
Total revenue	$ 6,465

XML 56 R43.htm IDEA: XBRL DOCUMENT

Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Balances from contracts with customers only:
Accounts receivable	$ 29,352	$ 27,585
Deferred revenue	1,547
Revenue recognized in the period relating to:
The beginning deferred revenue balance	434
Changes in pricing related to products or services satisfied in previous periods	0
Impairment losses on receivables	$ 0

XML 57 R44.htm IDEA: XBRL DOCUMENT

Change in Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 591,548
Foreign currency translation gain	251	$ 1,027
Ending Balance	597,183
Foreign currency translation gain (loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(6,363)
Foreign currency translation gain	251
Ending Balance	$ (6,112)

XML 58 R45.htm IDEA: XBRL DOCUMENT

Earnings Per Share - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	May 24, 2016
Computation of Earnings Per Share [Line Items]
Participating securities outstanding	0	0
Stock options, outstanding	1,109,353		734,940
Stock options, weighted average exercise price	$ 25.34		$ 20.80
Common stock excluded from calculation of diluted earnings per share	593,874	458,685
2.125% Convertible Senior Notes due 2021
Computation of Earnings Per Share [Line Items]
Notes, interest rate	2.125%			2.125%
Notes, due date	Jun. 01, 2021
Option To Purchase Common Stock
Computation of Earnings Per Share [Line Items]
Stock options, outstanding	1,109,353	805,903
Stock options, weighted average exercise price	$ 25.34	$ 19.68
Restricted Stock Units (RSUs)
Computation of Earnings Per Share [Line Items]
Common stock excluded from calculation of diluted earnings per share	703,076	404,781

XML 59 R46.htm IDEA: XBRL DOCUMENT

Basic and Diluted Weighted Average Shares Outstanding (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Weighted Average Number of Shares Outstanding [Line Items]
Basic weighted average common shares outstanding	43,621,270	33,891,702
Effect of dilutive securities:
Stock options and restricted stock awards	389,702	490,620
Convertible senior notes	315,760
Weighted average common shares, assuming dilution	44,326,732	34,382,322

XML 60 R47.htm IDEA: XBRL DOCUMENT

Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory [Line Items]
Raw materials	$ 21,826	$ 22,351
Work-in-process	3,828	4,083
Finished products	14,470	12,570
Total	$ 40,124	$ 39,004

XML 61 R48.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Land	$ 1,023	$ 1,023
Buildings	764	764
Leasehold improvements	15,740	15,673
Equipment	22,497	21,904
Furniture and fixtures	4,605	4,272
Construction in progress	3,052	2,581
Total property, plant and equipment	47,681	46,217
Less: accumulated depreciation	(25,007)	(23,800)
Property, plant and equipment, net	$ 22,674	$ 22,417

XML 62 R49.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Property, Plant and Equipment [Line Items]
Depreciation expense of property and equipment	$ 1,284	$ 928

XML 63 R50.htm IDEA: XBRL DOCUMENT

Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Intangible Assets [Line Items]
Gross Carrying Amount	$ 158,236	$ 158,084
Accumulated Amortization	$ (15,963)	$ (13,331)
Weighted Average Useful Life (in years)	16 years	16 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Amount, indefinite lived intangible assets	$ 700	$ 700
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Amount	51,860	51,801
Accumulated Amortization	$ (3,898)	$ (3,201)
Weighted Average Useful Life (in years)	19 years	19 years
Patents
Intangible Assets [Line Items]
Gross Carrying Amount	$ 240	$ 240
Accumulated Amortization	$ (240)	$ (238)
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Amount	$ 102,210	$ 102,120
Accumulated Amortization	$ (11,446)	$ (9,636)
Weighted Average Useful Life (in years)	14 years	14 years
Other intangibles
Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,066	$ 1,063
Accumulated Amortization	$ (304)	$ (209)
Weighted Average Useful Life (in years)	3 years	3 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,160	$ 2,160
Accumulated Amortization	$ (75)	$ (47)
Weighted Average Useful Life (in years)	20 years	20 years

XML 64 R51.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 2,664	$ 715

XML 65 R52.htm IDEA: XBRL DOCUMENT

Amortization Expense for Amortized Intangible Assets (Detail) $ in Thousands	Mar. 31, 2018 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization Expense, December 31, 2018 (nine months remaining)	$ 7,978
Amortization Expense, December 31, 2019	10,513
Amortization Expense, December 31, 2020	9,910
Amortization Expense, December 31, 2021	9,395
Amortization Expense, December 31, 2022	$ 9,395

XML 66 R53.htm IDEA: XBRL DOCUMENT

Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$ 5,246	$ 9,560
Taxes	2,049	1,668
Royalty and license fees	1,243	1,383
Accrued purchases	521	1,191
Professional fees	827	947
Unearned revenue	1,547	960
Other accrued expenses	2,688	2,220
Total	$ 14,121	$ 17,929

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

XML 67 R54.htm IDEA: XBRL DOCUMENT

Carrying Value of Convertible Senior Notes (Detail) - 2.125% Convertible Senior Notes due 2021 - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Principal amount	$ 114,989	$ 115,000
Unamortized debt discount	(12,513)	(13,395)
Unamortized debt issuance costs	(2,200)	(2,355)
Total convertible senior notes	$ 100,276	$ 99,250

XML 68 R55.htm IDEA: XBRL DOCUMENT

Carrying Value of Convertible Senior Notes (Parenthetical) (Detail) - 2.125% Convertible Senior Notes due 2021	3 Months Ended
	Mar. 31, 2018	May 24, 2016
Debt Instrument [Line Items]
Notes, interest rate	2.125%	2.125%
Notes, due date	Jun. 01, 2021

XML 69 R56.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes - Additional Information (Detail)		3 Months Ended
	May 24, 2016 USD ($) d $ / shares	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Loss on conversion of senior convertible notes		$ (1,000)
Accretion of the debt discount		$ 1,036,000	$ 970,000
2.125% Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Notes issued	$ 115,000,000			$ 11,000
Notes, interest rate	2.125%	2.125%
Proceeds from issuance of convertible senior notes, net of costs	$ 111,100,000
Notes, frequency of periodic payment		Semi-annually
Notes, date of first required payment		Dec. 01, 2016
Notes, due date		Jun. 01, 2021
Loss on conversion of senior convertible notes		$ (1,000)
Notes conversion ratio per $1,000 principal amount	31.1813
Notes initial conversion price \| $ / shares	$ 32.07
Debt covenants debt default holder percent to declare all notes due minimum	25.00%
Number of days within which entity fails to satisfy obligations considered as event of default	270 days
Notes issued, fair value	$ 96,289,000
Contractual coupon interest		611,000
Accretion of the debt discount		881,000
Amortization of the debt issuance costs		$ 155,000
Effective interest rate on the Notes		6.60%
Notes, carrying value		$ 100,276,000		$ 99,250,000
Fair value of the note		$ 150,500,000
2.125% Convertible Senior Notes due 2021 \| On any business day on or after June 5, 2019 and prior to the maturity date
Debt Instrument [Line Items]
Notes threshold percentage of stock price trigger	130.00%
Notes threshold trading days \| d	20
Notes threshold consecutive trading days \| d	30
Notes redemption price	100.00%

XML 70 R57.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2012	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,268	$ 1,531
Stock options, outstanding	1,109,353			734,940
Number of shares available for future grant	254,907
Closing price of common stock	$ 36.18
Weighted average grant date fair value of share-based awards granted	$ 18.27	$ 16.46
Total fair value of stock options vested	$ 1,339	$ 1,195
Total unrecognized compensation cost	$ 30,762
Unrecognized compensation cost, weighted average remaining requisite service period	4 years 7 months 28 days
Employee Stock Option \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			3 years
Employee Stock Option \| Minimum \| Vest Over Three Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting percentage			33.00%
Employee Stock Option \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			5 years
Incentive options, term			10 years
Employee Stock Option \| Maximum \| Vest Over Five Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting percentage			20.00%
Non-Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			1 year
Option To Purchase Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, outstanding	1,109,353	805,903
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, outstanding	703,076
Closing price of common stock	$ 36.18
Aggregate intrinsic value of restricted stock units vested	$ 3,224	$ 2,064
Weighted average grant date fair value of restricted stock units granted	$ 33.80	$ 32.18
Total grant date fair value of restricted stock units vested	$ 2,619	$ 1,616
Employee Stock Option and Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period	9 years

XML 71 R58.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 2,268	$ 1,531
Cost of product revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	266	141
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	170	132
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,832	$ 1,258

XML 72 R59.htm IDEA: XBRL DOCUMENT

Summary of Option Activity (Detail)
$ / shares in Units, $ in Thousands

3 Months Ended

Mar. 31, 2018

USD ($)

$ / shares

Options Outstanding

Options outstanding at December 31, 2017 | shares

734,940

Granted | shares

398,532

Exercised | shares

(14,531)

Forfeited/cancelled | shares

(9,588)

Options outstanding at March 31, 2018 | shares

1,109,353

Options exercisable at March 31, 2018 | shares

499,504

Vested and expected to vest at March 31, 2018 | shares

1,057,255

^[1]

Weighted-Average Exercise Price Per Share

Options outstanding at December 31, 2017 | $ / shares

$ 20.80

Granted | $ / shares

33.85

Exercised | $ / shares

23.70

Forfeited/cancelled | $ / shares

29.71

Options outstanding at March 31, 2018 | $ / shares

25.34

Options exercisable at March 31, 2018 | $ / shares

17.73

Vested and expected to vest at March 31, 2018 | $ / shares

$ 24.96

^[1]

Weighted-Average Remaining Contractual Term (in years)

Options outstanding at March 31, 2018

7 years 6 months 3 days

Options exercisable at March 31, 2018

5 years 6 months

Vested and expected to vest at March 31, 2018

7 years 4 months 24 days

^[1]

Aggregate Intrinsic Value

Options outstanding at March 31, 2018 | $

$ 12,176

Options exercisable at March 31, 2018 | $

9,300

Vested and expected to vest at March 31, 2018 | $

$ 12,015

^[1]

[1]

XML 73 R60.htm IDEA: XBRL DOCUMENT

Summary of Option Activity (Parenthetical) (Detail) - Employee Stock Option	Mar. 31, 2018
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8.00%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3.00%

XML 74 R61.htm IDEA: XBRL DOCUMENT

Summary of Restricted Stock Unit and Performance Stock Unit Activity (Detail) - Restricted Stock Units and Performance Stock Units
$ in Thousands

3 Months Ended

Mar. 31, 2018

USD ($)

Options Outstanding

Restricted and performance stock units outstanding at December 31, 2017

505,235

Granted

319,701

Exercised

(90,691)

Forfeited/cancelled

(31,169)

Restricted stock units outstanding at March 31, 2018

703,076

Vested and expected to vest at March 31, 2018

639,530

^[1]

Weighted-Average Remaining Contractual Term (in years)

Restricted stock units outstanding at March 31, 2018

4 years 22 days

Vested and expected to vest at March 31, 2018

3 years 9 months

^[1]

Aggregate Intrinsic Value

Restricted stock units outstanding at March 31, 2018 | $

$ 25,437

Vested and expected to vest at March 31, 2018 | $

$ 23,138

^[1]

[1]

XML 75 R62.htm IDEA: XBRL DOCUMENT

Summary of Restricted Stock Unit and Performance Stock Unit Activity (Parenthetical) (Detail) - Restricted Stock Units (RSUs)	Mar. 31, 2018
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8.00%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3.00%

XML 76 R63.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) € in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017 USD ($)	Jan. 01, 2018 USD ($)	Dec. 31, 2017 EUR (€)
Income Taxes [Line Items]
Effective tax rate	24.70%	24.60%
U.S. statutory tax rate	21.00%	34.00%	35.00%
Net operating loss carry forwards, expiration description			Expire at various dates through December 2037.
Business tax credits carry forwards, expiration description			Expire at various dates through December 2037.
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability			$ 12,812
Tax cuts and jobs Act, increased tax provision on undistributed and previously untaxed post-1986 earnings and profits of the specified foreign corporation			3,266
Accounting Standards Update 2016-06 \| Other Assets
Income Taxes [Line Items]
Impact on assets and liabilities due to change in accounting principle				$ 5,609
Accounting Standards Update 2016-06 \| Deferred Tax Liabilities
Income Taxes [Line Items]
Impact on assets and liabilities due to change in accounting principle				4,932
Accounting Standards Update 2016-06 \| Accumulated Deficit
Income Taxes [Line Items]
Impact on assets and liabilities due to change in accounting principle				$ 677
Domestic Tax Authority
Income Taxes [Line Items]
Business tax credits carry forwards			297
State
Income Taxes [Line Items]
Business tax credits carry forwards			99
United States
Income Taxes [Line Items]
Net operating loss carry forwards			19,652
Germany
Income Taxes [Line Items]
Net operating loss carry forwards			$ 743		€ 603

XML 77 R64.htm IDEA: XBRL DOCUMENT

Summary of Tax Returns Periods Subject to Examination by Federal, State and International Taxing Authorities (Detail)	3 Months Ended
	Mar. 31, 2018
Germany
Income Tax Examination [Line Items]
Fiscal year subject to examination	2017
Earliest Tax Year \| United States
Income Tax Examination [Line Items]
Fiscal year subject to examination	2014
Earliest Tax Year \| Sweden
Income Tax Examination [Line Items]
Fiscal year subject to examination	2011
Earliest Tax Year \| Netherlands
Income Tax Examination [Line Items]
Fiscal year subject to examination	2012
Latest Tax Year \| United States
Income Tax Examination [Line Items]
Fiscal year subject to examination	2017
Latest Tax Year \| Sweden
Income Tax Examination [Line Items]
Fiscal year subject to examination	2017
Latest Tax Year \| Netherlands
Income Tax Examination [Line Items]
Fiscal year subject to examination	2017

XML 78 R65.htm IDEA: XBRL DOCUMENT

Fair Value Measurement - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	May 24, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of other assets	$ 0	$ 0
Fair value of other liabilities	$ 0	0
2.125% Convertible Senior Notes due 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Principal amount		11,000	$ 115,000,000
Notes, due date	Jun. 01, 2021
Notes, frequency of periodic payment	Semi-annually
Notes, date of first required payment	Dec. 01, 2016
Total convertible senior notes	$ 100,276,000	$ 99,250,000
Fair value of convertible senior notes	$ 150,500,000

XML 79 R66.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)		1 Months Ended	3 Months Ended
	Jun. 01, 2018 ft²	Feb. 28, 2018 ft²	Mar. 31, 2018 USD ($)
Commitment And Contingencies [Line Items]
Lease agreement, space		63,761
Lease agreement, commencement date		Jun. 01, 2018
Lease agreement, term		126 months
Lease agreement, term			5 years
Number of options to extend the term			2
Lease agreement payment condition			Fixed rent with respect to 40,000 square feet of the Premises only shall commence on the Commencement Date, and rent for the full 63,761 square feet of the Premises shall begin 19 months following the Commencement Date.
Letter of Credit
Commitment And Contingencies [Line Items]
Lease agreement, security deposit \| $			$ 163,000
Scenario, Forecast
Commitment And Contingencies [Line Items]
Lease agreement, space	40,000

XML 80 R67.htm IDEA: XBRL DOCUMENT

Future Minimum Rental Commitments under Company's Leases (Detail) $ in Thousands	Mar. 31, 2018 USD ($)
Operating Leased Assets [Line Items]
2018 (nine months remaining)	$ 3,191
2019	3,808
2020	3,653
2021	3,342
2022	1,968
Thereafter	$ 4,401

XML 81 R68.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) (Detail) - Principal Owner $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($)
Related Party Transaction [Line Items]
Rent Expense	$ 201
Minimum
Related Party Transaction [Line Items]
Non controlling ownership interest minimum	10.00%

XML 82 R69.htm IDEA: XBRL DOCUMENT

Percentage of Revenue by Geographic Area (Detail) - Geographic Concentration Risk - Total Revenue	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Concentration Risk [Line Items]
Revenues, percentage by country	100.00%	100.00%
North America
Concentration Risk [Line Items]
Revenues, percentage by country	45.00%	38.00%
Europe
Concentration Risk [Line Items]
Revenues, percentage by country	43.00%	54.00%
Asia and Australia
Concentration Risk [Line Items]
Revenues, percentage by country	11.00%	8.00%
Other
Concentration Risk [Line Items]
Revenues, percentage by country	1.00%

XML 83 R70.htm IDEA: XBRL DOCUMENT

Percentage of Revenue from Significant Customers (Detail) - Customer Concentration Risk - Sales Revenue	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
GE Healthcare
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue	17.00%	27.00%
MilliporeSigma
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue	14.00%	21.00%

XML 84 R71.htm IDEA: XBRL DOCUMENT

Percentage of Accounts Receivable by Significant Customers (Detail) - Customer Concentration Risk - Accounts Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
GE Healthcare
Concentration Risk [Line Items]
Accounts receivable, percentage by customer	19.00%	11.00%
MilliporeSigma
Concentration Risk [Line Items]
Accounts receivable, percentage by customer	20.00%	19.00%

EXCEL 85 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 86 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 87 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 122 292 1 true 56 0 false 7 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.repligen.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.repligen.com/taxonomy/role/StatementOfFinancialPositionClassified CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.repligen.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.repligen.com/taxonomy/role/StatementOfIncomeAlternative CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 4 false false R5.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.repligen.com/taxonomy/role/StatementOfCashFlowsIndirect CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 107 - Disclosure - Basis of Presentation Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation Notes 6 false false R7.htm 108 - Disclosure - Acquisition of Spectrum LifeSciences, LLC Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Acquisition of Spectrum LifeSciences, LLC Notes 7 false false R8.htm 109 - Disclosure - Revenue Recognition Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Revenue Recognition Notes 8 false false R9.htm 110 - Disclosure - Accumulated Other Comprehensive Income Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsComprehensiveIncomeNoteTextBlock Accumulated Other Comprehensive Income Notes 9 false false R10.htm 111 - Disclosure - Earnings Per Share Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Earnings Per Share Notes 10 false false R11.htm 112 - Disclosure - Inventories Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories Notes 11 false false R12.htm 113 - Disclosure - Property, Plant and Equipment Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock Property, Plant and Equipment Notes 12 false false R13.htm 114 - Disclosure - Intangible Assets Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets Notes 13 false false R14.htm 115 - Disclosure - Accrued Liabilities Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Liabilities Notes 14 false false R15.htm 116 - Disclosure - Convertible Senior Notes Notes http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Convertible Senior Notes Notes 15 false false R16.htm 117 - Disclosure - Stock-Based Compensation Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation Notes 16 false false R17.htm 118 - Disclosure - Income Taxes Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 17 false false R18.htm 119 - Disclosure - Fair Value Measurement Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurement Notes 18 false false R19.htm 120 - Disclosure - Commitments and Contingencies Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 19 false false R20.htm 121 - Disclosure - Related Party Transactions Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 20 false false R21.htm 122 - Disclosure - Segment Reporting Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment Reporting Notes 21 false false R22.htm 123 - Disclosure - Acquisition of Spectrum LifeSciences, LLC (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Acquisition of Spectrum LifeSciences, LLC (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Revenue Recognition (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Revenue Recognition (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 23 false false R24.htm 125 - Disclosure - Accumulated Other Comprehensive Income (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsComprehensiveIncomeNoteTextBlockTables Accumulated Other Comprehensive Income (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsComprehensiveIncomeNoteTextBlock 24 false false R25.htm 126 - Disclosure - Earnings Per Share (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Earnings Per Share (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 25 false false R26.htm 127 - Disclosure - Inventories (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventories (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock 26 false false R27.htm 128 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables Property, Plant and Equipment (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock 27 false false R28.htm 129 - Disclosure - Intangible Assets (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 28 false false R29.htm 130 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Liabilities (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 29 false false R30.htm 131 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables Convertible Senior Notes (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock 30 false false R31.htm 132 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 31 false false R32.htm 133 - Disclosure - Income Taxes (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables Income Taxes (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock 32 false false R33.htm 134 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables Commitments and Contingencies (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock 33 false false R34.htm 135 - Disclosure - Segment Reporting (Tables) Sheet http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Segment Reporting (Tables) Tables http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 34 false false R35.htm 136 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation Basis of Presentation - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Acquisition of Spectrum LifeSciences, LLC - Additional Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureAcquisitionOfSpectrumLifeSciencesLLCAdditionalInformation Acquisition of Spectrum LifeSciences, LLC - Additional Information (Detail) Details 36 false false R37.htm 138 - Disclosure - Consideration Transferred (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureConsiderationTransferred Consideration Transferred (Detail) Details 37 false false R38.htm 139 - Disclosure - Components and Allocation of Purchase Price (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureComponentsAndAllocationOfPurchasePrice Components and Allocation of Purchase Price (Detail) Details 38 false false R39.htm 140 - Disclosure - Unaudited Supplemental Pro Forma Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureUnauditedSupplementalProFormaInformation Unaudited Supplemental Pro Forma Information (Detail) Details 39 false false R40.htm 141 - Disclosure - Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureSummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLine Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail) Details 40 false false R41.htm 142 - Disclosure - Revenue from Contracts with Customers by Geographic Region (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureRevenueFromContractsWithCustomersByGeographicRegion Revenue from Contracts with Customers by Geographic Region (Detail) Details 41 false false R42.htm 143 - Disclosure - Revenue from Significant Customers (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureRevenueFromSignificantCustomers Revenue from Significant Customers (Detail) Details 42 false false R43.htm 144 - Disclosure - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureSummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomers Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) Details 43 false false R44.htm 145 - Disclosure - Change in Accumulated Other Comprehensive Income (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureChangeInAccumulatedOtherComprehensiveIncome Change in Accumulated Other Comprehensive Income (Detail) Details 44 false false R45.htm 146 - Disclosure - Earnings Per Share - Additional Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureEarningsPerShareAdditionalInformation Earnings Per Share - Additional Information (Detail) Details 45 false false R46.htm 147 - Disclosure - Basic and Diluted Weighted Average Shares Outstanding (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureBasicAndDilutedWeightedAverageSharesOutstanding Basic and Diluted Weighted Average Shares Outstanding (Detail) Details 46 false false R47.htm 148 - Disclosure - Schedule of Inventories (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureScheduleOfInventories Schedule of Inventories (Detail) Details 47 false false R48.htm 149 - Disclosure - Property, Plant and Equipment (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosurePropertyPlantAndEquipment Property, Plant and Equipment (Detail) Details http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables 48 false false R49.htm 150 - Disclosure - Property, Plant and Equipment - Additional Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation Property, Plant and Equipment - Additional Information (Detail) Details 49 false false R50.htm 151 - Disclosure - Intangible Assets (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureIntangibleAssets Intangible Assets (Detail) Details http://www.repligen.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables 50 false false R51.htm 152 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) Details 51 false false R52.htm 153 - Disclosure - Amortization Expense for Amortized Intangible Assets (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureAmortizationExpenseForAmortizedIntangibleAssets Amortization Expense for Amortized Intangible Assets (Detail) Details 52 false false R53.htm 154 - Disclosure - Schedule of Accrued Liabilities (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureScheduleOfAccruedLiabilities Schedule of Accrued Liabilities (Detail) Details 53 false false R54.htm 155 - Disclosure - Carrying Value of Convertible Senior Notes (Detail) Notes http://www.repligen.com/taxonomy/role/DisclosureCarryingValueOfConvertibleSeniorNotes Carrying Value of Convertible Senior Notes (Detail) Details 54 false false R55.htm 156 - Disclosure - Carrying Value of Convertible Senior Notes (Parenthetical) (Detail) Notes http://www.repligen.com/taxonomy/role/DisclosureCarryingValueOfConvertibleSeniorNotesParenthetical Carrying Value of Convertible Senior Notes (Parenthetical) (Detail) Details 55 false false R56.htm 157 - Disclosure - Convertible Senior Notes - Additional Information (Detail) Notes http://www.repligen.com/taxonomy/role/DisclosureConvertibleSeniorNotesAdditionalInformation Convertible Senior Notes - Additional Information (Detail) Details 56 false false R57.htm 158 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) Details 57 false false R58.htm 159 - Disclosure - Stock-Based Compensation Expense (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureStockBasedCompensationExpense Stock-Based Compensation Expense (Detail) Details 58 false false R59.htm 160 - Disclosure - Summary of Option Activity (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureSummaryOfOptionActivity Summary of Option Activity (Detail) Details 59 false false R60.htm 161 - Disclosure - Summary of Option Activity (Parenthetical) (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureSummaryOfOptionActivityParenthetical Summary of Option Activity (Parenthetical) (Detail) Details 60 false false R61.htm 162 - Disclosure - Summary of Restricted Stock Unit and Performance Stock Unit Activity (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitAndPerformanceStockUnitActivity Summary of Restricted Stock Unit and Performance Stock Unit Activity (Detail) Details 61 false false R62.htm 163 - Disclosure - Summary of Restricted Stock Unit and Performance Stock Unit Activity (Parenthetical) (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureSummaryOfRestrictedStockUnitAndPerformanceStockUnitActivityParenthetical Summary of Restricted Stock Unit and Performance Stock Unit Activity (Parenthetical) (Detail) Details 62 false false R63.htm 164 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 63 false false R64.htm 165 - Disclosure - Summary of Tax Returns Periods Subject to Examination by Federal, State and International Taxing Authorities (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureSummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxingAuthorities Summary of Tax Returns Periods Subject to Examination by Federal, State and International Taxing Authorities (Detail) Details 64 false false R65.htm 166 - Disclosure - Fair Value Measurement - Additional Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformation Fair Value Measurement - Additional Information (Detail) Details 65 false false R66.htm 167 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 66 false false R67.htm 168 - Disclosure - Future Minimum Rental Commitments under Company's Leases (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureFutureMinimumRentalCommitmentsUnderCompanysLeases Future Minimum Rental Commitments under Company's Leases (Detail) Details 67 false false R68.htm 169 - Disclosure - Related Party Transactions - Additional Information (Detail) (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) (Detail) Details 68 false false R69.htm 170 - Disclosure - Percentage of Revenue by Geographic Area (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosurePercentageOfRevenueByGeographicArea Percentage of Revenue by Geographic Area (Detail) Details 69 false false R70.htm 171 - Disclosure - Percentage of Revenue from Significant Customers (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosurePercentageOfRevenueFromSignificantCustomers Percentage of Revenue from Significant Customers (Detail) Details 70 false false R71.htm 172 - Disclosure - Percentage of Accounts Receivable by Significant Customers (Detail) Sheet http://www.repligen.com/taxonomy/role/DisclosurePercentageOfAccountsReceivableBySignificantCustomers Percentage of Accounts Receivable by Significant Customers (Detail) Details 71 false false All Reports Book All Reports rgen-20180331.xml rgen-20180331.xsd rgen-20180331_cal.xml rgen-20180331_def.xml rgen-20180331_lab.xml rgen-20180331_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/country/2017-01-31 true true ZIP 91 0001193125-18-155618-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-18-155618-xbrl.zip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
C*,&G4ARV(N0IVKE??KI=H (R:A L%3[L\;\9-0M BY'21 ML!$[#1)"HJ=J@&WX*6D%!D&1%]UNBKNGP@&M?V<4+[7.Y>MXY!7(&0UZQENZ M5 S_SG!/R9R*9'?T:D-Z7 D+"H%-5;' DQP$ @=ONZ;GVA?^^O..WM1,[EW_ M$@:1,/9J;&,2&DV,R&?_GF?/-N;TV*%/F>((,9I .-$GIE,1$Q0G,H97P4RK M%F#P$WD^CB)6,RAB94K2\D&X.19K;6<41RW,*#CFK/YM1A.5B(Y01A8Z0M,K ML--38'.8DS36*NYD=&4+]AIV# 1? ^-,944]GV8;93QC@]TMT"&:$$W(;MZ0I\D/=#DD=L-RW1,_RH_\%V( MPZ*P \<*VV!9=A1_ADCZ1EGG*"&/@A!EW8]0P@!=YB0L6(/QP17'7$+2G%T6 MHKG+1#5/F2K=@A?+O$,/B+4XDZY*M\3WW+2\&-/8!-9/W'C*SY[,G<8I^P;Z MP1=]4C;,WBU2 J+TR!A;L%?5C9;,?TXO=V'P*0AW[M&E W[Z0V(]33BW T:.L&"YV?,:*0A\@#52//=A<'5PIS5]=%- M)Y",E+Y>(+_VT%5KE@0&(E[I;OE*?OIJ)@,;0#3RIC+=+J2 S;T%R?JR)MC0 MJ)'\0 CTHD97PVX)/-KU9#F*KY+KI?TM(R-D)Y)3[A0VD)<-"X0V+*>]68_F M3EIA>&Z0T$)$UXR\(Z;+VK(,U9_]#?T/_17-'V#I ^KFP:5B!YYYK"GL8B\= M.3"7NDD?1T/P^1A#:H6!^3??/:P]6F3@X;#?;]D!+GV4@Z<62Q'?! !)N N5 M:0O6B66]N!&^"[T5IG4UDV2M7X)@_=7;;J^_[?&*/J+E?KO"Z\,J9G5:FBJ= MZ.T#V$]T9ES^(N?YV7F3%\GZ(LOVM#?Z;BPJ^@,M= *H,^9C,JJL#A)33AR@ M)UIO+%CY$\+Q&WM^#43\B<[),B9\OS^9GXN ^E'63O/);>=!XF>4;E M@$^3\.*L M/"*Y_E:=( \S.9L.GSELC-J=ETEM>*YJ9#O&9U04[WE\'NR?/= M/"DXX?<>LU>VFPIZ*Q F/S;N5*Y=E%/_RM1'U5PFW8 6?A[* U4DX-690V4 M4OA(N)!H +P4*D+:W"L20<,R=G6$=K3O2/I=-S^BQ6@'=XK.:-6>YU^)F2=.[@VF:='\#:NW!3I_7QK;"6G];\F&]X]2KR"0C,=%+Q<% O:\$9U),%7]VMP=,K[RLRA7LDSL@ M)^)G95U01SVH;1(<0RZ:-M#2&]:TBCU]KH46-XV*$;;X,?5AXF,(Q&Z.;FTC*H-]AQ"XI%>K,$H)SD ME'27F]8I2>Y[/WA$9:61NR++V(M5?' 5S*=G/["P[\>\]"PXGI[7SXTJ@14W M7VJ4'2(E=7[2L@,1Y::RR43YH=M.E"-KG(I)Q5:WHDHKUI%-IU7:H=GBGC2, M@"6>[!ZO@F??^Q=>?UYC/_8VGIL_))9*0J.D&_)K;\L>_2%_.^SP^M*-7L@? M:%CUZFXY1VV&.H7U<1HE4=@B=AHWUPJ>4)FI]!&_S-LER\<28RCEC"Q%Z9.N M]*\E[JQQ?F :3THR9ZIAS][B9OT >L$!8-WB$G6/R\G[Q[0$-OOR+L1[UUM? M)X]-DN]OXQ<<-C[[ L/+J7I360$57B*8UM.*-3O9M+A[5KP^Y1JE;+.&C''0 MQU=/8)"2(Y94>^ESKDE-PH"I#_[M"%"W,IC;5AK-=^7-"15,YBK2TKCS+G?] M'GQU21Z5VPOULHG#NN82D^_,"W=6?[HMR2KR1BC,R;Q+-\O!NQ&O6A^==^)$ MRW](+>C.?5,[91Z0A]-VJV+!%(X5S^J7[(?QKZ4_CE#N3%)V]7K:93(8/GZF MR62&?:VV,9E4O.Y>K*@3=KGMWF%@W]LR6EIO, S&=GC Y4^;,LV-\0!UD\*4 M@++I^,[T[-RIW<8HGVG+^M<+OG_EN5>44]U)S7 ,L70HAWO:_-;".6AE@3\\7A''E&\1C#8 M\>G[1O4@A]7<&/:$L>(A 6--:W4_.7*7P%&F>; ;<)SO+9[\[,?$N+S\8W;4 M^?CBYJ6@#)A_.P\GZE-;!5,YIAHV2ZY@-3\H3/(U8L)N7G;N]&-2S4/2<+?= M*S0JCEM[*Z_;92Y;U)=<]_KD>B%ZS>Y\N9FM;CS?BS&9Q5[)/Z2T>8HSFK0# M'FIRDQO2TY_G7LGW0?AF!"197R<[;Z4"J.04UZL2Z9Z?4I;>PQ342;O,53:J MX33=7PV7P[FYLM9/W9W=A<$>A_';';&<.,TWW]/S0P/V*^[[1-V=4""5U-W& M2D^]W5_&(OF),CG*+[3L1=7.3LLG:AJ"))STOE%5OJLHL17O0[G-YH&Q+GWD M-S_,FSZZWSYB'V^\QC?S!NSUE%-$^"))HG$^FXW/ZB_RZ76(9?[8EG#*X>GF M@>C0^)!3D!F- R1[:%'\)'GCI*0BN@/_)%;1R>5X-+O60;(Z&D;FA +X;!^% M*^(7K#ED;^W-_B"]302%/<;F JR2/K'\[(K0/1*^3BH,UZMDSCZNC^,T",^W M=*VI"VE>0;/L.0H)E5B^0)'U9QJ6)%)C8,E4$ E>Z)9J NN4(]6'E*=GRT6# M9XW 7I#6+Z3354A %!^98@L4(_ GH=.R&?0_I=(9%_&E&X9OGO_,*D(*QEJN MK4&$23&DL/D_21=V>;D6]D.)- E+8I111XP\#.P&D-S>0C5*-EM&H+R6[('B M'0Z]8/W97X78C? 53OZK9 8"$N# Y/.E$-Z=3UOQF?2!LD[0]UDW SVZUA83 M#Z>)/-#U]+),#&L<%-Y M*.G'-DG?_&[44"IPU%0 MF^KCNQ\_U51=5 11HW%*G]'#+?7Y>Q'TW ,TIE1 MA= Y*_C&M_;1$=IY'F#HBIE[-D%>^XT7+0PJ;%(HK!Z=,/V$A7Y6["M,Z[)M M4"+'@"IZB-TPMD1)4U4E/>%GS_?IRK11529CO=[>IQ[\]=,]B!-^(6.-/],7 M)MC6SU^\^.7R$,7!+BUU5]IS?6O9VNQ&RZ33[<*@_-,&DW&V0\/ZH%JG7S*7L*4L)M,*K6>(P.,DIXBP%E[.HH.@@JX23$ M@@+[APK\)'Q#H1Z0U4;.5U1G3!24-K0PN7(0LR%?G\&9C>N@2M;*%7I P;\N M 1V>@*L*FK[_$L08C2?<0R]CP7V[*59"^!;]6(:FXJFYMC6[$@T[$'?,F/0J M=#Y;+B4P6'F"$7I9/IPBN%CMJ @+<"LV>DDD"_1I+;;;'E)5)&(;NI5?%YW, M%PME>(._L#JD+MH1;CV6&U]9[: [*#0'_@-]O_K.#6_#AYA>:V()7G4#0PP%2MK1$L)5U8 93;0QS%)/ FH:GL<):;0$*F MQ(>*0^;&=1EN2C0M 4]G*<4("IJ%!(,1QQ8;L517#3"@&B^ U3^# 8[:Y2;G M?+;@@851L6:.Z2 3!QK_]N/9N%CFC-#B;'1VQO[_.%@;H(7I&S78SR'?3Q7QT-E^6OKO"*Y;TY E=Z[ IOB/& M&P,@#.Y#_(+]R'O%G_U5L,-?<'R[>72_B#C$K)!$'=%-CL IMK;>\=*E@=JP"CY$#AE&; M9=80U:@,R\#5?GS7VM(.L*F>4$WFR_&9%M#9<(*G5RO.\%JQ +TMAWA2*K4% MS4$L%/89)&9.Q/)!K#B(TRAU]IKX87?8LI.,Y"$%GAYL R#/ M6MO0=Z0H77FG^T.2TWF[N79#>G\HRHX4;EJRUV5: F2A2K E^ZCDF3.=GN7) MJ!EAZODSTL7)&6PBNW:AQY8(W9JGJEUR1X_DIA)7%?!;SE^551O,#$^DIE=Y M6 $S+_K'1^RO7G9N^(^K8.=Z=>!+-S,ZPS?SHK /.LY3;DHD$:6)!1%&)#P5'?2[$$2LFF5(WM J.)!>@![]TR=DMB5,I8EH_1/LO=)3F2-QT]H@ M4$_%:C3>2L47ZIY0Y#W[WL9;N7Z<"QHAE_Q?60O!!K%S;:(EUM8J/\IQ0XV> MM*X^*WPIKW!#R\>0_E/E7C\])BWRWH_G9XBR!3H%$P8><&4*Y,RL$270I0GJ M[) >U;9S2RU D9*SH6)5XBVE9$5HU_YM5QF;5[TV[MH>FV$SB*J* 4)2%(>' M%67ILW\7!L_$)J)?PB!J6/@*6YA%DH@-Z3RYV7E>8KE$C1:XR^B-$*,(!B0] M(CH\$?*:1<'MN8+JE&S#>)4]%>L^ M[X!TUANR(,5P8,TPW#\<=CLW?*.;*/?Y)E-2^^,*;W!('_BM[,E<5EU#QAGT M1-X5+F+QYWGG7[,"J*G;IJ?/Z9"P'PRHP)WLC49YY/I8ISE-)81 MGDU8:)O#NJ@I_Y1T\J/IQ,;!%-#@XDI^+>\#I9V Y#@.I@3FS1Y?<&F@UYD# M2S>&LY$'3''L@/%2IJ.J\FR)7.YPN G"'>7K]FGK/3,O\4#^-]IX>$W74OC5 M"P[I\U<*\Z$B8>"X1HU;A5J:Y\OF,*?4,2IZ1GG7R9Y#TGGZ\)P],<^06G.* M)QBB9%?"6U'/P9X5('J) [I1L3[0<"<(483#5X\NDJ*RYO:9YI(W":R+A+JA MKRTPZC L0.[H%8>Q1X*V*_P4RRZ9&MJ8=2)B1A1VLTO+H(P>H@1M6NOH$C1] ML*W\LBU=W)1%?\"^1]!,[R%!@[7=-FLX;%$3,,1N O_Y$8<[IMH[]ZWYW+BQ M%0S,>*Q(3RF3<5&UN[ V1@JEM$;DG_[J$ YWPU\!:OV%=>K"1@FT?$IQA'S, M%1( 7TV&*4"84#LP&(OBV\TO 0DO'H*M.$2N?F440Y6N%5X 7N2W?B-V$9W1 M0)0(%$!Z2.*4)4E#1SORDKCV4S7]8[GA3/W!W>*(^Q2Q^#OCYE[J7&'K=3&I M&CRC O1VKB9Y[#9[CBT=&WY==BC3I\6IK[_ML1\U/'12^\RPX9?[ED\%F)R5 M''URPI 1@:IUU$<45N#HD>6=!F3AG[Q"B!L$,FGS/".JF_R1Z#98?&NJ@N!S M0 1TJ,NS<$1(L"#/0(=T;#ZX/8(%<.9 LZDUX4-3/D"$5S\^!Z\_K;%'(3*A M/U!D3$K((+_ZVV6R0/SD12MW^U?LAM?^^LJ-ZTOIQD\-(**I?_GK4=,\_3HA MA1):B!)#U_0++2T,CE_ M-+,B[6AI_D &G/2PEY?G#[NLT"FKTR(KZ.0B9Y65.49"-Y NV=/:P=^].+M M6U;B#2T @,5A0_XFVF(\JX&J0LX2//46L8JEL$S.!A@UV!X/0B)U](_4TMND M"7K2?]2!D_[Z;U?7M5$K_<$ #(K>5$*4-'/@E^O[7R^^_-6L57?EF!GO+Y@> M/G/O^0YMK<<#3HVR)@V$ZZ:'@M+/>0H^-NBP^1PHV$*6R,_.LBUZAU.'8(ZZ M8*:\=+.9E1UT@R*@\/&97>)A[UV+:Q1Q/C2,BVKO"H&RLRQAHJ "6HFHKT". MFD F<< WISH&.,+#VW^6)'.QHS.7U-#5FH!AHLJ'PLL$DS2ZIX?['XC=[E@> M%.@]2WV2,9C+J0F3*DL+U21RGJP%JE=Y"\AM810M@E+ M\_C1OXW98V-[>V?3=O-61&])C5:A]Y'T$KT$6_IF>X17!UII[C%TZ9ML5^Y; MI(SF5GHVH+N-2?G\+.=\)H/VO$-4ZA&E72+:IV7XUZNADC^(=GX0E67ZI6>8Q&5E7BV86: MW[BKE&1D/26$4W^-_'KP0K^_<-_H7N75#4WLP]#8PI7"P,IT*D$O)TYF*=8"R'E#:A0V@ MU:: K C@L]$[ T3.\S$WHO%AD&NA$F+4=NF.2VUC&I=DG]=!J_8=_TX8B?" M>.,>MO%_$H?!Z@C04. QN,*KK1OBB^V6CI:_KO5<9#\L]UP@5Z86QD42RMB;%..$'N=IM<]47K M T:[A!O#=94@5@Q0R@DBK*0WQ0DS*.4&H$(3 MI#J+8WX]E@A6YVD8_Y<7@AI@C. #M4_N"BMD(I0^!PO#"AY4SNE%9R^4&KH0 MGC*8#K&Z"E<^ HVB Q[F%K_$RR2:QLKRI(ICV(ACOYH.;,"\%[(*/9)#F'T- MB/B4!14C$BVS*+&T0%&1(VD']#M)>83\$=I0$5\I*9L04S.Z)L"4%6$!7NBB M%/NKM]M-4E;-6Z6+-[EQ%3>'0Y20)Y7S.]%)14Z=KNLS^C9M9.@2O[R/L2D+ MO<^$MFX;H]V8&X#9K#9XI'[VB2'@*+YW8WR]V> 5/4 M3CVD;*.-!AAF6QA3 MV(&;. +@9EW0S",\0GDO0[]DJ A?K9I@&"XD]3(5A&Q?TD?Q"X:O6=C)S,5 MEE&@76A^B&EEV!Y0/B)@!8[K7"E,/Y-S.1 G75B,X'XZ*$_!%>S:"5>1'*#>M#R;+?H:#((WRL])SQ<.?P?)@M>RM&_ 7 MLJO\_.K&A]"+WSAEA20:@.&ES(6*68GV8#)Z $6&= M8./8F M1LN1%N !\\7=-;_Q*OP<#"P%#PI93/.Y "J4&O#;KGK$XTTP$N+!X.;8[,2H MJ2ED@%2.+P=:6^5V0Q.\Z&,0GO^7%V_UOA PAD)Q1MI] :^\1-M5#MSB2EC^;.V/'X:=^^(PENE=($Q39 MTS&>C[Y2MA!F?-%M_&U$C]N3=T_>4%#PQBY)),PA-T*TYB^K IR>V8-F@\!J MFQND)RRAVPU+@$4)5XBQA1*^$&.,YH:DK)6>[(E0P1RZB!!CCQ%+& 1/&('5 M>!("#6K/EN24#.6(!3DF@PPK?$QWC]=XMZ>\)J<(TA5AN W!XCP>-RIYZ_R* M,2-4T!VEAV<659'I+S0_#E02&B8F;#);<70H5)A].%189PF:6H-%Q04*641:=TZK=F$Y5'9>?UF I>W/FXL!"O;VAITYBRI["",Y0%*Z -7 MC!U$_J2\OX]<_PT]'2+/QU%$HVUZ2AV$R-T0MM#_/A#AIR-$+&W)WCC8A_1I M,!)UTX/L7;;Q:M8(M;VP#F*DL*Y[;3LU8P)W?8 M1Y:=6VL2OI2S&1826U:HJM5RI4#)41,\*!\;7LCD?0D&MD>5QR%I+81T_^MA M]8+7ARV[6%DMNEB"6Y0^1&O%'-E!4D>/I##H>A2]A2E2"SQJ?O/=71#&WK_P MFF;.2U\:XK4#0Q2'&847R 3[RR-4(HLRNGIAM4PD]?$SS0&2!U9_@2=4XK* MR>W !BEA(-5@GV* B=0# [<-#DE \,GSZ0/O[#FL+U@,,O[71J'%94'^\=:) M4XD$H^A Z2!&:(2^\!\R-H,A'9+QD>-E8JXH55C\-!I<%35BA4!BY;._"G;X MT?V6/AKW$?MXX[5A1M0* #L"5N1?!)\4)PD)19201(1F]L(A^CXE^P-4K*=1 M6*_%JR M.51TDJ.* @M>?1:8#<_BRP);8.'I:XMRHY1]#&?O*0?2YC*>S,[X9C]"*2TK M[+^37$X28F$W]*V$0 A; 8 %!$O MTJ9%'.QY#3(TFBH19:L3\C\Y;5@(Z9'X.++:%D1M %6;;?+@U:@:3=FZ1SV] M<4]LV[XVGR4K8D4Z W YGDVR#%<.4MZ&/8CE.0.MDHE]P,"2M:5_ZA'/:7)Q M@$F7;7@J)4PV*@)F'MV'>.7Q0,?]Q.C\6/0KO^:>CO-"'T5SJ.FNJP!.78!L MTX"5ZPB#/0X)I&G"!*W/N85'0CJ)?HQH*B\;HF>+?@1F*8(3CRM MP*#K%6^)7UH_XM6+'VR#Y[=[[_DE;GX5OJV5490ULB)?IH5TER$MI8@*DBBA M"9[PIU%6!JV2A!_0.B,/BRDI@ZSBJETM(-CRMNQQG0>\HOF0)-AM>[9;W, D MHH1?3'%M>.9;DQ)* MA9_83;-,'5%.]V=0M+6:: 5HS4J!P5CD/C^'.+F6=KM)MSEOVHK%M#4SBK=F M7A3<>AXL5DA2PTN)VE!(1JNX3C]QS>%,SDRK:)-0E$68:\QW;6H"CS6UO-#) M?'[6BC/0I%=M4K;!RX*$5PECE$ 5< IL U./^%O\D?3]CPZ#7;2U!&,Y0])F MN#@;3^7 ABAQQ*A;B+N.DC<#T%;@'=FL+ *K6@*"8EJN_79S&>SH[BWC\QYO M:3HG2TED2Y0G-\K?5VI?V/4B:A:\/3A5F5SR!6+6(;7K;TY0RN+X.^0P/(:DZE[SA8[6T^EMF6" EZ4;71W_!955@L.F=Z M'(X-488YE277W^@SOA\8N8K"3L*%-".GDP]I4*R>5)\TI>;"7R=EF#[[FR#< M)0='_$A#OIWQ]!\)IF3S22;+^2)+!$K)(D(WJZY6HCQT8"#."=(N[M@"<5L2 MA;3+[/27V4P2D0)2BW0B675UCT@BO/KQ.7C]:8T]&HQ,Z _4T4Q*,0CY5<[* M)^+ZW&U2W.(3^5U]W[SY6P/Q0B,#"E-:ONS(;"LAEA5U8>3,(DBC9$X7R8;& MB92946RT*\(T'OZ*W5 .#<67(%C(NU>Q%X>/!$K+#AQTE(J+@F:IS&/@R+3X M"*BJP)S])\B[]M><-P3$WQFV_4KG\ELIBVG=\E,722@!O!6@22)'52*3-L\U MI[K%'PMOSMX?"=F&<6%_-FS=M$\5QS>K&35M#V?)ZMP[4MR;M-JR4=2--9ZFHQK"9$E.76[X"7MM[PH>GC)#1@CKKP?%R#/,+(#B+G7I=0CKI01DZX&^&2'VF+%6##/-:6+R?^'G N MZY(POA@W@ ,Z;TV3@ *@V#2]-6:9-:L!!"[L>JKWBO,:H?=NC"\#/_;\ V'U MEBPODU?_1",K3\ DH*2Y4C' ;.64$2_7P:7TT3VF%N-MLU(=Z;L40)@;2 =. M50>TB%L(_-B/NA574*FF*'M@6C6WB_@37A-.MP\DHCP01MXJ'RM9B1IE<& K ML:NPC%I.51'OQBCM'.6]UQM9Z1<&5&%20?7'AQ]1E*O$7J_1"53M[D1=OW!^ MYG9S_6WU0D864V9N_4LW>KGPU_0_U_\\>*_NEB:_-YJ7) GCGD..+X7*;UE" M45'G(^L@<1"!CRAQ5KN*_5#J!A+_0RBB5O $9XJ@0$?)SQ%5R"I3"/L!-RO$ MK#=0,_UCV"NH%03?N_TV>,,XO=92JL797**\O9U))+(Z97'1RI(K7=*&68&+Y1<(1>L-Q">(6>\?A59S47Z5TT<$/"[=7CL;8 MXWW6N[L^&%9V?)T'YEVYP.QF9)C^BGXW-FWO?";>@[/D2J:0P#R9&?*@HRQ* MV@0A*C'[SCRKAO%(G_!J/:\E/_SQXD1?3 MTKW)6.X94^_2.S>Z%R,N6SSB>I+ ,KYI99O;?5J1_YYP&7HKPBG[_6^D6WX= M_&XTC*>.*3(HF[ TF\W/EFE66>[@*"V4=,+J=13=I']C'0$]U#2L)L;V::(E M76U0=3AB=;AB=7Q___!;Q'TXV$R:6T>'4&3 ==$I:$Q:,-I\2T[X/42D5V=" MX7; XFA96S9-X!MS>N030\^*,$5D<=R(@JN)X2L")!69+LF\&KK;S_X:?_N_ M\5MMU,3?&:H1P.U<89OV/+OUD!352@DA1@D14N;K!FB0R%&5R$0M@49SRHH* MB(4W9N_!;A?X#',LAH]N#W$4D^F:+'W$H]74R"P2&CB1]Z#+[ 6HS(@8U<2- MIM5 (U2B#(82;=(Z/:4UB" ) ZW!J4U+IK!U%= ]!.%HIG\VBI>D3Q5;F520 M\7M"P'"PU(]_1Y)_ JF9]++4IZ[['SQXM,>#'7]P=K]87]S.C M]EWM6V%[>S:K&'A!!U%"4!;>1QQ'31QS-LXWHZJ1AAS/S%6^/TA95? MW;\'X>4ABH,=#H]24.H[$I*M36X"R;&DX$RS,C$IO1%B%%%&TH94KB%D=OK( M;&S72,U\*WM("DH#0>8_#X2_MDI,U8],XJS2L_Q[I]-9FE:9$("OM-1##D=: M#F-XX!I-Q>R/Y86S;GK &_C8C[G+W^9OC=MZC0&%6&4^K9A\3@AHB:Q1+$=9 M++-($!C8,2!X6@#!Q2$,]KCYK*W\B4D4E/I5\)/S[#(\:PY]A-99!J>0 =2L M.?91L>:Z@"!&_ VOV!O@MYN-M\(M!5;Y'YLT;"X'"N:QR);6&2&44H*V=@V" M,;M/D6L6Y3U.T)YSRCO&F5]6[#R-ZLUQXC63'D+7: K^Q4MXP'K M@=YXK//J'RHU!?$D8GX4ML(6RV-O\?0F,'V8\H+#27Z$^$Z2FT=TNQ'S4=NB M-U!D%B^/MKTDWM@$ HDKU6%W8#57+G9!&'O_XMU#ZD'()/"4N9.^ MZGU^-DN+@R6=?&"]H*(;E/0S0J6>4+DKO1!=)MKP\3.KE@.IE G;?E*0VAAX M.UM]!='=]&<;S$O\77^C5S;Q/;L3N\;A[:9XI+2#$H92URCM>X3RWFG9G-(KMT!3NFG-)9O77,UZ06X;#H Y6:^C,@[VNR&V=&^-[?N0M-;Q5/F4#IBGX_.JQ]GR/0[7 MX:2;0 A^\6!,5\/I !"=>EJL76GDC_0-/F:?C8_B ZNY<.*JWWZNP M!]?)MUJ,+R=FK2?).)2>>^>S["I0MZB%O4Y*>SP%Y]%-._*1B>.H Z.[ M7ZAH]40\ K%$?19%B=GM$4C_\L7L9M-Q?X] >CP9CZ"L'06/,#XQCU "1D^/ MD&GU-#S"(^E>7Y"04+/:)S 652;":6^GP+H\%:_003\*;N'LM-Q"!1W]_$*A MUQ-Q#%\#?39%:-GM%+X&*B;?:[\S<0E?@Y-Q"*JZ4=C17)Z8.R@PT=,9I#JU MS!5\?$LN&&[=*+KXY@ES=A4HV '[.ELJ^V=S&;#3I+/T_BGM _U.>[%O8[&? M'AR=>K Y2)SE\0V5YF6(?J7,(@ZP#AI9@=V&2\*,Y!S)C<[,[K6(;2#M R6 MK!VZ=,/PC6:ZDGGG )PY)&F4DF K]&(9PF[:+KC(-+4#:3?*5R[(M+"0FAXM MN(:B76Z9Z=":BR0*!BR)R!OX"R%BYHJ9F9:N:;RZKTK%#JSR6)._-3F?2BYA MR[$<[0BX',"@"I' LZ)"+$!W$Q D@2[4K%V8_RW"F\/VQMNH;V>7FEJ![H(? M^$>9*@"VKEO%)-92"NZ! 2[@XAOO#7G[QO]*?F M];;P>Y-.1\2$0M;J)#L2RVBQ]S R:K K:SWB.7U MH5]()'!#*-[ZE_1II#!BSWA>X:?ZK<^VKTV_*"1F1=).B)',%^?)VT&4&-K2 M[1?V_E9&CR9:K@G%'\T^$:1+M'$N&J6&;NG3;;EHMQM$*0(\^:-+/(;P&^Z@ M1=CW2(R?_#)F080?Q'SD=Y>V_0*3WN&.NX1NOZVVA[H$P?HUMNR"?@7-RJ^I[]X]-A1F:D7.W5%$N> Z^E%67XX]VO>B)0;!/5CW;ZRU>T1?*_A.[V_AEY8;\ H52 M38Q'(\W\R#KZZ6QZEH4DUZB@8CH T2G-^$@:R/<&M8KF'(D&-]_*8:B8="7T M #+SXN Y=/B?S36=VQO9W(&;F-&X91JF:[4"YJH0A11 MJL 5(#7+Z[3*"SJ+REIH92:5TA (X()@_=7;"H!UQYA6I9TWW>[5TOI&NF9 %YCU?8>^74 M]VS[VO1*3LR*[-/C\\ELZ22+N()8OKLB$(@9_+._"G:8LO.)B$3BX-CS#Y[_?+O'230R8>#1-C$LWW0_9H,#H8 M4 R%S4TGO461]))M"%/K1 5+J. )/3&F4/H]8VN$JFR@C(]A7$80N]NF8,,: MQ7EV%L6*:*OC3N<(Q;D,YOF676G MU*:+^OS0ZPLMHCD=1#.+5Z&Q'6.-KPL+<')#>R*(;[C&V-0"#B]E-N1+"$\7 M"P%F,GJ@5Q*UR<@'CX2,0 CBF6$#BHX48Q&2&B]1-+>!1Y/JPX'3[$F-!EL# MO0FA4CCXUCJ/J4)Q<=PA>; MY#>"&B?B[XP?O'.8D+6(Q7)!0I3SND4,7[-$?-K>6YJQ>6E:SMA[BW0$6?#B M*JTP*0[41=*#SG,XNG.]=9NO3;^"F,V2KJ5/0YWE8LJQ?$H#>+[J(DC9WME! M+MH+!#$^3U4-ASLUE236/1OQ'GKF?P,X"ZD\9#QWG+/YG#<##?A2L\SDTT$( MSL0#\=RT!DDX\PW<\]&-&.!-,[ /0N>,7']S=Y[/ ",*(N7:0$P_/$94ENWC MH]54B:(%)?$T"EK?GU 1U/CTU624W,E,J!];L,6;$MN_!\:4BD^>3J?GXQ8\ M0FWHL6968I78/V(?;[S6;?+:US"H*;,@O8XHI=R7;2IY M[^_[E!JW,)A1Q'27K;9&0OLP>/4BX&>76\Q,@)$C)0 A),1NA*]P\M_/_L5J M12M)D]7<6_,3[*"*.4,AB4= KLI.^9 M)Y+MQ9(9!)2<5=:@):$4NT FO.>FU-0*J"G?H9K.G+$LVH:Z+29?]&< P2<5 MV(6-(L(CCW][3%D]UN O/) !]]PG;^O%'F[8HVAO"HV_&C\*E2^7BS;\4=JH M1-RB":^7V-FZV/0=0E@ H MOD1<*63[3.>-8,M[0&D7-B0-#J(%-L==OI O<40E3VI*LEHFI1GO9[O@V6;7 MS5AM5)PEP(U?<$CO'!_"D-Y4Z1"#-I" !:^0+_EGQ^>363-\:1^HZ,3&X%27 M'M*:U?[S!\+$SMXPM=VD6U#;K"^+<%NL9A716FX(C]$2-_*E)Q:E9"LQ,N^; M*]_ Q+(]A68!;2(><&$?=?.40%Y=,7;@[2[$-/_M"F\P\0KK],#DPE\SGAN+ MJW"1HS M:N@S+867T#.>]:E%KC&,7,)J75J%8Y6V'FE79.)G!$:(K#!I26;Z[MJ*K:V1 M"_;VLB2TROFB37H9"NG!F[N-W]*N),>KVL8"U%<84J@3N5C6L+_.,$+FX3"A MFEF7Z2*?6J44> (B94HU\P@PF>$:)67K\DRH(FXX*1?!Q623HSC6UT#NXL$E M"Y&T'UJ/./J"N<_+2;:$=QT\ME0*S9XU.)"(TLXL#SU3ZLC'IM^@&T)FL3MA MM#-G@AAU1,A;X5;ZR^TDJY-@?5C%)^52FG#;X%B$&@/;AF#PWEX&NUW@/[RX MQ&PNXCCTG@XQW2-Y#.H/SSU@LF)LW<'O0=7TQD1W5N6KQ,S&YR6()SVBI$N4 M](G*G:(X0%?>]A![KQA=;S:8@"/8E)^H#)(G*E'!#.!Q@"D-)D=\I7<'5Y^H4)$,5XG7_[%BU_(KSX%X09[[/LK M[]5;8W]]3Q\"[^5U>O5KFU_J(XS"T?ILJ>JY*HRAG+/L\Z^$-_K;#YN".Y2Q MAQ+^+'9FYM2>Q$85948YP%%PB*.8+,?(KZUW?3KPKNP<>P\4C/MS&^ M(7/_T;,T']]^=?\>A)=;-XH:BVNJ43'JVI184P@0G'Q[-NOAPY9VP7G*"+8X MYX *<'HKP)S?Z&3H52^@KDD+,9V_!=WRW* R&7M0?<2;_"N 4@-\KU&3#$6\W*"C MGJ];"W%?>*(WIEL+\;:WM(HYEO942@.4MQB:'IUU((*K9J% M=KA"PV)2VD"K&)33C V88Y&3?-0MU1@0>7R.%"+*HLCXT;21!)DVQ=7Z91=' MTS;AL-EHFZ#8H"--.0W5_FZ:RRF+/C:?N2#@1#9I;CR?+:99LL+1!LL-7'5E M+7()IF/P.LM:A.-/N^"E_.3@5,HN:%*/M%QQWG6>Y30%G61X_"O?;YN(Y MEE"V>(;M+W<=;&XJM\]/8H*:8)MLM6EZ%2H("(#L/=_T?H-XC"M?F855N6N% MTEWGQ9S$*&2W>> N[_219%(1!8M%,0@'GN74+/](8@N,G":^Y @D@7L8>__B M17W*S>%@(>1)P1BQQ;(2*&:?< =BD,X#X6;H8JXEP<+=H%1SV@4]/ M1%AO%L&MU88;<-BL+1B )C5DWBZ3NX7-]9MYWQJ%'HG_JA-36M8L>LU0TTB.AU% M-(X=V<<,F_5B"8[:S\\:FL B2?GP:+)8G-6G'=M.RG1)64$3>#&@=K-K@8X- MQV$I4Y\\WXM>\#J[AW2[N<<1#E\;;O:TMX1 DI@=A9.@67UN&J&,;G+K+MFI M"S8H(PZ,+%U2,X#EHNZ3NWAVP*S=0KEH:]$,*.A$IV,-'T) 2O5@A3GK>7U* MLN$1J'X".6H"&4<(]W2H17A0^S^^WL[]!,+FY2\OTY.-9=W:1^:O9?<7H1Y= M"8]E^@LAJF'37XBB<(T5F*S=!!?*!XK#>_?KKRXQ+,_=JL5^XH80F!5RHQ(# M+8^03,BBG*YM@9\FF9.Z+D3074;,"O2T&B874\TZ 47:7X+P'[0 7;#"D1K4 M&EI"8$W,CL*Y3%%$+0<;I9N4:624;8.;+K$9WBBQ#Y[_89^0LP)Q[0;*A5R+ M7J P%\4T[2]Y>JXYV*Q_:1A3M>ZEC6D\GH\+#"544$(&. 3M)9%3D\AC9* ! M(K"F.B!XDD, X,;UUX(!8G\R:.*T/_DP?C%.'V>BS6 L6)UAIXEA4U9:'O*R M6>;BP-AA3##QZ'[[*W;#7_'N"8="K1]_:=1*C[J7/NQSQN-E9K24"GM_EM)! MOR>4@/:\>LOD<&2"-7&A-54MGB^WEEL.-[1^V\5SB%G=D8L0NS7MB[XR?:_A MF 79P9^?DY^3"PV,"'(S*L@E9 Q76>PKQ[B0(Z>"*!F :PM]97$X8S)"T=Y= M@01(+8#(+R@(Q!X CW?N&_W/9>"O/3E@'+6 Q6F='?DJFM/EDH_9?4(2K3*: MH #N)R 7S"E)E-,$1W8_(7DH/QY%2P O0IP _%S-#. ('G&X:Q\G]A4LX"D+ MLN8Q/3\G"V0NR.E36:"X5I>#BV5*!AR^ZK+P)^98( P 3,MX$$ SEQIDH? M=_LP>&4,)84WFMPMOX'I"8W+A4(JP:*\UT*)H3*UM(8,X*2F03ZG*I]7H@8^ MQS5:W=%$)U9&=]A$>/7C<_#ZTQI[%#$3^@,%RJ0$%/(KPL SF6#]V(O?.+6+ M>5\8@ *G6X7-W?4(!)21 J@OW%L-1$&-H^VXP%FK0(EEA''\484RA12_? MAB%]K(8!*X_QDQ"?1)?XJ[OE;$_TH61TJE!F3\$ S[/37];+"-562&R!1,D" M[!,84X!=>PD:#+PZ^733'@RF8Z+UV\UEB-=>W'QZS?O4*"J/^U>PNODD@QTE MPYX88H2@#[![2^7PI(*%D=BFJC@1B X"!,]]\K;LN9$+?_T0!ZM_T/B1#-_U M/P]DYA4-7ULSDP!IX44A1VV:7A LD63/82:$8.Y,Z!6O] #PMB9D5"+]/Q$6 MBFP,3Y*F6<&6C+)LQ%E+B0CIYA;A3KFR@C->G#7A#[Q\Q# 2.SR)3PV,3=4E ME-0&#,ZTA$R[ 60?P@ N[5W:]Y\OSL='T,JK_8!/;)W$*4UEJ[1J46E*LP0L M-7L2P*(LOQT D)^/Z@U :'L@1>+K(@>#Q@VS3B])$SJY!VCY&>[8"(YB_!4 M 0*;P'^FVQBT/)]H ,N?F(1&J5\%MWJ6OF%,FW^@^U*LDB20[7<6@5G[%_IB M\ BMLGK_K^[V,-!Q;NM,UUF2\ARG\"AR;Y%(3T_!4,,S=KI)9I%%Q2R-$::$_#P=L%1?54:ZD-!.5 M@SDHNI5I,]*[CAY'S/@%,[EL@?H1BD28K^H &OQM11'YWP*!7_T-K<5RNN"! MWX("B!H$R^I7YWA_2/#^Q:8YL+'^H5@)$,#XU5V]>#X.WR[\-=U:)JKDQ/*MTWURS@R8I:5+0(:7G D0-HMK8R2%OEAH$+? MS#Q$<; CH]?PTCSG0Z/0J/>NX&$7:=R8M0=]%;ZO)(ZD).80(#*@JN5SI8:Q M^&_>[K!KS/:H?F/4SDL=RQ\@G<\FF==G[8'3.GI(X92D@#5KCI54+;HNHY9; M)+]ZVZVW#T+\X#WO7*Z1BK\S?8>$QX3T%87%65:#(">#&!W#5T?Z"S'F" &$ M0$T2.16)&!FP6R)-B,@OB0A%!IEA/+]]AJE\8W*&*7H;K^2!4STXNWO,!E4,CD\XX]O7XBX M]/FM@*#0?TX^$8]<1WIF0=*-26E37)YE-TJJ9%#6Y0CEG:*B5_3TAFH-DL_ M8&A"3^E)GH_*<@>Y>K)GWM#."E3W@TO- _10+X2W^.+N\.VFLMJ["G:N)WJB M4?R]0;0+F9!?NDQF3GV/(2$!-#]J$LF1%LD4OEH-K(R?9BV X /'EV[T[_HI>F%G%WFN2W4(P[?D'"NGDXDS@BZ;4GD1-(JT7 MIPJ;Q(LT6J4%IFF/*.N23J#?TU[)K/$#RCM&1<\C5/2-BLYAP9U!UKP5/$9_35^>HZE)<]3$_&3<33J&?R3^5*WPP'/ M.H7081)P4/UMML'7"%&TKC"KPQM%/$DX&!6-GYYCZ1;>J!(_ M&4?386K.KF3J#ZI ;WO"PZ?,^MH8W>643G>&-+%%XKR/) MJ?1SK,OQJ@1A%%$FY%1<^GYTZZ!36JQ$_& MO:A.R!0U!G MM;/HI4("NH1-**=GF?J3]VAW>Y?JS$>7JE&1FP$]HHLLDNE@'>QI9_S\'EWRP\5:\ZRO#]F7_9-8L M@ K6YWJFKV+.RE@:H2I3)S5;Z=1OEOW\(?&%N:+L=_NU^S>28T M3\#[,$95IG-'D^=A'9^8T^F@+#T.1ZPLVWU-!5PZ_$PQ!OW?)F3$P[?$Q:3_ MJ'N7]-=_^W)3,Z;2'PS@O.A-8<(;9V"]?OS/Z_N;BR]7#V8!UY7K[,3R!8?D M\S5("M+QP%/SK4D$,L_12]R[/8Z+U]JCQOHA#0U,SE!"+N3S8J=96=^"&"JH M =<9T25@L8?'J'ELWRY__ \V':_5]"HNOEDA6FI@D3ZN=_MM\(;QE1?B%6G' MGHNY97MVXII84NU,U\B284K6EA9GB_DDJ9E%JV%D=%%&&#'**"$]*'!X3F$@ M<<<6B-M<;TN_S+F[.)(9Q%4HHS*ORR6M&FV.XQM>'>@!9[.;J'T%X12J+,C6 M9YN=39U%[@(^Y%2&G2<;X=Y'D+%A0=J!W$<:!MN+KVZXCM OH>O3!(4X0%7Y M;O K$21#!2R>^6"IH)>C#Y@ .8Q?+G8X]%;\JI@-'QH-B.N]*\2)68D]1@2E M5, #X'X".4<"P<:Z(BNJQKA'Y61TG"<4T M4]V"0VV=HCI]1#6.ID;3Y )+K"(MR_QJ/Y\.\2'$:;'D._>-;4E>'?!G_Q.Q M CK)T62;QQ<<8G<3\[<$>E(TO7W0CUU96UU.I^-TJZ&PU2WM$6U8EUF]7;1/ M.V67)#P?;4B_+#9*DL#BO&O#I?U-ZHGGOE#2)=(M(K"000[9>%P!$B M/:.B:X"]#Y.Z2E[^;)36R!:('D>2;Y=H4"%\#!*)^*Z]8=XX/;82 8M1VCA3 M"80=+NBC41/L1^@+?;#P\2O>OI(O C]^ ;J'-Z1>&,")N2WM"6!D[5H;I)SP^;CW([T+ ,WETF5R'.J#/*\2WHC/CVA!3U@-J&D M;*F]0-_[].!@Q[844,@HD]ZY9XPV.8-&=*@Z!;%"89U#$$67;AB^;8*0I8>U MVLQ1 Q!XU[F0-LWY8GF\.T:HH0HY:&#V$R\OP5?4NMQ2$5>4)&J2T3S\1/;' MQQ=7+W8!Z,;;>$X._@V?M*M0ZIQ2:K' "7$ MTJ-L@&6S1LD2MW"@N;QT<9!4?XI*0Q>_8$08 7D[6 I,I5/F!H5HQ?4=&IZ!.(:B;"DI";^Q'L&_0R)EB)MB7A8,(/RAA")8[83:423ZA@:L3>S"%!%F$,T#4 *SD).E,-KC(- MQB6-/;L>[ G*H,@]\EC#C(=M+B]C[BX(&=>EY_,>@^3QO)8W"'11M\2I*; L M'[Z>GSG27JQP1B.4,B%XU1#\60(0/9:"H%5%C\E3@Z"OD&I&FJQ/4M6U34[H M-S_$[M;[%U[_9[!=>_[S+V2:H4+=^@^8S$-L&^XB]"+RIROR3__Y#H=>L.X8 M>?7NS@(WU5<&^0S$(LVKW6\57*&4+43YRAYFI4%']>?XK3D(*^(7?@$B6\7I:!@3,#7[V8V(&'G'/LCN0@A:FG1&? M#?D4+F=2V94LR%FT0:E#QE*,XN7DX$';;'='N&O0!!AT2F=SB@=B+2U-0ZF9 M'?E3V-EB7H94Y9C9MO,QG3(+#\E*K_J" T[.6H^ )Z$G&P H=Y+ ;P (MPZ[ M[V?+Y5B(,BL.%C3(5YJTMH'__('F2]J*)HD3![%&P+!#^,CSUI,X]CI)EFD: M67$CTQ@25_1+2&]'M$])HB:F 27@0]K(9D56/S.R$KT18A1M2#74(B6# MTGWPYF[9_A$]S4O"O;"@#HZI%E,\0E239B#P=.?&K2]35;\QB)A*Q_)5ZF>+ MM.Q^VAYXBZ&'%$Y)"DA3YUI)V;:/980QYC>&K M_S?)ZW6W;:^I-+8P:NI - M%8.99F:?4&,N,Z,'?G*H34:GJXSFT-)JAE7L-"M&RPVPM)S"[>8R8"]UDI_) M3Y&W3LN\?_9+MTIJ(]B!@.F;84K#-\7'5 #X[(&;C>HZ %5NJ %D-NN6 WG9X;6@M/1#L NFG6"?'[I M3%V30#-^\ACQYE=,V";A]99$(NO+((JC3Y[O^BO"^L4J]E[9KI!X:E*B8C8R M4&%-X=1YO*P .Z(VG?2!TDX0ZV6$\GY0T9%>;"\31?CXF?;;$D4,J(^)),:! MHXLN)E^+.)25"(GNQ^!B]<^#%^*/A\CS<12EB^<6&Q$V \"OB!<% W7.:X"- M Y021075=!<(+,;7*"V;<2_=Z*4=?+U%>\7A4V!2N'$A7?K8!AU/-QW/IY2T M#8ZF#7T\S]*H(RM>VA70J/(94IKZ)V+,4I$O)?-"S MOT[!DSD_+:W HJ!=(7+4*#(8$IN,MQ&.0GU9@\ MBA^#3T&XP5Y\?*5'H2&<5VG@2C:8/9LZ<^?(J9#E;<0HHR@A35?^FYPXF$O1 M)G#=HQ"!$\KHH1"X( [J3[0)S=S)=11[.W;06HPG"LDO0#8;U?')\2)M"@+9 M9B2TS>]9@BZ?ZADNI6]0WE%P6,R M\1D7A_@E".D%?ZG!/VH$AL$Z)PKF-SL38"^= @NB-N"MGZ!\G*7!C=LH* S> M1&8IQAE70;;@ZW,4'92PE38 QE7"A;2ID0"K!5,)07OPU$7 1BQY0@$A<50U MOS8,E91B"WYN#W$4NSXM/:,PNN56P$@JL2)??VV2)X +X%2B:@^F.HO:"*R@ M651(='&,LPUB=1W!XXS%IE*CG'P)AB?6O7S:PF(I6F(Q0B.+IJ0.DO$A\V\_ MGHV+1=0(34=G9V?T_X\COA'R@^K<19>=5H*M8J%B@!5:! +5WO76Z57]"W]= M*L?=?%5>IJ59T+6Q(U]-?3DO0$BIHI0L.R.LUHT'O4"O76BG+'3V5$_I9#2M MDV)!?7D%PZUA3TIC,%CT_)6W=[>W7WT<-E^SYWUJ%&W'_2NL\!=9AF)&!C$Z MT)?O>POE<(2"!8G8HJJH$$@. X-@A?$Z^D1$N0S\5QS&M,C@%7X23T7B%D9! M(61#OIK)V7F^)9%00W1(48D>H@2A$*))0N=80AK-N<2BT[MTN;01]CT2XOE! M3"\L^3B];!=!3S^M1EH%6+/BH''VJQNG&?YL@DQRB.ENM]'MYN+5];;T M)L"G(*2'_NW78+30!L)N9X:E,; XRUZ!K&*@Z'F$2GVS (SU3FT_[__#)@@_ MT/2AP6[;=/$+AK27I.[A-=ZEKSE;>1E')\1$_J2?PJ$]#UL#)Z_61M??<+CR MHH:#A[9V0!Z#RXR"/4\@KZG4_XF_QQ^UQ):U.)&S )(#[^'..=,LR*AC9 +>=&WOF/SZ9242HE MC1AMV^:^CD++!*HM0H/C[\ALI3!859A5.#R^OBG5Q ;LR5_>F\ZF9_.9U"1G M_*JB?C%K..-,;>RLQ;*97%G,67R+[XYHE"Y>+O!N&4=RJ?13-9I.D/ MK"WZG;8&0D1'[AT9[DW9^9%9E,VY*B"8U38FNI6_,&VY:AE@D^74&5=L]RK8 MN9X/:;U=)'#D)#!JP>+,M;J8(%:%0PC>Y@O M*_?.J$";>$^!'#6!C%F\T)PJAL\7'MK^'T/7C]P5/?QNV[UK;0:$#1XO\K'O M,LOEJ!I6B:@%NW9ZQ>7@2$5<"%PUF:D(94)%682YMC?,6IO!8T[]I:^9,V[# M'/R39GJE;8:<+8^;R1JI!.+Z/',V+.(^OI7_TK0$ER=@ 0J/N5()KJ;<:!%R M,3^0F+P8$G[5KVRJ,@@4J,HF+,IG5:E0L "-?3*)EM/I>>OT:%5"U6!::)DV M;<2L9"Z5JLI@4+O/'Q.3N]C7U,(H*H5L2!]'GD^=18;"_%Y/L!GX8I_\$QSZ M9)Q4A&2Y_S>F#P%&$B\?VQ)Z[(RQ1#$KW0 UDVF3TCF2BMXK3$ MT6^^QVZDWN%P$X0[>LN_^#T76EVIF"[JKLZBK!4N)K1.PGEJA6DGZ9501H[9 M9*FC\M\&Q2+/]QA1QMA"9317@Q]:(TXWC8"5C._N%_+Z\1U5"A11'+%Z__!; M6RS1T,9L%"%F1&'79;%LQ.WWA&;T WSPH$O6)D0FL@+'#NT668L:6C0# ZS8 M]7R\OG9#W_.?HXL5F:8/; /L"F^\E2?>3VIM:!1B;=PH%-<\S]?!"5&4447? ME^BBE##7"DT 3:_$#&UE\=8)%5B,R1IG%6A2FM$4G;?UU1232[8U'XG+,29K M8$OG;.ID\7<=4AQ$#3N%-<3<0X@M\"3&Q6Z+KH>0_Z"+$;L5MM[4D8W2G"H%J536E;/S\;+SE(S_K+S3Q"3V^HZ!*Q/JVY1&A, M4\PK7'F1^_P,* %V94E^2"A M)A== ]T,J/:M,#<4Z2 )"5N"XHZRE*/?GVTP:8D UH)4?2_Z!ST4^HV(%=(U M,*UVW&;OC6U,&G\3(_*'$;-)=F.3TF.G@16*\,#0)Z?374YC^)$QR0J86M4# M@JS@S=W&;RG212-;_<@D=BH]2X<0SC0K_)02R!820,CH(853EJ)XM\F&H(AK M.A63/Y8;PL9ID?PH9>*7(%A'XO)GW$\-VCNO?VE[&<_'J=4S,IG-CQ"C!%CE MK+]46?&A]6$5VV#[32951H!0(7>#H*)AS))@MN)"&A 5H6&'? M#;W@4Q#BE1NUP('_L4D\<#F0]Z?SL_2L-B,T0ADI:$!HD,SA2P8*BT;[JN!" MK !(8/SF1WN\\C8>7C?6#1-_#P"/(R94=C27=824J %7$],DG]--/M.8$9H> M#S9\E6C)17Q8O>#U88MO-Q>K57C ZQO/??*V['VZ&T$!,86&IK,0I;B2-*C9 M='9^-DU2$#.Z[/W'A#(JD1Z^I!C/,PPE\=@*B9MS#P<0V]$AMI&,1"70YNF( M\BH;W+.PK ?584T:V>11&$>21C8?3V9366_""%OD2#H(*N=$!A2TN__H(*V< M[Q!+"^XV*HB4\6=_%>SP31!U0&\'JE"0 M5F=599=HR<5Y?I&&=8HJO:*D6_0][?@'.SW T#I+YN[#;N>&;ZPBV NM:1\A MSY?4GC7^HSN\A$ZEH_)A/G GJY"$!1A[#@ MO][MM\$;Q@\X?/56^.'%#?%'-\)K&K>0H(6-U<66\4)^NMW0[Z*8NSS MTZ8@#E3AB2.EA=<^?#S2:5-AZY-U@G)1X1"# NP,_=B+W_Y"(OHT>_/CVZ_N MWX.P=''_'N^#,/;\YP?\S K12P:*G2G#.+BN[,H?Q4(LJID_17E M(MA*,^\399U:$^694=A13*=580#^JB_@!)ZIUVAHSGOYY/E>C&^\5[R^\->? M?5H<,?_-9S\FPT[?L+B((APW'WMI) R7/].#:]E$+F=\-E_49+-[C"F/.>B2.EQ&T8)<'PU>B),/ MU%>OL.'>IQ9>6V?]5@(@P5L;5PJ'7\OY<8R6D/_0C'SP@$RO$H[BKNY*,!]D MR9HY/Y:24B0PC@_Q(<2_$D9WA]T]#4.V=^DS89^"\';/SF?\YQM,%J>JB45] M:,.@OSO#*OO+/,? >D9IURCI&V6=HPU9G>3=HZ1_\#@!4'_,I_!U=AGL=EZ< MJ.U )M4DX"UR!\NSR$(?E) M,1II:0X2<#3SI'#4LN1<%\J)CU!*WL*00:<&.*A,B%MS0T'.A/GSNH2F8/%9 M#2W6*IL!#4U!<"GF1W[M.W$X,V(MB%];MO+7)?<1$CO(;1Z=[0;,1V:+UF!1 M>1<&A+WX[8Z,6WSAKZ__>?#8PZERR&QI#H+.9IX45I)9S)H1'"%&DE6=S(G: M@DV=4CN]I#:/3#DCYJ-30F^P""U2.SZO"5NL2$GB0UB6<,C.!TK7$LG?R,IU MK1C^ZND%!.]:6%>8P,ZYV15YOE?!1#:+96PP")7O Z><6!AW ^@TS?K?[0.? M[R)"U,*SKY'DK?6&C>N[O'[.;BG4OW0])70Z2VAX;TZ(,,Z^ M'%\GT+&+4HZ82KC2D3!0A-*-6_G]K;'#N5*[HCCVT]N"1^7?CK>@R*.?!EOBC'\)$(41%*8M ?CYV!/9F8 RB"$\U *T(^RM&NC>/'9JWQ;7U@SPV'9)4' M&R()[O:L8N_52P,Y^;!(B1A(**3"H<+^P22[O">^GY=V 0YRDSJI5UZZQU$< M>BNZU&&W[M!OOI?L[)+H9Q.$.]>GEQR+/V5,V!'L=,$*/\!15KF53B(,:2$M M%H=]?"N^2?.Y+KZZX5KN&*_P^K1&A^E"E4EMZ4T5#9Z,C;CW.Y9]1NMH8\$88M\5SNW*M/_ MLBTD2N;YM+\3C)!TJZL>+26D3R(&D@>0BF.15+#F#9^_8._YA82H%Z\X=)_Q MEP-]RB9E,;H]Q%%, E;/?Y8XF%>#@7W1TV#:84Z"1 W>BNTA77G; U7-D8Z.'80=L50' MC/##)U4-0[J&Z'9S297DQV%6/,J+_O'QC?[O)W=%>I=U#"J4 -R" GL*ZX1I M[0V B%6T+_?#-EI)'TF9(/(#2GJSSC,,IJ#Z>3K1PR\X> [=_0MQ%1A-H4S7+-N'_1:M>RHSZ;CF>SU$Q3"B@E >3M^\C!K)?=6T+N B>S>\3 3Z M,60]8CE*8IG#1(NA5='1I E G.2YAA=/$0FA5N(Y0O"Y>90<\2!_.+HXSW+5 M$E*E_-S?,VJP6.DIG--%.,.($9HEZX5#+M78*/)D.))>.\S&L^P^2D)XA%+2R;7."O&F.O\FX*=? MU^F/9=N >33.*;C MH5Q8PM,(%5P!NC-8!4OXM085&?5M0\'VR,D-,B(G%971"H3QVV>?K,38_8'H M-G[!X>.+ZV=7,=9K]C2XNRUV1*.V0S(@;DXAUNLGH@KDI]I\:L(S*C&-&-B#*?<3A#GWO M^>@-NV'T [B[AO,[6J)6#<-\4@%NN[S/SR%^=F/\F=BZL_N]H!EG#X( M/Z<0*/<54GY/>3EVC#O^C'>4,X\8]W;X?OO'BWE_H1;!'3RDE]$2LVL9S3^$ MDR]=F[(%4F66WK.K+\DI?=BQ&"_&UGC[4=NENW?H[SL/6EH<+R^1%;'Z& ?? M(UH/2I>;W1C]2OSU"SH?CQ"M9/"'F@TX[@AT0J@/]Q]B3J";77AM"^)2;M[S M3)"(*.U/YF.-1X#])X&$^S^(_^\R5+5HW\L5^,K63,$&A?QYX56HV7<[ 51] M#ZCO+PVUGB)$@VU877_#X[,B<;++0G\\GDZQ2-NT: M?6SVTA]3+YU^5RU"*'32CR4GC7)>R8=#)G/PYDZ[AV'\KH9AF0R#SWS6FC<] M6CX:$SH<.1&X.D[F'7)1^\GPX+RO0^I/0;C!7BR<\" X>!>'T4=BR==L(JR; M7I3DW)*8&LC3VC\DS-GF1'Y:T2KLVZT%RPJSGL',T3%_L-Z7\_V%D(@C,,]; MZ_Y=N-VJ3"KYRPO3/C=A=2B'"Y_CTV<^.M5;V MD?WQBH0AGUPO9/M3P-!HY^\=NN96H16R "?&\W;JOGMT7$V5?8*H2(C*)$Y( M>3\^7O.85C([D9OJ]9GI=4WUNJ%Z;=OZ?_[CS"+2C@YBFI$SCO]?[?Q3Q2$THEL&QY:T7_/)'S.DHKD \R 207*Z]]H'V57@,RT9G- MHTF3#[$;QB>HRVE-E[04QK[T8F"#;J_PBE60R-0[?V^12B_%-J2)29>%_A0DDRE8U_XVO+HYBA_&H)%0*E M4KR[6X']AXHYZBQ]P):'3$ \AV'O7!^Q]^6B2Y946\;F]TQ+UTSI+=/(.'BZ M\/@N''P'P56<2LN3Y?K]?TD>SK:B^&(S]U&64YX.!A_8T[U)8HN^SZPL MXTJ>[+KDR>BO:VL\I?(E[V@NUSW X_\:8 M# =VC_%]A@H[9#2Z$D+2'DP\O M)'RRYWQ;]7I/1-TALRF $E"_"6%(#"\SIF#FC;AWJTRI\^&WOA>SC M]COJ6NB?1''"&M,J%:LU/BV1G5<_, 19*BA(EN14E;0[Q(4P+,YRD=Y,$LQ:?)S,Z M)^4)(5X[?#=O&FI]#F^YF.@K 332 MYP?1I"_M?^3_ M7E\SK):RIRN-JF1CW=OZ[1V>PA%/JQ32I[;3\7P EUAB; 2;5&Z;JBL50'!! MU(Y<*G-XUG)N)#4)3<*HQ\7O=B MIN\24OUE2Y:SD-Y_S3@\X;)WNH5A<-RG[P'8 M-H/\_9S+\,YZG?XR.[QVQ^-];J'[^^$ MO+-0")6B0P.7DZ3BH9[Y%N/DJ8-2CKUU[KU:"@ISL,J'.;UOT[] M,>XV%S_0S'CBN<\E2>Z'>T2[N;/3G!OOU5]:GBP7\P'.!\MUR$_ZF6N-2GY7 MSUE+874@_U8?@1-W<@ Y%K*]GZ8;U'6Q8(#Z.\W/01O(CC"]HM W%G^X=88^ MU?VQ5A_Z],9;DWRMGY+@#+1[$6A/<#(WG8.C,GSO>+JGD$%4_3$H M9Z ;>ETX.:$+HAW$4W$20Q]_O_L+HH./SPD=FL/X$YT71+N.YBF&X+U?6=8< M#77GYX0"\L&?$9_-!BG)=W+/P9_8@)W&8ZG@2ATB:C?YDONI>/Y!,Z^DNW]7 M?ETQ!^3<.=/ULE4G-W[*!0B'&8S_7QUIV1V'K#W;+3')I2RV*9K,FID\(1VXO5) MK7"M?X@SUAXSR'O;O8<:TQ.<6:S0\A![_IIMX'1GG.R:=7Z=>MCY@]/=RS9?G@_GV4@T(*^H\@"N:.=S'(":S5:UT0SF;D?G>_[^[:VMN6\?! M?X4O.WO.C-NUE=2Q]RW7G9S)UIG$G3,[>>C(,IVPM26O+FGR[P]!2I9DZT+* M$J& MT"L/_'S3>6R3IOJTAM* ?XW9]22N?W/]_XB%[]*-D2=)IJ^[^3K7B*6ED=ZL M*QP!*JW5@J;Z_UB>*%^JG'9:>;9=)CZ$]VHBF0Z*-?9>!)I7+M"_02E9Q'Z1 MWC5^'W^,9]PYM.-K&_?3A_3"E?7'C+A@#0X^DO]5%TLC23_2V,VL['P5JBK^ M+3QO5SWR8:K2MN\+6O6XFOW3(W<>^>%SESZ7ZJ_M:R0 KZ[*V)+XT#M M2>WZGW1%<1.$MT&>9"O]FB(?KX==/H3,N$&3.;=*2OY'[<(-:,@>H\J<%1!? MJJQ^(G;^RSL2L2F%7B%VQY9&YFY26[4YCUC>1N\1VU />XB]8:\? ; 'UJP' MV+RNT !;.^' F0_HWN=R-LF@"7WLW(![@8'+M1? A@A1[0(R2HZWV7!7(!)+ MZ&BH'H]B#Q<]/X3$^15=A&+Y]HT%I5U4]*Q1"R]@0&,FE-[^Q^E\XB:Y(4") MQPI.BSP!-;00<;1D5A/)S.&@PLSRD"A31"_049..+'X:$R%Z*3 ^$1A/*S&" MG!UL0;HJG/0BTU=I7K9ACN^&YXWB1&_*8?.^MF<-H,*=OX05O M_&=9WZJ];!)+2ARIYS^FNWVD*6&24B8):?($Q(F@C@6T#D07N'N@K]2-8 ^K MX_$F8&R/"C8MB\UA3UU#>E#TG[D:8;/I\"2&%WSS_1&V1?K1YM9U"I<"2AYJ M&2Y+SXE@351,RI0X4+21L_%X.#W[?B+@$=,@G,CG3NR_"/5ML#\Z8!]IY:$- M82REON@:J=7LD!4E"')PP!Z8.][$^H_(9\&2.0"7ZA6\FK=,AKUJ5M1G MY]/3)-X!1;'%7M D6:+82W-M"FOMA$6-:6H&F MF"EI PQ+$&[D?#U8$/1?2 M=%6+%)7OF,91&2/J4_N3X3"W2S.E@[M@T9YTEJYT1I%49WX'.*I4"BJ*_D.] M9]_>OO!1ZUH%00?/8Z!GGPD=VXKC3Y9$/T!SG%"6AE#&L5)F9(4X*=0#*D;N MF$MO^9^UX$@?Q$#%KG4=R[$RPS&QS>H)R!!!!QL1#06R] 0RCH8#&M"! D@B)^G>O6Q+2: MBVD:IS(-RSV*@+LN CKTE [[X M]7[,?9H+8RD*8QPA1<94"(D#V5$Q,+<7Z](M;/F',*Q>M*RS GLXOQ$DL V^ M@1S[TYIR.8S;>LYH"HT\E1?'NCWGYXNW7O+^DASQ91"+T I8SN;9]W"N*]?4=**J[8NY;7+5S8_(U.+R&L MOTOO2''$M7<7])FY;M<2A5!JI4M9QFE!ER!GBE00P_5796X@[[,*%= /OU4[ M1RQ] =6/-9@8G9QJ^[,>S W;$=PZ%%RBY]_]@D_UE*]2%VAPN@V"B"ZO(A_V M9DGW#CON _'CWB'ZTKL-]0F9AI\6=QK6:4W:KXU64$:C7?Q.I=)<<5=$_<"D M2]V=]J?816,T',!<7V$H\(\V&]M_GZUN7D'23VZW+!9%/0%U>^PW&^>=1^.+Y+&0T0'4$ M>KC(H5]#^3B0WV[7(A;9ZR0)="V_J$UEJKQJ%.SU_&C$HB])',^037-^)*&, M/Z1N76SK0.PE"YRU%T2^.";J>NXG!Q3!*;-7@4[<8;>&#>>QJ:@Y#&!R3W'I MTR4++VW??X\OW3W?P)F)$D.H>L,@#"O84%XG^3*:QG$6XHHD1[+T!D12Q(%< M:R(*I%U$ 7-I$)"0R^H(N@%Q@#*)2:,&/P5#S(*J3C>]P=(=VS!Y)">8N=^" MLI2.VKO8^-IG2&,PEYPW*$5:AC;APS=.O4>H.TYP5?P-X)H#YLOQZY(&CL^V MV*?PM(RZ%J&%>FSE#!XT%_& ZB[_\!;!N1/.5@!3,1[FX3>DZ4G RQ=8&+EU M^2L/?%YP15?4YYSRCW?,7K U"]_O?>^5!6*2L!M17U"7KMA^6#3GLBSB,*5<.;$Q [8(YP_&#D"AP/"=CSR$63"Y( X@DU8X0(@:Y%5\M4ZX'9!MRJ\D1\43"\FRX?.//>V*D4)7I#QFSE0/R.6N*\2\7G1% MPJOXZB[MB@R_V:60F&6$$YP][0X1:W)K1; D3,EO,;7?!^)F(N9&L/(QVU(9 M;GCL.5_^B((PV?J6ZX??SH. AK^G_8%VVM2XF]^=8C7;WZ9C(M3ODML ^4LW MGL]_B3;1&I;I^2?*GMUKVX>D>%#$>6QD1\*D'1YZ'"%;$5#''9P>$RC#';(>:^$EO!;-!WO7A"R7!ECILQ3(83U.E) J@[WH\0PU(6P^ : MS:'![*W%[$F+:M>5A?KVG\*P;\H40XLO >E]TJ,I]#* MD4OMS5FXII"*7[)7MHPJZSD4/VO2YHL8T'"(T\2O QVY3R6AA.O@CY?+TI?+ M&!JJ3"R'B5(U] (9?[+PY8&NY1+4"]O.O6L^@ O?JR.$)A5,-%6SIF./<>G7 M+#&QY4F0PXXV78IM-10;#8MJ1EV)4@7]H>#7MY=T8_L_818F/L!-DD%E];SJ M=TQBLXH1]:U+9U8RUMO1$Y-X\9$(DLAU\UH4U,H)FLKI66 MF@:8;+&([61 ?WGW'G/#F0M7$\$=3/>4]XP;VL_TTG-?J1^RQ9H^4I=Y_E61]^4>YMI9< M6];0&N$EWEKW86E*K5W%HPRA>0.SU?G2V];6<2]\U.10NJ!]Y8W\P[&5()^3 M@07)A!#VVL_14EG:4AD;:%<85VZP7::#XP?<(J7MOTM Q!_VL1!__1UTG.NC MS \&[#QM3:/_D[SPMZ^W\^LK\C@_GU\_FK7DIGP+N_WF,MCP(4Z8HAR@.>Q\ ML,P]F3 \,]Q]RH?T%QRLLT4V[OQV .%T[ .S!;#\F*N6B3Z,AK;XTMG6G&BB/0!21LA MHI4>CL6.TD-:6IW(K*G<1>VG8HM;"XB-7IFNB9DK#U**="CM/!:9P_PG_\P_ M\3^@?#?_\!=02P,$% @ >V2H3#.NQ9\[3P $5<' !4 !R9V5N+3(P M,3@P,S,Q7W!R92YX;6SM?=N3V[::Y_M4S?_@S;SL5JWCV,FY)'7.3*EO/CW; MMGJ[VRSQ\O;VV_^X]__]5_^]C_> MOGUS=?/XYK]"$ ,@2@V+.B)+STYL/W[W_Z]OO_O3VN[\^O?_33S_\ M\-/[/_^_>NMDL\5PN4K?_,_P?['&?WESE2 $XAALW]SLJ/K?;^[N+K]],XOC M-P^L,7GS !BA(/JV'"O>+9!BA\C?OZFM\O49Q]\F>/GNPW????]NU_";?_V7 M-T7CGUX);'3X^OVN^?MW__7I[C%<@77P%B*24FH:'=E@;5W?__CCC^_RWQ:M M"?R)Y*/<)6$.C@*!;[@MV+_>[IJ]93]Z^_[#V^_??_M*HF_^G4WX-YS$X $L MWN0T_)1N-^#OWQ"XWL3@F_)G*PP6?_\&+P%ZR[;HN^^+_O]VE839FIT;%%VC M%*;;6[1(\#JG^ILW;-PO#[<-\C'8Q)".DQ^DM#Q^[UC+=\+!WO4E]8'V_.61 MGG# YI@O]L?E/B&037$9!X3 !021-N6*PYYR#?[U)$#T>9(8B>DV7 MUQP]-1D.5_2:NL=4J.BU"*4)#"[I"PHRNMD@>LPVM&-^C<7W.+EAVV[FQ"E/ M87!9C]EZ'>#M?$%_%"R7&"QW0.(DRL+T ;P E %R@Y,U/3DI#L*4_ S3U65& M4LIW,;G8?@I^37#9GDJ6??9U$'(,PE7.+YK^(TB6.-BL8/@ EOT.1)?9AEGL M(UPB*AF$ 4KWDYM96.O(0QSP!Q "^!(\QX#QC"M0<#TIQ"8.<]>I37+D58"6 MX!;-0BJ"9S&51J(Y%? P8Z08K "]$UY (4KU8RHP#BC&/X,F)8+HMD+O;:7(*>!S+.4::#,#-!3FM.9R>27 M257@*(L!$^'IEY F&()>GUOK> 8)IG?*!N!T>Q]39D4QNZ8"XH;=TCV(YH]Y M"L)-?RB:$QE]W7Q*, MRI!,?WX*7LW? ]*AA]A=.MT#2#.,F'X-DX@\9L^_@C!]2JY?@S5$^DR".!- '$NE'P" ?OW$ J= M^AQFO0=KF*Y+ZSZSC5$0 0KA$(*/YE0F]R^CAPM\@@BNL_5#;NROD?,%187= M+$!;ZC>^]UK1#8]#B M7F2-A]AUZ52VUVI\IQ4G''K=AS[8(3:7/X>UU1G?3ME,0Z]TYYO=#GLS"Z>Q MN4;C&ZHPV=#KY;I]A]UCK6G'A('Q,]!A\N&_@:8_=NC/73[;"%8\P,>O.N?0 MJ]^IM/?!EDW(PG*/G-K#GH&N%(P4&>-GI1\=0Z-TEZ#E$\#K*_"<#G$ZVL>W MLBKC.RN:9>@55B>&Q494#NG2#'N9$*HL,D$S=UG3LY?W&F*'^U(RZ]BA4)@W $\3PGL-3P?(O#GF7-B<>% MPQ#V*_WIA\:$YZ0<]F#HS#JXW1HLV9\/8,,">-%RV)6KS#:"%9LWTRO/6:Y^ M4TOKO:.+;S3XJ=L*T;NC/2 N0_+:GII/MHAJ55U.1]\3 M'59 5O[KX:DI3OTE8(F;\2WEBJ__!VQ;R&IO=S+ZJ/"3H#PVM25KD$>LJ-.I M*+]*U@%$7!K+7Y^*FAL8 WQ)S_DRP?Q=;K8Z%6TL\9LQ7)1^#M9M7T9KL^&I MNP/+("[FGKW"-EYWV*([38N /.<5D3+R=AD$&T;87]Z!."6[GS *_U*CL/QQ M5>:%2CO@EO[UD%!!0ZOTYG*;C-:BT?![3;4)QAT>M^OG)&[9Z>;O]_34IU MV.A_W[RARRA2^N^*%7/)S&E, 28@;\EZ0A89OOW[-Q^^>9,1NL1D4P2I6@%) M\-DR.(ZYLZM R+G##H^F5%+A\6&B>!QH6A4@WT\4$(Y870'SP\2!.=*)*FC^ MY*$Y5&LK&WH7KO$#K2FR:C&QW!(3I6.U2^^VYX7/[V[M"= M-;"32[%,M 6ST4'P7WD#<,Q'G,8VS%W'F9*?0:I&?6L72VLX"+.4+H#3WA+U MLEJ.=PDA%..\9 )_35JC6%GI/D/\/H#1+;H,-K!,E"\O/=[BY!VMK*B?[!DE9<@S@.TTD:U M-99P"PZ;V:%U7[5N%P%?%N/;"GQCLEXV5K(K M"4UOOMJM_SE!H9#Y2+NYXJSOCNS')(F^POC0)WGT:QNT'29O4>'G^C6,,Z9- M2^A6ZFIG364V*J6(2WNMB0]#*$"I?;_T'L@9ZRJ)J:I,V!67'L:<*'<;XUHD M0HIR=\MK$PN&(]'>CLE01W\,U1K7.32[H8(W^VJL5'S'5 MS<7G7=C%QAKN=W9%J3#;UM(2Q9L 1F4I7\K[:@=:#+Y*3SLKXM0EX$L'PBXV MUO# 2@0B$.T*I]0L653^AB'DK42AHP]XU*"WQ:8NNA0X>1F")X< MIS8LW(RXDV/!4<(J8-R,O%/EPG4DNL3:)6D0GP,2' -"'1!%MTX5&N-F/)4R M7N+PAE[9!"\ /R?. "6V2+B>9: ,4]/\[GJ.@3(L2I85U],.U)D2#Y?['9P0'3]-O4S(_(S5-*1FP'W?7"3QC#LP?O@#]TA>/*PB0H]-P7-/NB) MG%05;FZ&\O?[9 5!7A5P;DJB?8 3M:YP)E);B>.JH'E!BA+B+M^#\X<4(@ST Z[31)?58_F81)!=?] M%,OMB,,!?&+I:!-+;>&B(S6VQK]5@J*;ODQ]3:Z9[%+AXZ:(J(>/2D)DA9B; MLJ(F8KK)LA5\;MI&]>!3B;7<(_:]Y_+M$7H50EW$CL_3T<[3\:%,(S ABOT7 M>F+ZM(M[Z][@KL?D=D'K6"YP/42W.TH[J#A5(-V7,3TP0T^N,&EX :;3IW"13J+*<&(3O0" M;'AO6IRVDNK&HAYV;.F$SLY2V,EC$O.M_\U6MBAE87)E:AZ_3.I!LS'0*K%J M<9O;H'WG4=])P1+:N(GJ_ ,(O4#KY13ADH=> 06W()KO-:6:OOF&UZ2 MPJ6XVA8MJ Y>@1A MAHN$'@P)_=45_2=:%N]R=CQ3O:>SAAV5;)(F=Q!?_]HF;1)&#I0J=ZSKD?EZ7Y[3=]3OVB\\9?UD'F! MZNAPO"ZNA^/U@6COXG$]&$_B49ABN(L/P3\X(X8MD$>5"PP)(EG*6LPT5;+C^MQS"K('-KN7 ]<5L)D;Q?V9>K:,7/]>1O5^&V>KN3Z MDS=J^+1ZR_L]>N/*)]4:--+O%1Q73LU1Y$^W\O<_%K @JE*D9=LS!T;F/':] MTKWJ\1DPW+%?.7QWF!&;!5VO7*^&C[XWLU_- M>E=P,V:0<;^RJV)**C]UJU]QUS/B9#[34@R'Z$RY7T:Z:^!)%W9_Z#1T]%GJ M 2'E1SZ=[BUKFQG!["G9FSCY2F[ILC&@V-FHY[KW2Y"GY %0W2J$^5.MU67] ME#!*[W'R NFB+[9?"(ANT=Z$- M3^%+XG\3Q7(-,92/F:[9F8LL?^>&@QQ@\ MIU>0Y+6U[C%8PVS- T#:STKN;^O#QH7[D.X,!@$!5Z#XD[,PK2%LK?& N@= M3Q ,*0,JJ6_^H-92L.CN8WH4:,M?/EC!8?>XHEX.IJR7G970BRJ$0>EOKC,8 M[BKX/:SDDB\6].:;+ZY?PU6 EN"!7H]SU,Y0.$O2&N* M)83#5I8H;5S'M^C@34$^[9)^XUI-5>14>T&UKJ-9T\%[ACIK.NPZCC4Q-RNB ML^DLIMYG'*O8:R;E^T'R A2J XQD?:5CLWP]N MJDMNZ.VR$U=+*96*0CF]PHNUXV"^4L;>O=AFOBAK*-;-%VW.;\Z>]!ST_'"0 M\%!#@X$ER+BR/#Y4!WT_'#H=CYT!Q\1+BWFS_[G0W70\\.AV_G0'=Q78N)3 M^;74I%@6"DX0_6M8N#SP96Z@V:M:>0-(V?8F!CLKSBPJ7#3_-PMH@P4,1=:L M8>8R8I6A:G'IYLF/$?U12O]&Z)DKCM(M:CPV>FRHT1O RHM$!85DOO@$*,E4 M%L[?L\R#KUON8\X>ZHYB0Y/ULU.-:;/G'X5!.X44 MZA;KMTH/*_5KRA1TQO+63+T677B$P9/C7_?K,ZU$,!3 MJ^MG[E;DRX-M(HC1]2IBPR&OEPKE>DFRX7#62WCM5N/,G^?>Z::]BJ9M\MU\ M3 .<>OB[9>;V*ZE6;, U.L][M&,H#QW# M=87RI%1-,^RC5T97A;R;RJ=RV5XC^[-'\WLW3=N]T-064RHTIUSEUI3^7J'I MIF2AAJ9:W'B%E9NWODJFPA0?HA-G0?AJP+X:;=H MD>!U<:1LU C>G_M'5M8ZP!'YLHDH&Z;M__S^KY\ JX'-28%3ZVNE\G%EQ;E) M,/_[)RU5FKJ-86.5%T%,A7?PN (@O4L*MB18$+?Y6&AOK46JT,%('8P6-^21 MX['U:]#M?>(G81T.Z>,(RUBW=]S#O8I M9AX7HKF_,R>6M"Y-7AJI_\@C0T2XU4>F"'4\%,<])S1$)07ZC6D#A2G<_0(J1D0NF?_B>W^R)>AUE)_VGA /L"+ M?$EKAZ5GPZI8&N#K[KOR1-I]('I*]JYOSN*'7-,[6=W ! M'D,(Z!$C=W>7(W*7Y/'CT0U$,*5G^X4%T= M7+(,VD*2.'A%] L!BRQFZ^%Z M47H,:<5TGQ'Z31-2V[AR#4!LP9?V&\MJ!#X43NN14%Z(M?3X /K=IN26D Q$ M<\S^9'R]^2IN\5OUA789?"2XR"RHPBXC6<-]AL-50 "]64,PB^-2GOF8)-%7 M&,>LO@XS=3P%KU<@RL(\IW^V9M>,^J)[S&'$"=="TL$_JT6[%V)S&UN.*W^ M-O?U,ED_0Q3L>6!!:[U@@&33% 88R?H:X1]/.$"D$&)X_C"M(4:^QE:6.4/1 MCF?VAT ZPT@0HAK##1/<:O+; W@!*&/R9UFIZH=K9CX>I( M#DC#&:&\H[EUI9^![&XU/=M(D)-YZ(5=K#PI3F_]9%V6Y&'4K."&"+VMHAYV MGM!^ 7&RH<(7"%)5R'JY$HS4'5>!VGVQ_13\FN#+.""B0$&= M$4:VPHJZS\%:K+WKCC*NE4JM,$I=K3P\+KZXK=ZI109"E;4ACT$5]1C1"H1? M@KB/#Z@L_04)@VD#J&B]I#)WKG(+KRI!AU$\.K:3:0#YB/GO&DJ[67GF)ER! M*(NI"M1B(*&75.U?P@=[=(>QLE80TS&7'P&BRC(3I&?1FO)V)GOF@0!%&6KQ M4=0;PXCE:^?XH,R%'V5^W,A*R"(.(K .\&\LC";_![OVQ8B*^UB-,E/U9NR# MS5JVJEO5U//Q:TJ<) V?NQQ/UT.@5!P0PO)41U>-^Z%)NIB9+>ZO='D3V;A6NKV\-*DT#-C_N[V-M.D@.9Z>+N]R30I[(;T MA'5[T\G%Z\E,>%NWMYS/OT MC5IQ_9$BE=" 1H$O;4.TZ[:B#NYGM2N&X]N=,)XB9W?C00I1K$B_9X,F@9\T M4L7U)X$,8"CRGO9[Z6<2\$E<5+V>[#D#!!7B,HX+27*#(%R_,I1B0!I2C)Z+ MN=LK?^/'SQ><."R8V3',8KH5@7L )G5-.Y\N;P(]X4WA?)*\"02U%+@=HA\\ MHEI?=,UN<\HB A:SXGFN31M)[\HA4C[AV^'$9I^RZU-:?4JK_22X<25>N96T MX(/^3QWT/U X_#CW R6&#G9V M\]UL'V;B?30C,%!Z'XWWT8P#O2G:P]>;!(&B=G\5Z#I?-")@O77<6\==*/MI M(@&&O7E"?U%[$D7=3FERTK/',<.,RQC)?;#5\]T,2(-1K^1@).,,U)N*/)LGH^'< MS^=5*;@^!:\GXZC'#?T%XWY5RIPN P (>8G2J6<_HS/GBUR.* M^_'%KWWQ:].X^N+7[A2_'KY0M%NQ?N=>H'C2\7V^W.THHA0=S4#W48KG4N6M MSI^''#K5*O9)9.X;^GRMXM$5.E6L5>RFD>*TM8K= MM#BG]!01;1@Q4] M9IM-G%^'0=SR%(_/]O;9WF.OA;H[MM9N1KO8)QEE8\L/MJ=P.-9+UD1^=GD!9UX^_X)3'5^X]M=>4#;QW6 MM>LY[3R5<>5&N!6S/NF8[W$X9_K4='73#.NCI4_\Z.OQ5>5#GM5!.Y!>?-RR MN&BK7(%Q-22YKTHG>[I9K"JY&NIJ"=6]4C:5F%8?YN ]4MXC=3Z >8^4]Y\8 M\I\\9NMU@+?S!?U1L%QB%@8)\UJY.(FR,"W5!G)#X;],4'XUD)]ANMI%$^V\ M=V5[AJ -7\LA^27=,CN_M)N5"B;M1(FL-,(NYVR?X]B'J%:&04# %2C^O$6[ M@]IF*!*T'HJ:9!O$Z;;=/JS69R#*'H,8D'(.%NA+CFLSZ?0\?VLK!SFJ#(2, M]R[!Y2I R^K,M('%;SP4+=+S)>TS$&6JYTNQIPW^6])0O_+J-Y[$5:+:V^+* M>+=A1ZYHB#;1D>8TLN)7D1]P85.;8K.JE-10^EO7Z[H5N0M2AR?8=7-Q)XSV M',A54W 7=+1D-==]A : XW^);AG(34+6\F%VL7J//[E/&RQ5(=?U&@P&@.-_ MF&X69S !V1%66I44SAXK[R[0 4?]X)W2P.V= MH0?D(TB6.-BL8/@ EMK9)AS;VBR.\T)/_ #(@Q8VK"$S H/[((0+V!ZHR6]G MI;I]@MCM6KR+_ #);S+_D*##*.@7^80XC<_9&V0&Q>N,50T4'M=&D_/W<9C! M[7."T]6,W*=S)[S29_=5-"[[XKIRL(BF'1>'S M<#Z^3!TET>?G5>SIJ-@J][GPW#@>,:TL,C2+'1U+G*Y[5;4 :JHRKKM4M:!I ML4RX[CE5PJ?5MN2Z@U0JZC<$'SZ,4S-X/L(E8E]0@-*]N=-&>+MV>R&_G17S9K &\T4##J$QB]_>&SM/9NP<@VW &]R\PT>4M;_<#P!9N&Y8A_F;L.D%2.V5L!I.*WZ[8V=:C:I5G7#6YG:-4> M0RY][;%;"M[NO2)I')D-P\KNO;:*Y,\@+5^YXH5RB;I8,:Z4D=*ML8VLPGCM M(:.M1.WH-I8EDU+_U0ZX2HY9H&W*_5078 D1J\5T$<0!Y21M]@*] <:R,_< MY[7(*4WS9\I*/6 # UNI9]%D@)S%';8: M4>4-F;'95Q$Y3_/S[7H30,Q\/:R^XQQ5-UH;XQ&T]D;G3HD&?2LGV#!7])$U M]MJ$YB7HO.6P+Z@F;U[7=5XS)UC$.EW7BGL?4['2Y7K5T=[P'NQ5#Y/V^=I>]?6(.9VGZ?=P_R^8]=4NLK661RD(,IC7"^3 M-9U]!1"!+Z!XSL&2I5U&%A.E9;8F[6&L9(6K$2FR16D-87F-3SA I'A4?1;] M2K]6IA>)T^'5.MNQ7A\!3;63^>(I>)5Z$^0]S]F*:"C[_/>,$L"P2A#=:6&( M87M;;VTLT!'QA9L$ [A$A5(=;O./C)X_]I&A]D]N=U0Y6S'09%;SG@^.ERA* M6-S'SBJ2\+=5$E/)AA1$<4D_:GAF]/[RP:I8VE5R:283'Z^^EUE[DYMKZ;'$ MZ;B%>A/H#<7I7+=U#W-RZ>?8S\9=G-UK%#F!GC?\] %+\5)V/@Z\+W[ZG[J[ MAK4.JEP'*"=2L$"HKW%@$QH$*L#>.P68-^?RDLY%>E:CFD/[49N$]?;H+<\H M@@5MMRB/WV#_L&*WI6C]:Q M9JY^GAG0R-A6K)]? QP]T5D$-H-F&T/1PP(X>*9SG9YVXF.?TUM$V%/P]",3 M -K2T#Z]MXBR&$#2!\KL4,J7U-#K8IY_E M. F-S-SF5JSCDB>=#PWDO.9&N,WAZ&W^*D%#[^O(GQEAIRJ(*?]=)RA'A\S2 M%,-GRHTI2D_)?8!3&,(-Y_@B\PHO+& M URN4AZC''[>\_?!<,[\/)<(*3H9#EWH\>(+ J68? M);*$M[A*#T#1?1P@J40RR%1&N./3U^0^@2B=(T#_>D/5MMJ#/>P*H5<*O2P> M :*:]N0JHRUI@VWQ?]J1ST8-CF[5E-NF&S9LW8,<)5?-21T4WSK8)Y#! M7,U/ZHG\ #>WJP[;\2 MOO5=36WJB;\A&ZFK22@]T=6QM[F:?&(4PJ9)S_5\ M.[YYF8_0%.0J57/I/N?5I/#O^L.G,CON'E2.C=750R>W*\LBJ+Z?)B0%%<+UHP-,Z*7I[3O9IN M,7B*0@A#5FJ2Z> @.K!A%&:\FHW#1AC5U9%Y0.+:%W283F#"9(,""GV*Y/J4Q[9]>HG4G^0T>W0@?S298,.A[!; $=V MS]>%-SUD7/4S=L.N]SWJJC-1VP;9^8IT55?V1H.ZJ:FG!#6YE%A3H'45$]PU MYO43G)0OWF.AL5?< YWB.7$?4M'M[71DPY 'DJ^O]8MT2*C4= :&O8J+WE(Y M#E']A$ENWH14@K$MBR:+"LFUM[5*=;6_$BNBJ(?5%=Q ! D]FA^3)")Y30&J MK '$C#/R7M:71'/S"!H:)5>"IV,4M;$*HT/P==/ ;V]8!#K'1)^1ZOK^3G! MO[$' Y(0$+T%"7J.VO!L06L7\O;)Z5+*J(@8FKL*D<;5V@I2$\W)'"*A)*[" MOEVWQ&HB);H87+>R:D(EDAQ=S:[H"%4NXO6S'.BHN=[$;%_?IRQD W"Z96%/ M['D15A%JPWP\EBO67P&Z^!#F2Z=_CT%^0E T6RADYP MD=$3S9Q+E)+;]08G+T5,VT><$)XV(.YCZ:52%C.<5XO-[Z\E/>+"-8AZ^-"F MFPPCF#+A$T4W$7]38@FO[T-ZN\"Q'MY-O^5%9I 0 "KOJOZD0DZC%K3/B&F MGP)Z'R. MW4N*L)4T,$&_=R;0&)-E?<;U6I$.R+I-*IUR"RK"AU'M1Z^Y578 MQ4K-EKW[B$N:R'6BW-TK$"/0+I798J-R@O()F2Q\0F6]D)E<-X=UPT:B([EN M&.MXH 0"K^OVL6Z(B<195^-N^B$F4%-=K1_2#S"AG<3U^B'=().I-?W27\=K MU^Z'FCF3:[<"(S\6^"+VCBP8^?-$AL]ET]O2*5MX_*=25R&<;+Q%%Z!T#N8I M0S+&Z,\:S?,>=3;+,8,TFKCBY'#+I#T1D_"9FE*]&=*;(;T9TN'1DM7VG!$"TAX)6#U"=3*2)FN 'T#QKB19P0T1/F4BZF'G M6:H7$-,S%3V!<(62.%ENBP+RPE7(>KDBC_<(.H((IN .OH#H\*#6S$EULQ$O M&DE_H)&M]V+[*?@UP9=Q0(C@'3V=$4:V0F$TF:S;R-92(2U]$49WE'&M] L! MBRR^@PN>AJ/4U<::6)3^5QC'S(-[@+MR$JO>&'82_"*PZ,U5=$<9X4J+%QL@ M6N[VK-M2CX<9X5HUN$^7D>RLN(7KJ^^I4F8J%0 [.]BPWTGG 0@76 ?Q,#>-3,IFFB M@Q3?"&'19>RNFWHZRME-(Z)$07?=KF@ PP-&YGJ,HP'$A(8MUR,>#> GO/Q= MCW\T@-_QY>EZ#&0GI;ZE6"I'9G+]INUH+6BF^'=032>.JXGOV:T 7355NGGN MU P$KKY-HX^8W!3OZDM^1K'B.J*Z!=R>0YBR2?SJ#H0*L?ZYNP* M/;=46!^&UEY\7&C7FUQ0\3#7 MG5Z=K<%=#IBK@K57O[B9!ZI<9W+*6#^H]-C>1 3E.B^_?F6/CH.;!)<_/0;( M/Z0C,MD>8_D &*$1>Y?IAF(>Q/\- EZPD8F1QX\((_.&MC4"PGZP,UEWDIG9 M_/U@Y['N)SJ]N0TO1CN3E7]-S*V;CC6R57OEVBO77KDVJEP;D2] M@4\X)M4TG(4D,.$@5<. %B+EA(-63>.9JR8^GM5;,+T%TULP1P:5MV *'_R> MA2'.Z.I@\ SC_#EY2V^ )1E*R7VP9?N7!U>7CV;RW/N"'C94M!+'6T1A!T_! M*R!2^CGM+5)?.P5*U+>TMTC]/4X6@)#\$[L!BDO@=;*XCH=D&\3*>W#4VD[1 MI8))/H 7@#+)I\MI;(/NZ_4F3K8 Y%F!&N=?WL^5^"*W#&EY%J,NLY-TLE/( M(+_UV),G.6%!3&0E: 4]#!"]X>(KT*Y:NHV<,*[6 MZ*H]NQ]J/$W/Z>SWSFC)] VG,^#[?IEBP+JDP8_WY20]]61R+@!]>'1.X$2, M_I(?R@6_K9]._<@-1@$)PF9"4Y"])"ATLAZV]3V*,/HF[!"V? M %ZSD\?9T$83(Y;PIZ_)?0)1.D> _I4%<-T#'#(!9 G:!8.KC+:D#;;%_VG' MUBK ID>W:5(6RR5-K;B%/[HJC,O%'SXT4ZHT*!%5^" =2F:N6HA[ ]5ZK7'$$AVXV84=1:E[!_0R_X[4QJ2HB>_.)22'!5;>@@H8DL]9]F,8% MR(W,;9,CG*WNU@L;2S9+']ER)L;;^QS4%4AA2&GVEMR)6')O$3W%@*0/5"A[ M3)ED5MW32NL0#F!_?>=KY?T4I!GC*%<44R7B&QWLT^^MU-XZVM4ZZBV/WO+H M+8\CP$?#H":6)+P=4N76=C9"U=N/QF8/<#OHRYO6O/G(FX\,F8]:V>U(*_SO MI%_FS[O'8 VS-4>/D_>SDL?=H*IPO4&TS)UO2@LYZ&)+E_:6O)/'9%:?:?%7 MEI=RCV$(WJL%: KZCW1U#^S,]UA=V7]4JV,5V\@JB2/Z,P+"+*6B+TO)HE_T M5; EVJN5CC?.U5?2_GSQF";A;_E)?,)PN>2^'M]WU'$B4=NLSNNNCV%_E4S5 M91<5)ND#^#V#5&"Z#[;L-VJG6]3?B)WQ8#KZK\OD!=![-27Y=04601:G_Z# M EP>J:?D"H0QE2QG<;Q31S]!!-='\L<0,]C?TYL@!!K9 +7F8Z =XMPWJDCZ MKO4(*,?T_ ,4;N<+>DI@$L&P_!+4EL+O;G]M=7OB]6(!PK1A!-)V3K:-,:Y5 M>O^K][^>G_]5Z0[]G#%3+%6SJ03R,TQ7$/V\@N&JL*90CAJ3I^212N-DL9T_ MQW"9*[.$B:R0WH @FI%K>CVF3$_/;T;YG6I\1OL[^@ BL,[-0@6W5M906SN. M;ST:IY73=7QKXGF<=7N/:F5,:=*\IOB][:]L2M$>'&[]D8YTEQ R1Y5UI#"* MMG%:06L;N[D3@,H9XN5NY]_7,TY9!V:IU&FW[6WM5*;$2HVK2@7#9!\8)HB;,+;9UJ1 M:3K?H, &ZVKUQ-Z@"5U KE9/[(T:+U;4K;*)&C!)=5=7BR3V/DK">(I^E1*G MAMHNQF:/VGLOI?:-[ZBP?.^QU(H0J9#S:D#W&*L*Q@ JSR6H(@T0/ M5;A.5HDXB4>YPMFK';SXJ JCR>H<^EZG"K3)*R$*R1H56I-7/L3)('N@/GA] M0R]RL$)N\MH%IWS=A\DK#QP'JV';PH*ED^"5\!$%+G@ZTNJ\[0=5A-A3KZ80H60+Z;05DPA M]W5Z"R"W()F&ROAVWLX6373"L;R:=E<,N)N(L.GX)6YV(1[VFQC MAB2S MY1+G#W7=(LHC$8%A[O_Z9ZZ%F,:U)S5G]4U+U_H1LT"QV]**^C-@YXPJ?B\ MTU.6_Y)%_\M26L=#GUN[L]?$B_"SDZ-_.+];Z!8?].YLY68.>P==2,QYQ=8&W^6S)["6#,1/Z;!.?8;I0GC6OQ MJ/R=*+J/ R0MK#?(5"/"+">2+B9< 5EY,YT1QKG"IZ])SQ56(UA;89ZK)5I MT< &?:4]16#[KK>P2*'PDV^VL1F0U!K!40]%&H81.A^$:B3DI+$/YHS]KH(_ MXA R.Z?PR$U8/U -+]TDD&A>S'4L#GSFKF?@R=!HQCFXGCAFW(TZV2CY09#D M2"K.A]4/"F;M9G ^YGY0(!OZR Y*_X%W@=*$2=[=_ CSC@LY]NY7"3TEFEU# M>%PO.3K@'I@/$7*]KNG(-N/8%^UZC=21<22^X\SULJLCVPC]6"/7"[Z.;(.D M@1"N%Y<=<#]*AY3KA69'=J*[AJ>X7MEV9#*2-%K#]>JX(]N/OM'RKI?D'1F7 M,Q]B[WHUX'/;0'&P/C,-H13GL+U\L=#!H"V[MMQLKSK MU9.'AEBC+H'KE4Q/ K5"@85>]5 ]SHK%")ROCWJ2XZQ?M\CURJ MP=%15(K\ +B),- ZN\&F1ES*0][18S,\-) MU J;F9S+"FH@IF,N/P($V-7 MLP&-?BVNJVP#B4(^DEI)6FD^AR<4#5P_B$J241VO%M7+];AP;8R4A"+7 [BU M4=,4(5R-O_;)X]QU*ZI*]_&$DF<'AMFX1'G*#$:;MNULO0[P M=KXH'6OLT55*J@VKMEMVXG%9/]VRNOF"^_I6&E]2M6O>1?7*6\5,9&QGV#F- M/,/2F\3VZ'D.,">9\AR+>UZ_ AQ"PKA%Y\S1 M.DB@*'\CKSEY@MG/_#L^6-L#8,(;1,O+!.5\*@MB]D3]"3YP94K.\2S?)'@! M8)K?C*A6H6"?(C30*9;/ZR2:%OA%/YK.<1>:.6X#P7HPR3GB5*N#T11B!H*, M/]^9HS>5\OOGB-8O'\X=KX.FX6[5G5VC^Q LY__URY: M'?LX%Z?B!*J$G*.>R5\F3[O[,)">V862)L[#$TTE UJ# "L(L%?66D Q$5QG>5Z?.ET1J"?+[P\*5MO4'NYZV-?K=.*YFWB';:5,(&6F 4[\= M_;W#KN=0#;0+'63H;ME6/Q9(H]P6%TT2Z^%C?+J]?^&W9@AW=;^W+HK;X1KY M[3 3!^L?NK"Q$>H."_^,AF6^I>RP]B]IC'BG>CZLX762T]GL_9,:5K9(TWWE MW\T8I:JCNFG>%C"Z*ZJA&G5Y3L.K1F94(]5O:*)O:8Q485+=M8D^SV%EUR19 M\=6F>-O#Z=X>[!0<['K%^W%N5:=\X:K.%]OMTKD,*04FDA M2KMZW(S_1DBSC7^79P3O\AP_1]FZ1'Y[5ZI%]L#R%809*U<]7RQ@"+ 8R/;& MYU_EDE-QCSV!NEMR*S"\5D9FOZ>W.^/'RUW0-7G,GG^EU\I34KD>V@A2Z^CK M@(K&'V4VEJ\#JKB'\L=*C:6A"::R@=D33-GQOZ7"Y@N,LB 62#3M;4=!]<\P M7>42").J5W#SE @NTJZCV-1?6B5.,S$$HL/O>L*73SOT:8?V3^&@R7('G,-C MZ5,X1W J.7)'B>GW'E.?%GL6EF =S7OR*:X]]*_6IX".[7FN/]4G5->$_%6F M(;DN%W14&???>)MMS_7TW!Z8R>S%IWO=< SNJP= %4;(''PYS_J"8,HX'<"+ M!*\#%(+JQQ;?Y_)>+?^*V*C]*RV?$>%\1^TOL7<=Q?L^G/%]7/^>T3-YB^@9 MR/*US=,5P$^K -EX#:PG-6=5"U.^5JT'Q^S3,PGT:[%(8]F .DEV7\J3KF!? M88;SXLO)IW>+5Y?6%2Z\-BAP"^%AWRO2G=XM;#\GZ"4/ !VFP+GV_![= ><_ MM]<_U-?W,-P;0-V(< MG_2PDXV%=@] X.&H_KC):,L\> M?\4O=FS[H4KV6=T&/C)WW)&Y/O+3%=^FC_STD9_V3Z&/5APUDI(86G=CY'R8 MHO4ML.O@-+)AP]@V?*W>P7?^;)2[?I6!S^4PV/2V&RE 8L3Y/(FJM;:WVOJ7 M+R]XXNO?&O34G.:>/_+%^4>FSGU+_5-5I]K+TXPSOG+; F*\D]HG?.& M'D>2^&>XM)QH)]ZF!_^NJ9UZL'V#.OQ[:N/ZHE1+T/OGU4Y11;:_F6'RKT/U M3(#OG 37ZVF:"63;^H*R/O76EV1U,678EV0U?-K:KI^'QR_"0R?NXY.K1>./ M,ES3AZ^>9_BJ+RRK2[4O+.O#BWUX\9F [\.+1Q 4Z['TH=J^L*Q3F/J(;5]8 M=M3(&BHL*[%M^.*R7;4DUV4#7US6%Y<]M;OK%M'?@J?@%=3\Y+2_YLHFHPDO;__F[/PN-Q&I];1B%9M&O&4GS>X;>NI_! MUXK4>TSW)D-A<0N)G'=:8]A8Y440Y[[1%0#I'9N&L0+^@KC-QT*[T$(GZ-#? M%99O+-X6Y)?_.*2\_/$O5]<'%-9^8<0%=57R/LHH[F#P#&/*SOB.,$%K*PYG MRN%("L/+ A0A_VAO:\4ANU@ %EA0L>@'RL98ZAI$&?W@YQN BUN.YZ15'V \ MZWL 88)">F(*5I#> 'H)!S%EYFE&"=DV&FLM7&]D'Q"PQV.6I:M?X MHW@!2%KF)P66VSI@.]0(*9CI?%(WGJ(C?G%/A,YT1 E+RGG,R3S&S M#43+:Q,M[Q)"+@.,MXLB2I_'&P4=QD7_'5S#0MDD<_2%\*Y7C0&LK(_%$Q<' M1"CI';4S_?R;/E)/0BY0M M*!>4Z#5+C_7^[MW=QJ7NTZ:]T_O[!9+2.%B*6A< 4:9TN&TGGOS46#WA )'< M3$H[W22XQJ+IOP!V3U=#";60/(F'P]4P.BVD M19Z/TP7+C1@@H7&S6_4TQQ#2<3[UJD[F"F"*UF97:TXI875J>[>K%:,& =N0 MP=S5-<+JP4&\$UZ6YZJB^*<)A-*@N'8K#4/Z0S3P6PRNH?49']A#>&EK[C&45HH*3_/8VJ+^CS$KM.VQKZ58&4!?. M^OF.PUGI+RQEGJ!RCW@Y&;46I\7JD7<+/=JYA1S(MCCG'(5"F!(5&VVTL4JE MN(CH02L?0:T1\:-PC;JNG"G)00<>WHK)NQHVH2Q?R3PXDSHW_&J+38;KK >G M$S@*KBY_BA18E;?->]N\U#;O6/1:)T >K]T-5NOOK' L&*T3(,RPX&K$F??> M:'IOVI3E5N%N++KV; .+\IUBL6TC6^2/ M5NIJ=4VM3XJ+U]+6Q2UG=0^7?T)W%> U8RT\7W^]B6T:]YNJ0&S5UG)9Q):3 MR//'BSM96\(9 M/&VN9MF9%LLX!;!:>9'K1IW!,)4Q>5>K7PP)+-]RT"M4@S*9Y\3CV=3X77P*5O^/VMU .QWK;SNFHKUPU:(QXO!$B^[^RV2]AD4IDAF*BDJ9M$\( MC3S$RK%,5I,>SLGS/"EW,V(YY4_$??E+UL6&C5JPM\H)L7ICG+/'E7,6[D! MP&R)01$)@T'0MOTMK0:8O=2+Z"X47Z: U#%Y&0Y)7DK<[.S"TMIKBD:LN2D.' MJ1!M7$T2[P)2+QG158=CY]/&%_E<]1X:^C"/]5U7_8%]/M(C$='5G$@=V]SD M*E[H@B,1(YUU3'7&J5V]<;;VA2Y.ZAS,?<=<)\.[ HC>0V?+0VQ):$IK^\9:/LA)1 O<9"G]_R>( MX#I;/[#)XMI=]X5.@.F_-P':DL(P8*-(@'=[>P=G$-0?^6-',2IR8XXTZ+#[Q.=M=7UW6>D<:_X:V)FO;MQQKK:!\ NHH@) MDC?TM@QB<:WUCN/9"298@2B+P7S1>E&(BD@H=3U+JX4>.*YJ6]YZ<7">U.2O M]F>9M7F+JZ$ PX)9%[!<#1(8','ZQ>YJ$,$I0*S)@ZZ&$)P QIH:X6IT@3Z* M1M1N5V,/NLBVDW.O=P5)]:R>TBEJT8#\ .(@90G^.-T^X0 1JDJPO,W67+,K MD 8P[O\,Y#B,JWWR%EA0%(H*@_OUZP8@PJWTUMK6FX0+=$IV+TQ=:+:Q1&7^ M >?/HP*2SK\B^GFOX*:JJ'6Q_9R@D*KH]/NB\R^+)OP5=1S/QNKO,40AW 1Q M3H-PJUJ;VJ#Y@07&"N+OJ]];HTX(9+V%%0IKUX(P :.EH6UZ:]>8S+DD[3:B MM(U /CBZ"N@[0X,.3 M0*)YZ=2Q.)#$7#?X\"^X.BCMHH_K-D75R_3@^'05D5WW%'2!DZ-ANNX24!5] M]B9$X77M/$?7%JX:EU\+!W05,571;G(E]'2 Z7+LW,Y:T@6NDD7=SE(R'R?MX972#U.<'I:K8&&(;MPHF@H17G"MU"%A/UA6XK M3NFWPY[$D7F)A'VL1/ ',:M7E$N['Y,D(I^!I)0AOX.=@H#<-][;R>>VMUJT MCO>"D[">CX(6[VIXB8]-._3?J^CO8HER&H$.4A6[#E*;%-8L^HS%\9)E*)K"5ZXH6@^PB6""XH& M2B_IEY6L6$3XRAW*/%93,1<\Y*NOE7>,% 3_#")1,_5/P M:X)WN!U9=0^]YHJ]C028?00(4,GM.@9A2J7_?X @3E7YD6:R+MXU7J9W MU+>-")AS2T,C>_L)QC'<)!A0>6(M"!UL;60G_+;^] "$Z$% M.E$%E@,*]M'31]SS8MO\OEC(/3WLK(Q)J7XH5CSL/O*H;*V:;G[OX?<>?N_A MM^/XD,KGKKH].@K2)PJ/> 'X.1DK=-YC='"&^&)XPP/"%SU=!T@J=>]MV5)E MT76?D3I4[;J7ZXXC;>^L$;G=]0_4H'(SV:@XPQCZ$+K3@CJU>+N!D&V3A9R/ MRAL(2V7=9(*)^+,P3++\G8,0P!>&X,5V+$[M8]J$-DYN\U&X'+U#WCOD?6:] MLP$%/K/>!T+8"83PX0(^7,"'"YQIN, 8/%L*;F:^).X]S=[3[#W-3N22GR-6 MWF2N!HNW@O?&:6J&;76P)FFK]AGD/I#*1P/Y:*!S"''QT4 ^&LBU6@TG]Y]^ M3E) GI(;B (4PB#>IT^3BX! LG>E0K2TZ"REL]\G,0SE%BI!!QM&MF,0V\D^ M;G?.QGMWC>3[ST/FGFQI:)5>88I1LY%-EBW_WEMK?3D>B.FE:%Z1#Z%5L87Y MNFY*;/_>)_=$DAP.T4ER.F!.(/!EA&) R&6R?J:_93-7T75/=,X+>E']9D,* M5*2,(UJI=;8B'1Z3)I-OA5V\S.AEQNG)C"I?D9<:O=2H*C4J7C9>E/2BI!J$K[J*%[4]Z+^T&6@6LXDN=C6_B4[U)V&LKOF!Q F2P3_ -%M M1&\!N( @FA$"4E(RR6B&HCL8/,,8YJXX0K(UB/)K0!T.,[,8B5A_W##7<[:^ M12$_7/VXD5="W55"I1+%WB??B:,+G:&9!Q7XSV[F=J4U3_7(_J\S4W3YL:5*$IHOI\N--X1\%5Z^P-"NX9%'PDI-?]S.DOBDS(=0.4EZ^]$#FL M$&G/IST.4;)7%:]\\I]ANMJEL^66E9I!9:OD*^HRDHT57T$2+)>8ASXAF/*$U VEK95OA M,CH-X94>K_1XI"^BM%-Y* MT6ZEN$S6=-850 2^@%M$NP+6V*J32TH33XV7='-%N^WQT/?O&6,#8CO/02.O MA7M=[A1LN_UL>OW-ZV_*LJ'LVIB,ZN8%02\(&A8$^SJJO CE1:C*Z#$+PVR= MQ?3P1?-TQ0K='IV^NX2H.3/ZCNJ%22],NBM#>6&R9P9'1U;E94TO:WI9LUW6 MO XP@FA)[@%^7 66B\4=$B,3[7C-K0BC7"#5B'?/-NJ8P.S%Q&'%1,FW[P5& M+S J"HP"5NQ%02\*>E%04Q2T%QAO7R#T(M4I;) _ [A<4:U^]@)PL 2?,U94 M9[[(-U'7\J@SEAZ[53= 2KI[Z=%+CUYZ]-*CBME1QHF\ M).DE22])MDN2]SC9 )QN[V-6]@U%+ Y]PW[CL.71+8F,NX,2:5?>;U2K4;>4 M:@WAY4QWY$PO2!W7O,3I)4XO,73 "TA!:IXL-)A$V;WB_9CDD1?81Q3 M_L+'2R+"Z8UAQ_DO/PJ\( !Y3Z\">"'S%-R_T[5^T4Y)A$8,$_%SJO=/49V$OC7AKWTKB7QE6D<9/\;#+"NE"OZ2=K3.:Q M+Z_P>(5'4^$IWZ\D]\&6H449%/T)SL#^+3,(S)K=>S\7K4UJNQS2=31?4VN, MANMR%\EN&X-8]I:XJ(<7]MT1]KWL>AC?(?]4IJCCZ FDG>^BR+AN97%9_AN7@,.H_#B4>P,N=7NYT5K#R''1''%3[WJI'0BX3M(F'%?^>+RV3-PH?SZ1] 3)M$EPE) M2?[:V45 0'0?;/->=BV&JB0_UTF6"6;]!K4B>/;OU M)DZV #P"_ (I=7O>43^ILSBGA?YMOG@ 8;)$\ _ %@63XOBJ!]J:GL\N>ASR MPQ2^T,.I&8.L-=@8UYT?[7E^=Q*C&"@,; 6/]@W#.$#+XKJ^V!Y=QODE5]UT ME#?$ ?HBF)*WQWPUMB7N.DB MS4[&[B(T7PTH&D^FV(TBP-VER K)'SR2VGI(A=Z?W$:/:U$\D)*D,UNO [R=+_:'\/HU M6-,O/S?)27VYBKV][#BZ^\_+CMW,L*K?BQ3Q(S0BXE> M3/1B8KN8>)FLUS M@BM1=)G0,&U]R''LOT^?M> M]IRR[-F)GWAAU NCRA6J]#BYETZ]=.JE4Q/2JHO42K9=HO43;+2VJ%U?S M@JX7=+V@VR[HEFGO]P%.MT\X0(1R:A;LXG".D%N2'V\#)4*_M-N8UJ)NB-89 MP4ND[DBD7L ZN 15V<(4I7$](52+*7E1TXN:7M1L%S4?P9+]^0 V"6;*FA7H3T(J2[XI'DL_>BH]1^J<)\O,CH148O,G86 M&2T6P@_#),M-J"& +XR,UFKBTN9VHCY12('%1>E32'Z[ "A*- VLU'.HQ2&0GHY_X 7@#*P,;LB+ H[HNG+1!2^^W.9Z66=52>G@W6,)PJ[J^MX@ MY U" P6T:0D[OD2Z*;EYNN72O:FMU=0FOQ!+C'Z8+D:C-$?^[1VCDSW10__Q M_P%02P$"% ,4 " ![9*A,U>(G*UKQ #O"0H $0 @ $ M &UL4$L! A0#% @ >V2H3'2IT>ZK2P 7C\& !4 M ( !XQL! ')G96XM,C Q.# S,S%?9&5F+GAM;%!+ 0(4 Q0 M ( 'MDJ$SW_$K 9H (]]!P 5 " <%G 0!R9V5N+3(P M,3@P,S,Q7VQA8BYX;6Q02P$"% ,4 " ![9*A,,Z[%GSM/ 15P< %0 M @ %:Z $ &UL4$L%!@ & - 8 B@$ ,@W @ $! end